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Abstract
Premature labour is a major problem in obstetrics and is the leading cause of perinatal morbidity. At
present there are no effective diagnostic indicators of preterm birth, and there are no effective treatments
for this condition. Current research is therefore focused on understanding the physiology and
pathophysiology of the birth process to potentially develop better diagnostic indicators and improve
methods of therapeutic management. Prostaglandins, particularly PGE2 and PGF2a produced within the
intrauterine tissues, play a central role in the initiation and progression of human labour. These
prostaglandin responses are mediated through a family of seven-transmembrane G-protein coupled
receptors, EP1-4 for PGE2 and FP for PGF2a. It is thought that one of the targets of prostaglandin action is
the family of matrix metalloproteinases (MMPs). MMPs, particularly the gelatinases MMP-2 and MMP-9,
are thought to play a role in rupture of the fetal membranes prior to parturition. The aim of this thesis is to
investigate the cellular pathways by which PGE2 and PGF2a act via their receptors in human fetal
membranes and the effect that these responses have on the production and activation of MMP-2 and
MMP-9. The JEG3 choriocarcinoma cell-line was used alongside human tissue as a model of chorion
trophoblast cells. PCR and immunohistochemistry were used to identify and localise the prostaglandin
receptors, EP2, EP4 and FP. These receptors were localised to the amnion epithelium and fibroblast layer,
chorion trophoblast and reticular layer, glandular epithelial cells, stromal cells and vascular endothelial
cells of the decidua, placental syncytiotrophoblasts, smooth muscle cells of the myometrium and also
JEG3 cells. To investigate intracellular signalling, amnion and chorio-decidua were collected immediately
after term elective caesarean sections and treated with PGE2 and PGF2a, and selective inhibitors and
antagonists, as were the JEG3 cells. Samples were homogenised and assayed for cyclic AMP (cAMP) and
analysed for extracellular signal-regulated kinase (ERK) phosphorylation by immunoblotting. PGE2
elevated cAMP levels over 2-fold after 10 min in amnion and JEG3 cells, with no effect on chorio-
decidua. These effects were inhibited by the addition of an EP2 antagonist in amnion and an EP4
antagonist in JEG3 cells. PGE^ and PGF2a had no effect on phosphorylation of ERK1/2 in amnion or
chorio-decidua, though in JEG3 cells, PGE2 and PGF2a increased it by 9-fold and 2-fold respectively after
10 min. Pre-treatment with an inhibitor of MEK totally inhibited this stimulation, and an inhibitor of PLC
and EGFR kinase had no effect. The ERK1/2 phosphorylation stimulations by PGE2 and PGF2a were
inhibited by an EP4 and an FP antagonist, respectively. To investigate the effects of prostaglandins on
MMP production and activation, amnion, chorio-decidua and placenta were collected after term elective
caesarean sections and stimulated with PGE2 and PGF2ct, as were JEG3 cells. Quantitative PCR was
carried out to determine mRNA levels of MMP-2 and MMP-9 after this stimulation. Zymography was
performed to reveal latent and active forms of MMP-2 and MMP-9, and reverse zymography and Western
blotting carried out to quantify TIMP levels. Results show that although there were no major PG-mediated
changes in latent or active forms of MMP protein, MMP-2 mRNA production was up-regulated by both
PGs in JEG3 cells. These results suggest that prostaglandins are acting via the EP2, EP4 and FP receptors
to activate intracellular signalling pathways which up-regulate the production of MMPs. This mechanism
could be involved in rupture of the fetal membranes, and the PG receptor antagonists could potentially be
used to block this process to prevent preterm rupture of the membranes.
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An understanding of the regulation of parturition at term would be of great benefit to the
diagnosis, management and outcome of preterm birth, a major problem in clinical
obstetrics. Preterm birth occurs in around 10 % of all pregnancies and accounts for 70 %
of perinatal morbidity. It is defined as birth prior to 37 of the usual 40 weeks gestation
period. During pregnancy, the uterus must be maintained in a relative state of
quiescence, allowing the fetus to develop. It must then develop coordinated contractility,
and the cervix must dilate to allow the passage of the fetus along the birth canal. The
transition from pregnancy to parturition results from a complex interplay of maternal
and fetal factors. For a successful birth, maturation of the fetal organ systems necessary
for survival in the extra-uterine environment must have occurred, therefore
communication between the fetus and the stimulus by which uterine activity is increased
is necessary. Preterm birth will result if this synchronisation is at fault. In this chapter,
literature will be reviewed to give an overview of events which occur at human
parturition. Regulation of these events will be discussed with particular attention to the
involvement of prostaglandins, cytokines and matrix metalloproteinases.
1.2 Parturition
Parturition is the physiological process by which the fetus, placenta and fetal membranes
are expelled from the uterus into the extra-uterine environment. Labour is the sequence
of involuntary uterine contractions that result in dilation of the cervix and delivery of the
fetus, placenta and fetal membranes. The first stage of labour begins with progressive
dilation of the cervix. The second stage begins when the cervix is fully dilated and ends
with delivery of the baby. The third stage begins when the baby is bom and ends when
the placenta and fetal membranes are expelled. During this stage, retraction of the uterus
and manual compression of the abdomen reduce the area of placental attachment. A
hematoma (mass of blood) forms, which separates the placenta and the fetal membranes
from the uterine wall. The fourth stage follows this and involves myometrial
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contractions to constrict the arteries that formerly supplied blood to the intervillous
space of the placenta. These contractions prevent excess uterine bleeding and return the
uterus to its normal size (uterus involution) (Moore & Persaud 1998). A complex
balance of fetal and maternal factors is necessary to facilitate all the processes involved
in labour. In this section, the structure of the pregnant uterus and its components will be
discussed, followed by many of the different events which occur during labour.
1.2.1 Structure of the Pregnant Uterus
The structure of the pregnant uterus is shown in Figure 1.1. It consists of maternal
myometrium and decidua, and the fetal membranes and placenta which are genetically










Figure 1.1: A pregnant uterus.
12
1.2.1.1 Fetal membranes
Fetal membranes consist of amnion and chorion (.Figure 1.2) (Bourne 1960). The
avascular amnion comprises an inner epithelial layer which is in direct contact with
amniotic fluid, a basement membrane, a compact layer which varies greatly in thickness,
a fibroblast layer consisting of dispersed mesenchymal cells, a spongy layer rich in
proteoglycans and an outer reticular layer, underlying the chorion. The chorion is
composed of a fibroblast and a reticular layer, basement membrane, and its primary
constituent, trophoblast, which is adjacent and adherent to decidua, and continuous with
the placenta. Fetal membranes release many autocrine, paracrine and potentially
endocrine mediators including prostaglandins, cytokines, steroids, peptides, MMPs and
TIMPs (Challis et al 2000). Although amnion derived prostaglandins increase at labour
(Bennett et al 1992, Skinner & Challis 1985), whether significant quantities gain access
to the myometrium is not certain due to the high concentration of prostaglandin
dehydrogenase (PGDF1 - see section 1.2.3) in the chorion (Cheung & Challis 1989).













The major components of these fetal membranes are the cells, and the extracellular
matrix (ECM). The cells are responsible for synthesis, degradation and turnover of the
ECM, which in turn influences the functions of the cellular component during
pregnancy. The fetal membranes require sufficient strength to withstand stretching to
approximately double their size at term (Parry-Jones & Priya 1976) and also fetal
movements (Patrick et al 1982). But they must also be able to rupture at term, and a
build up of normal elastic tissue may prevent this. Thus, it requires a unique structural
arrangement which is adaptable to changes in the uterine contents. The major tensile
strength is due to the presence of interstitial collagens, I, II, and III, together with
smaller amounts of types V, VI and VII in the amnion compact layer (Malak et al 1993).
The basement is mainly collagen IV, which provides a scaffold for assembling other
basement components such as laminin, entacin and heparin sulphate proteoglycan.
Collagen IV is also associated with the basal lamina of the amnion epithelium and the
basement membrane of the chorion. Type VII collagen provides additional attachments
linking the basal lamina of the amnion epithelium to the ECM underlying this in the
form of anchor fibrils (Keene et al 1987). Collagen XIV is also present in the ECM of
the fetal membranes, and the decidua. Minor collagens such as this may be important in
mechanical stability of the tissue and provide resilience for stretching (Bryant-
Greenwood 1998). Type IV collagen is associated with the chorion trophoblast cells
(Aplin & Campbell 1985, Malak et al 1993). This may be important for attachment to
decidua, as at parturition, separation within the decidual striae occurs, leaving some
decidua (capsularis and parietalis) attached to the chorion (Bryant-Greenwood 1998).
Besides collagens, other components are present in the ECM. Elastin has been identified
and expressed in the fetal membranes (Hieber et al 1997). This explains the elastic
nature of the fetal membranes. The thickness of the elastin fibres in the fetal membranes
is relatively thin compared to that of the uterus (Leppert & Yu 1991). The thinness of the
fibres may represent a compromise between requirement for elasticity, and a necessity
for normal rupture at term. Data suggests a high cross-linking of elastin in the fetal
membranes with the enzyme, lysyl oxidase being responsible for this (Kagan &
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Trackman 1991, Pinnell & Martin 1968). It is possible that a lack or reduction in elastin
in the fetal membranes could play a role in their premature rupture Microfibrils,
composed mainly of fibrillin have been found to be particularly abundant in the
fibroblast and reticular layers of the amnion and also chorion trophoblast (Malak & Bell
1994a). These are thought to contribute to the elasticity of the fetal membranes, infact it
is not clear if microfibrils alone, in the absence of elastin, could provide enough of the
required elasticity to the fetal membranes. Fibronectins are synthesised by a wide variety
of cells and are organised into ECM. The whole family arises from alternative splicing
of a single gene. They have multiple binding domains, capable of adhering to many
cells, hence them being termed 'glue-like' (Feinberg et al 1991). Oncofetal fibronectin
(onfFN) is present wherever trophoblasts make contact with extraplacental ECM, and
can potentially be used to predict preterm labour (see section 1.23). Laminins are a
major component of basement membranes and are formed from several subunits linked
by disulphide bonds forming a cross-like structure (Timpl et al 1979). They have also
been identified in the amnion epithelial layer (Alitalo et al 1980). The precise role of
laminins in the fetal membranes is unclear but it is thought hat they may have a role in
adhesion, migration and differentiation of invading trophoblasts in early pregnancy.
There are also a number of other extracellular matrix components in the fetal membranes
including integrins, proteoglycans, decorin and plasminogen (Bryant-Greenwood 1998).
While ECM is crucial for structural and biomechanical properties of the fetal
membranes, cell-matrix interactions are very important within the fetal membranes for
regulating cell actions and behaviour. The interactions allow the cells and matrix to
respond to the changing needs of the tissue. Cell-matrix contacts can influence gene
transcription within cells, for example the MMPs which can then act on the ECM.
Mechanical changes in the ECM can influence autocrine/paracrine responses in the cells





Amniotic fluid is 98-99% water. The chemical composition of its substances varies with
gestational age (Modena & Fieni 2004). During the third trimester of pregnancy, total
solute concentration in amniotic fluid falls, while the concentration of urea, uric acid and
creatine increase. Amniotic fluid is in a dynamic state, complete exchange of its water
component within the fetus taking place approximately every 3 hours. Exchange of
water and solutes within the fetus occurs via gastrointestinal, urinary and respiratory
tracts and, until around week 20, the skin of the fetus is not keratinised, so amniotic fluid
exchanges freely with fetal extracellular fluid. Also, the amnion epithelium is a route of
exchange. The primary function of amniotic fluid is to protect the fetus from external
trauma. It also acts to store waste products and inflammatory mediators. Prior to, and
during labour, concentration of cytokines, IL-1, IL-6 and IL-8 (Halgunset et al 1994,
Laham et al 1993, Romero et al 1990a, Romero et al 1989a, Romero et al 1992a) and
prostaglandins, particularly PGE2 and PGF2„ (Mitchell et al 1979, Romero et al 1994,
Romero et al 1989b) increase significantly within amniotic fluid. Unpublised data in the
laboratory has also shown that production of MMP-9 and activation of MMP-2 is
significantly higher in amniotic fluid at spontaneous labour compared to elective
caesarean section at term. This is supported by further data showing MMP-2 and MMP-
9 levels increasing with labour (Fortunato et al 1999, Romero et al 2002) and will be
discussed in more detail in Chapter 5.
1.2.1.3 Decidua
Under the influence of progesterone, endometrial stromal cells enlarge, proliferate and
store glycogen, converting the endometrial lining of the non-pregnant uterus into the
decidua of pregnancy. During the first half of the pregnancy, decidual stroma comprises
mainly large granular lymphocytes and trophoblast associated macrophages with some T
lymphocytes and very few B lymphocytes (Chard & Lilford 1997, Starkey et al 1988,
Vince & Johnson 2000). As pregnancy progresses, numbers of large granular
lymphocytes decline in number resulting in term decidua being much less distinct and
lined with flattened epithelium. T cells and CD16+ lymphocytes increase in term
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deciduas, whilst CD56+ lymphocytes decrease, possibly reflecting immunological
adaptations of the deciduas during pregnancy (Vargas et al 1993) It is thought that at
term, cytokine production by tissues at the feto-matemal interface, including the
decidua, favours the Th-1 type, such as IL-1 and IL-6 (see section 1.2.2.4). Alongside
cytokines, many factors are synthesised within the decidua including hormones such as
prolactin and relaxin, and prostaglandins, which, at parturition, are likely to act in a
paracrine mannerwith those released by fetal membranes (Dudley et al 1992).
Decidua is divided into three regions in relation to the developing fetus. Decidua basalis
underlies the conceptus at the implantation site, is adjacent to the chorion and is
involved in formation of the maternal side of the placenta. The decidua capsularis lies
over the surface of the conceptus and the decidua parietalis lines the remainder of the
uterus (Ritchie 1995).
1.2.1.4 Placenta
Soon after implantation, extremely rapid trophoblast mitosis and differentiation begins,
with invasion of the maternal uterine stroma. By day 21 after ovulation, the chorionic
villus, the definitive functional and structural unit of the placenta, is already established.
The trophoblast can differentiate into villous and extravillous trophoblast. In the villous
trophoblast, the cytotrophoblasts of the floating villi, which are found in the intervillous
space, remain attached to the villous basement membrane. They form a monolayer of
epithelial cells that proliferate and differentiate by fusion to form a syncytiotrophoblast
which covers the entire villi surface. The syncytiotrophoblast is multifunctional, but
mainly works in absorption, exchange, and specific hormone functions. The extravillous
trophoblast has cytotrophoblast cells of anchoring villi in contact with the uterine wall.
These proliferate and invade the uterus, leading to complete remodelling of the spinal
artery walls, with the muscle layer disappearing and endothelial cells being replaced by
trophoblasts (Evain-Brion & Malassine 2003). A diagram of the structure of the placenta
at mid-gestation is shown in Figure 1.3. The placenta has many functions including
mediating exchange of gases and nutrients, excreting waste products, secreting many
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hormones, including progesterone for the maintenance of pregnancy, other steroids and
cytokines and contributing a major role in maintaining the feto-maternal immunological




Figure 1.3: Schematic representation of the human materno-placental interface at mid-
gestation. Chorionic floating villi are bathed with maternal blood in intervillous space
(Evain-Brion & Malassine 2003).
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The myometrium is the outer muscular portion of the uterus. It is composed of smooth
muscle fibres which are made up of actin, myosin and intermediate filaments which are
embedded in collagenous extra-cellular matrix. Myosin consists of 2 heavy (200 kDa)
and 2 light chains (20 and 17 kDa) which are arranged functionally into the head and
tail. The head contains the actin binding complex and has ATPase activity which is
involved in contraction and relaxation. The tail plays a role in formation of the myosin
filaments and transmission of muscle tension. Actin monomers (45 kDa) are
polymerised into long, thin filaments which form cross-bridges with the myosin-heads to
generate the contractile forces during uterine contractions. Intermediate filaments act to
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link proteinaceous dense bodies with individual muscle fibres, helping to coordinate
uterine contractions. Transmission and integration of myometrial contractility is further
facilitated by connective tissue and the arrangement of fibres into random bundles
(Huszar & Roberts 1982). Ion channels within the cell membrane can also act to regulate
excitability of this muscle. The contractions of the myometrium will be discussed in
section 1.2.2.3.
1.2.1.6 Cervix
The cervix has a high content of connective tissue, which is derived from collagen fibre
bundles (Uldbjerg et al 1983a) embedded in a proteoglycan matrix (Kokenyesi &
Woessner 1991). Collagens type I and type III are the predominant collagens present,
with small amounts of collagen type IV. Elastin (Leppert et al 1983) and smooth muscle
cells are also present. This connective tissue helps to resist stretch which is important in
maintaining integrity and retaining the fetus in the uterus. Ripening of the cervix is one
of the key steps in the coordinated control of parturition, as will be discussed in section
1.2.2.2.
1.2.2 Mechanisms of Parturition
Several parallel mechanisms work simultaneously during labour to result in delivery of
the fetus. These include communication from the fetus - the maturation of the fetal
pituitary-adrenal axis and the placental clock. Structural changes also occur, such as
rupture of the fetal membranes and detachment of the placenta, and cervical ripening.
Also, changes in excitability cause the myometrium to contract. Factors involved in the








































Figure 1.4: Diagram ofthe proposed mechanisms that have been implicated in the onset
of labour, showing an integrated cascade of autocrine and paracrine factors (adapted
from Norwitz et al 1999).
1.2.2.1 Tissue Remodelling and Rupture of the Membranes
In most pregnancies, labour begins at term in the presence of intact fetal membranes
(Alger & Pupkin 1986). They usually remain intact until rupturing near the end of the
first stage of labour. Rupture of the fetal membranes during labour is though to be
caused by general weakening due to uterine contractions and repeated stretching.
Experiments show that the tensile strength of the membranes is lower in labouring
tissues, than those obtained from non-labouring caesarean section (Lavery et al 1982).
The fetal membranes have been examined, and an area with unique morphological
features identified along the line of rupture. This has been termed the 'zone of altered
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morphology' (ZAM) and its features are consistent with structural weakness (Malak &
Bell 1994b). These features consist of disruption of connective tissue layers and marked
reduction in thickness and cellularity of the trophoblast and decidual layers. The zone
does not include the entire rupture site, thus it may appear before membrane rupture. It
also seems that the fetal membranes overlying the cervix are located at one end of the
post-delivery tear. Due to these structural features, and its localisation to an area within
the rupture line, it has been proposed that the ZAM likely arises from the cervical area of
the fetal membranes and may have represented a site of initial weakness in response to
the increased intra-amniotic pressures during labour (McLaren et al 1999).
Tissue remodelling of the fetal membranes plays a key role in their rupture. Changes
involve decreased collagen content, altered collagen structure, and increased
collagenolytic activity. The matrix metalloproteinases (MMPs - see section 1.5) are a
family of enzymes which are capable of degrading virtually every component of ECM
(Hulboy et al 1997). Degradation of collagen within the extracellular matrix of the fetal
membranes is mediated primarily by MMPs. The integrity of the fetal membranes
remains unaltered throughout most of gestation, partly due to low concentrations of
MMPs and a higher concentration of their endogenous inhibitors, TIMPs (Vadillo-
Ortega et al 1996). Near term, the MMP to TIMP activity balance switches in favour of
degradation of the extracellular matrix. In human amnion, MMP-9 activity increases,
and TIMP-1 concentrations decrease with the onset of labour (Vadillo-Ortega et al 1995,
Vadillo-Ortega et al 1996) and in amniotic fluid, all TIMP levels decrease with labour
(Riley et al 1999b). Other studies have shown that, in the fetal membranes, MMP-1
activity increases before labour, MMP-9 and MMP-3 activities increase during labour,
and TIMP-l concentrations increase after delivery, thus showing a pattern of controlled
collagen degradation (Bryant-Greenwood & Yamamoto 1995).
Fetal membranes may rupture before the onset of labour. Premature rupture of the fetal
membranes (PROM) defines rupture at term before labour begins, and preterm PROM
(PPROM) defines membrane mpture before the onset of labour occurring preterm.
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PPROM is one of the most common causes of preterm birth and will be discussed in
section 1.2.3.
1.2.2.2 Cervical Ripening and Dilation
In order for the fetus to move from the uterus into the outside world, the nature of the
pregnancy cervix must change by softening and dilating, permitting the fetal head to
engage at the internal os and descend towards the end of pregnancy. This process is
termed 'ripening'. The process by which this occurs involves two changes in the
intercellular matrix: a reduction in collagen fibres and a marked increase in
glycosaminoglycans (GAGs), which decrease the aggregation of the remaining collagen
fibres. In the human cervix, keratin sulphate, which does not bind collagen, increases
peripartum, and dermatan sulphate, which binds tightly to collagen, decreases. This aids
the loosening of collagen bundles.
The profound collagen degradation occurring during cervical ripening is likely to be
mediated by collagenases. Studies show that levels significantly increase within the
cervix during the latter stages of cervical ripening (Osmers et al 1992, Rajabi et al 1988,
Rechberger & Woessner 1993) and labour. MMP-8 and MMP-1, the two principal
collagenases (see section 1.6) have distinct collagen specificities and are secreted by
different cell types. MMP-8 is released in granules from neutrophils and cleaves
collagen type I twenty times faster than collagen type III. MMP-1 is produced in
fibroblasts and degrades collagen type III fifteen times faster than type I (Hasty et al
1987). Studies have shown a release of neutrophil derived MMP-8 (Hasty et al 1990)
and an increase in leukocyte elastase activity (Uldbjerg et al 1983b) during cervical
ripening. In-situ hybridisation studies have failed to show an increase in MMP-1 release
by cervical fibroblasts during cervical ripening (Osmers et al 1992, Rath et al 1991).
However, culturing of cervical fibroblast cells with PGF2a or IL-la, or stimulation of
these cells with cyclic mechanical stretch increase MMP-1 secretion, suggesting a role
for MMP-1 in cervical ripening (Yoshida et al 2002).
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Prostaglandins play a role in cervical ripening, in fact PGE2 has been used for over 30
years to ripen the cervix and is still the most widely used and effective cervical ripening
agent in current clinical practice (Calder & Embrey 1973, Kelly et al 2003). The
mechanisms by which prostaglandins effect cervical remodelling are currently poorly
understood. It is not clear whether reduction in cervical collagen caused by PGE2 is a
direct consequence of collagen degradation caused by an increase in collagenase activity
(Rath et al 1987) or that prostaglandins may be modifying the composition of GAGs,
altering the interaction of collagen with ECM (Calder & Greer 1991). PGE2 may also act
as a vasodilator and synergise with chemotactic agents to facilitate leukocyte infiltration
into the cervix thereby effecting cervical ripening (Kelly et al 1994).
Cytokines have also been implicated in cervical ripening. Studies have demonstrated a
significant increase in IL-8 concentration within the cervix (Kelly et al 1992, Sennstrom
et al 1997) and lower uterine segment (Osmers et al 1995b, Winkler et al 1998) with
levels correlating with MMP-8 and MMP-9 concentrations (Osmers et al 1995a). Other
cytokines such as IL-1(3 and TNF-a have also been shown to induce cervical ripening in
rabbits (El Maradny et al 1996) and guinea pigs (Chwalisz et al 1994), however the
remodelling which they cause less closely resembles the physiological process.
Nitric oxide has also been proposed to play a role in cervical ripening (Chwalisz &
Garfield 1998). There is down regulation of cervical iNOS expression during pregnancy
and up-regulation at parturition in the rat (Ali et al 1997) and in guinea pigs, intra-
cervical application of sodium nitroprusside, a nitric oxide donor, induces cervical
ripening which is morphologically identical to the physiological process (Chwalisz et al
1997). In humans, the role of nitric oxide in cervical ripening is less clear. It has been
demonstrated to induce clinically effective cervical softening in primiparous women
compared to parous women, prior to pregnancy termination (Thomson et al 1997).
However, there is evidence to suggest it is successful in arresting preterm labour with
premature cervical dilation (Lees et al 1994, Rowlands et al 1996). However, this effect
may be due to the tocolytic properties of nitric oxide and not the consequence of a direct
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cervical effect. It is a possibility that, because nitric oxide interacts with prostaglandins,
MMPs and cytokines, in addition to acting as a vasodilator, it is involved in pro¬
inflammatory remodelling cascades.
1.2.2.3 Myometrial Contractions
In the myometrium, the actin-myosin interaction is regulated by phosphorylation
(contraction) or dephosphorylation (relaxation) of myosin light chains, and this occurs
via myosin light chain kinase (MLCK) (Adelstein & Eisenberg 1980). The activity of
this enzyme is tightly regulated. It is activated by binding of calmodulin and calcium and
goes on to phosphorylate light chains of myosin. Phosphorylated myosin interacts with
actin, forming a functional structural complex capable of converting the chemical energy
of ATP into the mechanical energy of contractions. Inhibition of MLCK occurs via
PKA. This phosphorylates MLCK, decreasing its affinity for myosin light chains, and it
generates cAMP which facilitates calcium uptake into the sarcoplasmic reticulum, thus
reducing free calcium.
In pregnant sheep and non-human primates, a pattern of myometrial activity known as
contractures has been described (Nathanielsz et al 1995, Nathanielsz et al 1997). These
are an intrinsic property of uterine muscle (Lye & Freitag 1988) and consist of
prolonged, low amplitude increases in intrauterine pressure. Prior to parturition,
contractures switch to uterine contractions, which are shorter, more regular and generate
a higher intrauterine pressure. Studies show that this switch generally occurs at night and
is related to alterations in maternal plasma oestrogen concentrations, and maternal
oxytocin function (Nathanielsz et al 1995). Pregnant primate oxytocin levels have been
shown to have a 24 hours rhythm, with the greatest levels apparent during the early
hours of darkness (Honnebier et al 1989). These authors also showed that a competitive
oxytocin antagonist inhibits the contractions. This increase in oxytocin may be due to




Human myometrium can generate uncoordinated contractions, termed Braxton-Hicks
contractions (Braxton-Hicks 1872) from early pregnancy. At parturition, the
myometrium functions as a syncytium, facilitated by the expression of gap junctions
within the myometrium, which increase in size and number (Ciray et al 1995) with the
onset of labour. The concentration of gap junctions correlates with the frequency of
uterine contractions and the stage of cervical dilation (Garfield & Hayashi 1981). It is
suggested that the activation of the myometrium results from the coordinated expression
of a cassette of contraction-associated proteins. Connexin-43, the myometrial gap
junction protein, is one of such proteins, and the molecular mechanisms which control
the expression of this gene have been analysed. Oestrogen is though to increase
transcription of the gene. Since oestrogen plays a role in modulating myometrial
contractility, this up-regulation of connexion-43 may be critical to the processes leading
to increased synthesis of gap junctions at term, and hence contributing to the onset of
labour (Lefebvre et al 1995).
1.2.2.4 Cytokines as Pro/Anti-Inflammatory Mediators
Cytokines are soluble protein or glycoprotein messengers that are released by immune
cells and effect immune cell differentiation and function, in addition to other sites of
synthesis and actions. They can regulate processes occurring in the extracellular
environment by autocrine and paracrine means. They are relatively selective, binding to
specific cell surface receptors, which are coupled to second messenger signalling
systems and intracellular pathways. The cytokine family is large and diverse consisting
of interferons, interleukins, growth factors and chemokines among others.
Helper T cells can be differentiated into 2 subgroups - Thl and Th2. The cytokine
environment at the time of ThO cell stimulation determines the differentiation process.
Generally, Thl cells produce pro-inflammatory cytokines, and Th2 cells produce anti¬
inflammatory cytokines, though there is some overlap of cytokine classification,
depending on the biological situation. At implantation, the cytokine balance at the feto-
maternal interface is largely neutral, while on placentation it becomes biased towards the
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Th2 type. By the third trimester of pregnancy, the general balance favours Thl-type
cytokines, which continues on into parturition (Dealtry et al 2000, Lin et al 1993). In this
section, the changes in expression of various cytokines with labour are discussed.
1.2.2.4.1 Interferons
Levels of IFN-y produced by decidua, in vitro, were significantly lower in cells collected
after labour compared to those before labour (Jones et al 1997). Contradictory studies
report higher decidual and trophoblast IFN-y mRNA at non-labouring term elective
caesarean section compared to spontaneous vaginal delivery (Vives et al 1999). Also, it
was found that IFN-y levels increased in supernatants of placental, amnion and chorio-
decidual homogenates following labour (Veith & Rice 1999). IFN-y concentrations in
amniotic fluid were found not to vary with labour (Olah et al 1996).
1.2.2.4.2 Pro-Inflammatory Cytokines
Patterns of expression of cytokines in the fetal membranes and decidua suggest that
inflammatory activation occurs with term labour (Bowen et al 2002), but much more
profoundly with preterm labour, particularly in the presence of intrauterine infection
which promotes the process. The onset of labour at term induces elevations in amniotic
fluid concentrations of IL-1(3 (Gunn et al 1996, Opsjln et al 1993, Romero et al 1990b),
IL-6 (Gunn et al 1996, Laham et al 1996, Romero et al 1990a) and TNF-a (Opsjln et al
1993, Romero et al 1992b). Concentrations of these cytokines seem to vary in an
interrelated way (Gunn et al 1996, Halgunset et al 1994) and to correlate with the
amount of granulocyte filtration into the placenta (Halgunset et al 1994). Concentrations
of inflammatory cytokines in cervicovaginal secretions increase during spontaneous
term labour (Cox et al 1993, Steinborn et al 1996), peaking when the cervix is fully
dilated. Cervicovaginal fluid levels of TNF-a increase profoundly after rupture of the
fetal membranes (Steinbom et al 1996). Osman et al (Osman et al 2003) found that
parturition was associated with significant mRNA increases of IL-1(3, and IL-6 in the




In addition to pro-inflammatory cytokines, many gestational tissues also produce anti¬
inflammatory cytokines, such as IL-10 (Denison et al 1998). A decrease in levels of anti¬
inflammatory cytokines may lead to increases in pro-inflammatory cytokine levels
which are associated with parturition. It has been reported that basal chorio-decidual
production rates of IL-10 are significantly decreased with labour (Simpson et al 1998).
No labour associated changes in IL-10 have been identified in amniotic-fluid (Dudley et
al 1997, Greig et al 1995, Jones et al 1997) or in decidua (Jones et al 1997). IL-4 levels
during term labour were only rarely decreased in amniotic fluid (Dudley et al 1996).
TGF-P is present in amniotic fluid and is thought to maintain pregnancy by opposing the
IL-1 and TNF-a action to stimulate prostaglandin production in intrauterine tissues (Bry
& Hallman 1992, Bry & Hallman 1993) and also may act as a natural progesterone
antagonist. MIC-1, a member of the TGF-p superfamily is also present in amniotic fluid,
fetal membranes and decidua at term but changes in concentrations with labour have not
been found (Keelan et al 2003).
1.2.2.4.4 Chemokines
Concentrations of IL-8 in amniotic fluid increase throughout pregnancy, and also with
the onset of labour at term (Laham et al 1993, Romero et al 1991, Saito et al 1993).
Levels of IL-8 in the lower segment of the uterus are also elevated with labour (Osmers
et al 1995b). Some studies have indicated that IL-8 levels do not increase in explants
from amnion, chorio-decidua and placenta during labour (Laham et al 1999), however
other studies are contradictory to this. IL-8 production from placenta was reported to
increase during labour (Elliott et al 1998) and from amnion and chorio-decidua (Keelan
et al 1999a, Osman et al 2003). Concentrations of RANTES in amniotic fluid increased
with the onset of term labour (Athayde et al 1999), as does GRO-a (Cohen et al 1996)
though no changes were found in IL-16 associated with labour (Athayde et al 2000).
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1.2.2.4.5 Other Cytokines
Leukaemia inhibitory factor (LIF) is undetectable in amniotic fluid during and at term of
normal pregnancies, but can be detected after the onset of labour (Waring et al 1994).
Uterine expression of LIF and its receptors suggests that it is involved in the
establishment of pregnancy and reduced endometrial LIF contributes to human infertility
(Cheng et al 2002, Vogiagis & Salamonsen 1999). Mice which lack the gene for the LIF
receptor show abnormal growth and development of the placenta (Sharkey et al 1999).
IL-15 mRNA and protein levels in the placenta increase following the onset of labour
(Agarwal et al 2001).
1.2.2.5 Progesterone and Oestrogen
High progesterone levels in the uterine tissue are essential for initiation and maintenance
of pregnancy. Progesterone acts locally within the uterus throughout pregnancy to
suppress uterine contractions (Beck et al 1982) and decrease gap junction formation
(Ambrus & Rao 1994). Almost 50 years ago, it was postulated that the removal of this
progesterone block initiates labour and delivery (Csapo 1956). To date, evidence
suggests that levels of progesterone are unaltered during labour. In the human, maternal,
fetal and amniotic fluid progesterone levels do not decrease before the onset of labour
(Boroditsky et al 1978, Walsh et al 1984). Progesterone is involved in the control of
parturition though, as addition of synthetic progesterone antagonists (e.g. RU486) or
addition of inhibitors of progesterone production (eg. inhibitors of the 3(l-hydroxysteroid
dehydrogenase enzyme such as epostane) initiate myometrial contraction and delivery
(Selinger et al 1987). Thus, the role of progesterone could be carried out without need
for alteration of the synthesis of this steroid. Methods involved in this progesterone
control include sequestration of free active progesterone, inactivation of progesterone,
production of a natural progesterone antagonist (eg. TGFp), modulation of progesterone
receptor coactivator and corepressor levels and changes in the levels of progesterone
receptor subtypes (Mesiano 2004). NF-kB is constitutively active in human amnion at
the time of labour and has been shown to repress progesterone receptor activity, thus
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contributing to 'functional progesterone withdrawal' at the time of labour (Allport et al
2001).
Oestrogen plays a critical role in parturition by augmenting uterine contractility and
excitability and increasing uterotonin production in the fetal membranes (Mesiano 2001,
Pepe & Albrecht 1995). In human pregnancy, maternal oestrogens (oestrone [El],
oestradiol [E2] and oestriol [E3]) increase dramatically at mid-gestation. In the latter
stages of pregnancy, concentrations of these hormones in the placenta are at levels 10 to
1000 times higher than in non-pregnant humans (Siiteri & MacDonald 1966). However,
these changes in oestrogen levels do not appear to affect the fetal membranes and uterus.
The oestrogens seem to exert their effects by increasing their bioactivity by
interconversion of El and the more functionally active E2 (Madsen et al 2004b) by
17(3HSD enzymes. This intracrine (see section 1.51) regulation controls the amount of
biologically active E2 available to interact with the oestrogen receptors (ER) (Labrie et
al 2000a, Labrie et al 2000b). The capacity to convert El to E2 (reductive activity) is
high in human placenta and low in amnion, chorion and decidua, though enzyme activity
is not affected by labour status in the placenta, amnion and myometrium, but only in the
decidua and chorion (Madsen et al 2004b). The oxidative reaction (E2 to El)
predominates before labour, whereas after the onset of labour, the reductive conversion
of El to E2 is greater (Mitchell & Wong 1993). Expression of ERa is increased in
labouring tissue, whilst ER(3 expression remains low and unaffected by the labour status
(Smith et al 2002).
1.2.2.6 Oxytocin and the Oxytocin Receptor
Oxytocin is a small peptide hormone consisting of only nine amino acids, and was first
identified through its potent and specific stimulatory activity for myometrial smooth
muscle (Dale 1906). It is widely expressed in human tissue, including gestational tissue.
Its receptor, OTR is a member of the vasopressin receptor family of G-protein coupled
receptors. This receptor is expressed in human myometrium (Soloff et al 1979), decidua
(Fuchs et al 1982), chorion and amnion (Chibbar et al 1993) and has not been detected in
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the placenta (Wathes et al 1999). It is coupled to the Gaq (Ku et al 1995) which
stimulates IP3 production and intra-cellular Ca2+ release. This can stimulate the
contractions which occur in the myometrium.
It has been shown that expression of OTR in the human myometrium increases in late
pregnancy, with decidual and fetal membrane expression staying the same (Wathes et al
1999) and uterine synthesis of oxytocin increases after the onset of labour (Chibbar et al
1993). These findings suggest a paracrine action of oxytocin in intrauterine tissues to
regulate myometrial contractions at labour.
It has been shown that IL-6 up-regulates OTR in cultured uterine smooth muscle cells
(Rauk et al 2001) though contradictory results have shown IL-6 and IL-1(3 down-
regulating myometrial OTR mRNA production (Schmid et al 2001). It may be expected
that pro-inflammatory cytokines such as these would induce OTR expression alongside
their role in promoting labour. Oestrogen seems to be a regulator of oxytocin synthesis.
High plasma concentrations of oestrogen correlate with high oxytocin concentrations
(Amico et al 1995) and treating decidual explants with oestrogen causes an increase in
oxytocin mRNA and protein (Chibbar et al 1995). Oestrogen also stimulates OTR
synthesis (Adachi & Oku 1995, Soloff 1975). Administering an oestrogen receptor
antagonist in late pregnancy in the rat reduces oxytocin levels and delays parturition
(Fang et al 1996). Progesterone also increases uterine oxytocin content (Fang et al 1997)
though it reduces uterine OTR synthesis (Soloff et al 1983).
1.2.2.7 Fetal-Hypothalamus-Pituitary-Adrenal Axis
The concentration of Cortisol in amniotic fluid increases during pregnancy in humans.
The majority of Cortisol present in the amniotic fluid at term is produced by the fetal
adrenal (Schwartz & McMillen 2001), though the fetal membranes also produce some.
Thus, the fetus is also involved in the onset of parturition. A number of theories as to
how the fetal adrenal interacts with the placenta have been proposed.
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It has been shown that in primary cultures of human placenta, Cortisol is able to compete
with the action of progesterone in the regulation of the corticotrophin-releasing hormone
(CRH) gene by binding to the glucocorticoid receptor, thus preventing progesterone
binding (Karalis et al 1996). CRH is a peptide highly expressed in human placenta at the
end of gestation, which has been suggested to be involved in regulating the timing of
parturition. These findings provide a model for functional progesterone withdrawal at
the end of human pregnancy, which may be involved in the initiation of labour. CRH has
also been shown to stimulate prostaglandin output via COX, and cytokine production
from fetal membranes and decidua (Alvi et al 1999a, Alvi et al 1999b, Jones & Challis
1989). In fact the prelabour increases in COX-2 expression in the fetal membranes
parallels that of CRH. These observations suggest paracrine/autocrine interactions
between CRH and prostaglandins and cytokines and implicating CRH further as a
placental signal for parturition.
Another hypothesis suggests that increased levels of oestriol at term stimulates placental
ll-(3-hydroxysteroid dehydrogenase (11-|3-HSD), which converts Cortisol to its inactive
form, cortisone (Wilson & Parsons 1996). This lowers the exposure of the fetus to
maternal Cortisol. Negative feedback to the fetal pituitary releases corticotrophin, which
stimulates fetal adrenal dehydroepiandrosterone sulphate (DHEAS) synthesis. DHEAS
is then converted to oestriol in the placenta after being 16 a-hydroxylated in the fetal
liver. The rise in placental oestriol production could then stimulate the release of
oxytocin, prostaglandins and gap junctions, leading to myometrial contractions and
cervical dilation.
1.2.2.8 Placental Clock
After isolation and characterisation of corticotrophin releasing hormone (CRH) (Vale et
al 1981), it was discovered that this hormone was present in human plasma during the
third trimester of pregnancy (Sasaki et al 1984). The CRH gene was then found to be
expressed and synthesised in human placenta and fetal membranes (Grino et al 1987,
Riley & Challis 1991, Warren & Silverman 1995). It is secreted into the maternal
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circulation during gestation, where levels have been found to increase exponentially as
pregnancy progresses (Campbell et al 1987, Goland et al 1986). The discovery of a high-
affinity binding protein for CRH (CRH-BP) (Orth & Mount 1987) led to the finding that
levels of this fell during the third trimester of pregnancy, leading to increased free CRH
levels. It was then shown that women delivering prematurely had an early rise in CRH,
and those delivering post term had a later rise than those delivering at term (McLean et
al 1995). This led to the term 'placental clock' and it was postulated that the increase in
CRH acted to control the length of human gestation. In support of this hypothesis, levels
of CRH-type receptor 1 (CRH-R1) increase within the lower uterine segment with the
onset of labour (Stevens et al 1998). In fact the myometrium expresses 4 different
i
subtypes of CRH-R1 at term (Grammatopoulos et al 1998, Grammatopoulos et al 1999),
indicating a role for these subtypes in parturition. The precise roles of CRH during
pregnancy and parturition are unclear, however it is known that a series of molecular
events mediated by autocrine, paracrine and endocrine actions of CRH are activated
during pregnancy and at term to prepare the fetus and uterus for parturition (Hillhouse &
Grammatopoulos 2002). The rise in CRH may contribute to relaxation of the lower
uterine segment via CRH-R1 and to stimulation of myometrial activity either directly by
binding to CRH-R2 and inducing calcium mobilisation, or indirectly by stimulating
prostaglandin production (Jones & Challis 1989, Stevens et al 1998). Measuring plasma
CRH during second trimester has been shown to potentially be a useful tool for
predicting preterm labour (Inder et al 2001).
1.2.2.9 Lung Maturation and PAF in Parturition
The fetal lungs must be matured to ensure survival of the fetus outside the uterus. It
follows therefore that the fetal lungs are directly involved in part of the initiation process
of parturition. Platelet activating factor (PAF) was first identified as playing a role in this
signal when it was found that PAF concentrations are higher in amniotic fluid from
labour than non-labour (Billah & Johnston 1983, Hoffman et al 1990, Nishihira et al
1984). The lack of PAF secretion from the amnion and the fact that PAF has a direct role
in lung maturation led to the proposal that the source of PAF was actually the lung
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(Billah & Johnston 1983). PAF receptors have been detected in type II pneumonocytes
(Eguchi et al 1994), cells which line the alveoli in the respiratory part of the lungs. Prior
to labour, these cells change from storing a large amount of glycogen, to being glycogen
poor, lipid rich cells with lamellar bodies containing surfactant (Bourbon et al 1982).
This shows that the lungs are prepared for secreting surfactant into alveoli to prevent
alveolar collapse once the fetus is breathing in the extra-uterine environment (Frenkel et
al 1996). PAF has a role in glycogenolysis, reducing fetal pulmonary and hepatic
glycogen stores (Hoffman et al 1988). PAF has also been shown to have a role in
initiating uterine contractions (Nishihira et al 1984, Tetta et al 1986), and also to
stimulate the transcription of COX-2 and release of prostaglandins from the fetal
membranes and decidua (Alvi et al 1999a). Fetal surfactant has also been shown to be
involved in prostaglandin production from fetal membranes. The surfactant is secreted
from the fetal lung into amniotic fluid where concentrations increase with gestation, and
arachidonic acid is released from the lipids of the surfactant, thus providing the amnion
with a precursor for prostaglandin production (Bernal & Phizackerley 2000, Lopez
Bernal et al 1988).
1.2.3 Preterm Labour
Preterm labour, as defined by the onset of labour prior to 37 weeks gestation, remains a
major problem in obstetrics, accounting for 70 % of perinatal morbidity and occurring in
around 10 % of births (Hack & Fanaroff 1993, McCormick 1985), a value which has not
changed in the last 20-30 years (Challis et al 2002, Savitz et al 1991). Causes of preterm
birth in general fall into three categories: iatrogenic; where there is a demonstrable
complication of pregnancy such as pre-eclampsia or fetal distress that requires
obstetrical intervention; premature rupture of the fetal membranes with or without
infection; and idiopathic preterm labour. Generally, 30-40 % of preterm birth is
associated with an underlying infective process, and 40-50 % of preterm births are
idiopathic (Challis et al 2000). Preterm premature rupture of the fetal membranes
(PPROM) is defined as rupture of the fetal membranes before the onset of labour, prior
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to 37 weeks gestation. This occurs in approximately 5-10 % of pregnancies and is the
leading cause of premature labour accounting for around 40 % of these deliveries.
Risk factors for preterm delivery include previous low birth weight or preterm delivery,
multiple second trimester abortions, multiple gestations, placental anomalies, cervical
and uterine anomalies, gestational bleeding, in vitro fertilisation pregnancy, hydramnios,
infection, cigarette smoking, low socio-economic class and black race (Creasy et al
1980, Mercer et al 1996, Norwitz et al 1999). Presently, there are no effective diagnostic
indicators of preterm birth, and no effective treatments for this condition. However,
there are several biochemical markers which could potentially be useful indications of
infection and the risk of preterm labour. As mentioned previously, cytokines and
prostaglandins are elevated during preterm labour. Cervicovaginal fetal fibronectin
detection can be a good indicator of preterm labour and PPROM (Goepfert et al 2000,
Ramsey & Andrews 2003). Other markers have also been tested: CRH in maternal blood
(McGrath et al 2002), intercellular adhesion molecule (ICAM-1) in chorio-decidua
(Marvin et al 1999), |3-hCG in cervicovaginal secretion (Bernstein et al 1998), MMP-9
in amniotic fluid (Harirah et al 2002), glucose concentration in amniotic fluid
(Gonzalez-Bosquet et al 1999), and salivary oestriol elevation (Ramsey & Andrews
2003).
Infection induces a maternal and fetal inflammatory response which can lead to
production and release of pro-inflammatory cytokines, which induce prostaglandin
production leading to cervical ripening and myometrial contractility. These cytokines
and prostaglandins are elevated in preterm delivery. Infection plays a key role in
PPROM - there is an increased chance of infection occurring when the interval between
rupture and delivery is elongated. Bacterial infection within the uterus can occur
between the maternal tissues and fetal membranes, within the fetal membranes
(chorioamnionitis), within the placenta (villitis), within the amniotic fluid (amnionitis),
or within the umbilical cord or the fetus (funistis). The bacteria can invade the uterus
from the abdominal cavity through the fallopian tubes, needle contamination, through
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placental blood, or passage through the cervix from the vagina (Goldenberg et al 2000).
Generally, very early, as opposed to later preterm deliveries are associated with
intrauterine infection. Treating infection in women who have intact membranes but
symptoms of preterm labour with antibiotics does not usually delay delivery, reduce the
risk of preterm delivery, or improve the neonatal outcome (Gibbs & Eschenbach 1997).
For women who present with rupture of the membranes near term, promoting delivery is
usual to prevent intrauterine infection. However, if the rupture occurs prematurely,
treatment should be directed to conserving the pregnancy and reducing neonatal
morbidity due to prematurity. Antibiotic treatment can increase time to delivery and
improve the outcome of the birth (Kenyon et al 2004, Mercer 2003, Mercer et al 1997).
1.2.4 Animal Models for Investigating Parturition
It is difficult to find a useful animal model of human parturition, since mechanisms
involved are so very different in other species. These differences make it hard to
extrapolate any animal data to humans. Some of the differences and similarities in
events at parturition between species are compared in Table 1.1. In mice, many other
rodents and rabbits, the corpus luteum is essential for progesterone synthesis and the
maintenance of pregnancy. In these species, luteolysis determines the timing for the
onset of labour and is mediated via activation of the FP receptor in the corpus luteum by
PGF2« (Cook et al 2003, Sugimoto et al 1997). Luteolysis causes a fall in maternal
progesterone levels, which is rapidly followed by uterine activity and labour. The
luteolytic mechanism does not apply in the human because the corpus luteum is only
important for the early stages of pregnancy, after which it regresses. Progesterone
withdrawal does not occur prior to parturition in the human, and the placenta is the
primary source of progesterone production, and oestrogen production alongside the fetal
adrenal. The fetal hypothalamic-pituitary-adrenal-axis appears to have a supportive
rather than direct role in the human at parturition. In sheep, and many other mammals,
activation of the fetal hypothalamic-pituitary-adrenal-axis and increased glucocorticoid
production precedes labour. In the human, an increase in glucocorticoid production does
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not precede labour, however, placental CRH may contribute to the timing of gestation
see section 1.2.2.7 and 1.2.2.8).
Species Steroid Progesterone Oestrogen Glucocorticoid Site of Prostaglandin
synthesis changes at changes at changes at term prostaglandin effects
site at term term term production






Non- Placenta No decrease Gradual Little change Uterus/fetal Uterine/gestational
human increase membranes tissues
primate








Decrease Increase Large decrease Uterus/fetal
membranes
Luteolysis
Table 1.1: Comparison ofparturition events in different species. Adapted from Gross et
al 2000.
The mouse has been widely used to study parturition, despite the obvious differences
between events which occur during parturition in the mouse and human. There are
similarities in the changes associated with increased myometrial contractility during
labour, for example contractile PG receptors increasing in the myometrium. Mice are
also advantageous for the ability to create knockout models, and modify the mouse
genome through transgenics (Majzoub & Muglia 1996) to assess gene function. The FP
receptor knockout mouse, for example, fails at parturition (Sugimoto et al 1997).
Whether results from mouse models of parturition can be extrapolated to human data
though remains a problem with these studies. The sheep is also commonly used as a
model for parturition. Increases in prostaglandin levels precede labour, as they do in the
human, and uses of prostaglandin inhibitors in this model have been shown to inhibit
premature labour (Grigsby et al 2000). The sheep has also been used to investigate the
role of MMPs and TIMPs in tissue remodelling in the placenta (Riley et al 2000). Non-
human primates offer several advantages for the study of parturition. They show the
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same patterns of progesterone, oestrogen and glucocorticoid changes prior to parturition,
and the placenta is the site of this steroid synthesis in late gestation, as opposed to the
corpus luteum in some species. A great deal of work has been carried out on the
involvement of prostaglandins and their receptors during pregnancy and parturition in
the baboon (Nathanielsz et al 2004, Smith et al 1998, Smith et al 2001a, Smith et al
2001b) (as will be discussed in Chapter 3). It is possible to carry out in vivo studies in
the baboon, to repeatedly sample blood and amniotic fluid, and electromyographic leads
can be places on the myometrium to record uterine contractility (Nathanielsz et al 2004).
Besides non-human primates, the data obtained from studies of parturition in animal
models may not be very relevant to humans, and care must be taken in applying any
findings to the human.
1.3 Prostaglandins
1.3.1 Discovery
In the 1930s, Kurzrok and Lieb were the first to observe the actions of prostaglandins
when they stimulated isolated human uterine strips with fresh human semen and
observed changes in contractility (Kurzrok & Lieb 1930). Subsequent independent
studies confirmed this (Goldblatt 1933, von Euler 1934) with reported contractions in
smooth muscle induced by a substance extracted from human seminal fluid and sheep
seminal vesicle glands (von Euler 1968). These agents were named "prostaglandins"
since they were apparently produced in the prostate gland (von Euler 1936). In non¬
pregnant women, Eliasson demonstrated in 1959 that prostaglandins, like human semen,
caused spontaneous contractions of isolated myometrial strips, yet PGs administered
intra-vaginally stimulated uterine contractions at the time of ovulation (Eliasson & Posse
1960). Subsequent studies showed that human seminal PG is secreted primarily by
seminal vesicles (Eliasson 1959) and not the prostate and further investigation showed a
variety of tissues produced PGs. They were confirmed to be fatty acids due to their
solubility in lipid solvents and their acidic characteristics. The chemical stmctures of
naturally occurring PGs were determined (Bergstroem et al 1963) and subsequently, a
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variety of PGs and related eicosanoids with profound biological activities have been
isolated and characterised.
1.3.2 Nomenclature
All prostanoids exhibit roughly the same structure as they are all oxygenated fatty acids
composed of 20 carbon atoms and containing a cyclic ring, a C-13 to C-14 trans-double
bond and a hydroxyl group at C-15. Prostanoids can be classified into prostaglandins
which contain a cyclopentane ring, and thromboxanes which contain a cyclo-hexane
ring. The prostaglandins are classified into types A to J, according to modifications of
the cyclo-pentane ring. A, B, C and J are thought not to occur naturally, but are
metabolites of the other prostaglandins. Thus, the naturally occurring prostaglandins
consist of prostaglandin D (PGD), PGE, PGF, and PGI. The thromboxanes are divided
into TxA and TxB, TxB being the stable metabolite of TxA. The abbreviations are
commonly followed by an index (for example PGE2) which indicates the number of
double bonds present in the various side chains attached to the cyclo-pentane ring.
1.3.3 Biosynthesis and Catabolism of Prostaglandins
The principal precursor of the prostanoids is the poly-unsaturated fatty acid, arachidonic
acid (AA). AA is released from membrane phospholipids (Figure 1.5) by phospholipase
A2 (PLA2) in response to various physiological and pathological stimuli. Around 10
distinct PLA2 groups have been identified and can be categorised into secretory (sPLA2),
cytosolic Ca2+-dependent (cPLA2) and cytosolic Ca2+-independent (iPLA2) (Dennis
1997). AA is converted to the prostanoid precursor PGG2, which is subsequently
peroxidised to PGH2. Both these reactions are catalysed by the protein cyclo-oxygenase
(COX) which predominantly consists of 2 forms: the endoplasmic reticulum-localised
COX-1 (HIa et al 1986, Needleman et al 1986), and COX-2 (Hla & Neilson 1992) which
acts predominantly at the nuclear envelope (Morita et al 1995). COX-1 has been shown
to be constitutively expressed, with COX-2 being the inducible form (Morita 2002).












Figure 1.5: Prostaglandin biosynthesis. Arachidonic acid is liberated from membrane
phospholipids by phosopholipase A2 (PLA2) and then is converted to the prostaglandin
endoperoxidases, PGG2 and PGH2 via cyclo-oxygenases 1 and 2 (COX-1 and -2).
Specific synthases then act to synthesise the specific prostaglandins. Prostaglandin
structures reproduced from Hata & Breyer 2004.
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form, termed COX-3, which is a splice-variant of COX-1 has recently been identified
(Chandrasekharan et al 2002), though its role in human physiology and pathophysiology
remains to be established. Following COX activity, prostanoid synthesis is completed by
specific synthases, for example PGES for PGE2. The important role of prostanoid
biosynthesis in pathophysiology is demonstrated by the well-known clinical effects of
pharmacological COX inhibitors. Non-steroidal anti- inflammatory drugs (NSAIDs)
such as aspirin and indomethacin act by inhibiting COX enzymes (Mitchell et al 1993,
Sadovsky et al 2000). It was originally thought that release of AA from membrane
phospholipids was the rate limiting step in the synthesis of prostaglandins (Lands 1979),
however, COX enzymes have also been implicated as the rate limiting step in this
process (Needleman et al 1986, Smith & Mamett 1991).
Biologically active PGs are rapidly broken down either by hydrolysis or conversion to
inactive metabolites. PGE2 and PGF2a are metabolised by the cytosolic enzyme, NAD+
dependent 15-hydroxyprostaglandin dehydrogenase (PGDH) to form carbon-15 keto
13derivatives (Anggard & Samuelsson 1965). This is followed by a reduction of the A
double bond, catalysed by A13-15-ketoprostaglandin reductase, to the 13,14-dihydro-15-
keto metabolites (PGEM, PGFM) (Anggard et al 1971, Anggard & Samuelsson 1964).
These enzymes are ubiquitously expressed in mammalian tissues (Tai et al 2002) and the
metabolites, PGEM and PGFM have significantly reduced biological activity (Anggard
1966). PGE2 can also be metabolised by 9-ketoreductase to form PGF2ot and then
hydrolysed to PGFM (Jarabak 1980).
Prostaglandins have a short half life and are metabolised rapidly, suggesting their actions
are local to their production site. Newly synthesised prostaglandins diffuse across the
plasma membrane into the extracellular compartment driven by pH and membrane
potential. However, metabolic clearance requires energy dependent uptake across the
plasma membrane followed by cytoplasmic oxidation. It has been suggested that carrier-
mediated PG transport is involved in degradation. Several prostaglandin carriers have
been cloned (Schuster 2002). Human prostaglandin transporter (hPGT) is a lactate/PG
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exchanger and is expressed in COX containing cells (Lu et al 1996). Another
prostaglandin transporter, organic anionic transporter (OATP) has lower affinity and
specificity for PGs. PG transporters, besides being involved in metabolic clearance, are
also involved in the re-uptake of PG in PG synthesising cells (Bao et al 2002). This
reuptake may control the net release of PGs as a negative feedback loop when PG
synthesis is stimulated, or in quiescent cells to maintain a basal level of PG. PG reuptake
within the cell via PGT can also provide intracellular access to nuclear membrane
located receptors as will be discussed in section 1.4.5.
1.3.4 Prostaglandin Synthesis and Catabolism During Pregnancy and Parturition
PG production is compartmentalised within pregnant maternal and fetal tissues (Challis
et al 2000). Arachidonic acid is present in the phospholipid layer of fetal membranes
(Schwarz et al 1975). The amount of arachidonic acid in the fetal membranes increases
during late gestation (Curbelo et al 1981), and decreases after the onset of labour (Okita
et al 1982, Schwarz et al 1975). Levels of free arachidonic acid found in the amniotic
fluid increase after the onset of labour (Keirse et al 1977, MacDonald et al 1974). This
suggests that arachidonic acid released from the amnion diffuses into the amniotic fluid.
Phospholipase A2, which catalyses the release of the arachidonic acid, is also present in
the human fetal membrane (Grieves & Liggins 1976, Schultz et al 1975). Activity was
higher in the decidua and amnion than in the chorion and myometrium and levels and
activity did not appear to be different in labouring tissues than in non-labouring tissues
(Grieves & Liggins 1976). Recently it was found that labour is associated with increased
expression of type-ILA sPLA2 but not type IV cPLA2 in human myometrium (Slater et al
2004).
Human amnion is a major site of PG synthesis, predominantly PGE2 (Challis & Olson
1988, Gibb & Sun 1996), both COX-1 and COX-2 have been identified there (Rose et al
1990, Teixeira et al 1994). There are only very low PGDH levels in the amnion (Cheung
et al 1990, Keirse & Turnbull 1975, Okazaki et al 1981). However, in the chorion there
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are very high PGDH levels which have been localised to the trophoblast layer (Cheung
et al 1990, van Meir et al 1997). COX is also abundant in this tissue (Gibb & Sun 1996).
The decidua contains low concentrations of COX-1 and COX-2, and little PGDH
(Cheung et al 1990, Okazaki et al 1981). Overall, in the amnion, chorion and decidua PG
output, and COX-2 mRNA increase at the onset of labour (Gibb & Sun 1996, Skinner &
Challis 1985, Slater et al 1998, Slater et al 1995). Evidence suggests that although
PGDH levels do not change in the amnion and decidua (Skinner & Challis 1985), in the
chorion, mRNA expression and activity of PGDH decrease in human labour, at term and
preterm (van Meir et al 1997, Van Meir et al 1997, Van Meir et al 1996). Although
amnion derived prostaglandins increase at labour, whether these can contribute to the
prostaglandin stimulation of cervical ripening and dilation and myometrial contractility
is uncertain. In fact, the amnion produces little of the PGE2 detected on the decidual side
of the fetal membranes (Sullivan et al 1993) most likely due to the high PGDH activity
of the chorion (Cheung & Challis 1989, Sullivan et al 1992).
In the human myometrium, COX-1 and COX-2 levels are greater in the pregnant
compared to the non-pregnant state (Moonen et al 1984), although there is controversy
over changes of this enzyme level with the onset of labour. It has been reported to
increase (Erkinheimo et al 2000), decrease (Zuo et al 1994) and stay the same
(Giannoulias et al 2002, Moore et al 1999). A significant decrease in PGDH protein
levels and activity is found in the myometrium with labour at term and preterm
(Giannoulias et al 2002).
The amnion and chorio-decidua show no differences in amounts of either PGES at term
or preterm, with or without labour, or advancing gestation (Meadows et al 2003),
although a report suggests that chorion PGES activity does increase with labour (Alfaidy
et al 2003) and decrease in the placenta. No labour associated changes in the expression
of PGFS within human gestational and intrauterine tissues have been observed (Slater et
al 2002). In the sheep, PGFS mRNA has been shown to increase following induced-
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spontaneous labour in the placenta, but not in the myometrium. PGES mRNA levels did
not change (Palliser et al 2004).
1.3.5 Role ofProstaglandins During Labour
Prostaglandins, particularly those produced within the intrauterine and gestational
tissues, play many distinct roles during the initiation and progression of labour (Challis
et al 2000, Novy & Liggins 1980). It is thought that PGs play a role in rupture of the
fetal membranes through the stimulation of matrix metalloproteinase (MMP) activity
subsequent to extracellular matrix protein remodelling. It has been reported that PGE2
stimulates MMP-9 production in human fetal membranes (McLaren et al 2000b) and
PGF2a increases production of MMP-2 and -9 and an increase in activation of MMP-2
(Ulug et al 2001). It is widely accepted that PGs play a role in cervical ripening and
dilation (Fletcher et al 1993, Keirse et al 1983). There is evidence that PGs play a role in
placental separation (although this process is largely mechanical). A link between
elevated human PGF2a plasma levels and placental separation has been reported (Noort
et al 1989) and also a link between administered PGE2 at the induction of labour and
placental abruption (Leung et al 1987). In cows with retained fetal membranes, due to
the non-separation of the fetal and maternal cotyledons, placenta tissue concentrations of
PGF2a were significantly lower than in normally separated cotyledons at 6 hours after
parturition (Takagi et al 2002). Uterine involution is very closely associated with plasma
levels of PGF2a in cows and sheep (Lindell & Kindahl 1983, Thompson et al 1987) and
the administration of PGF2a promotes uterine involution in cows (Lindell & Kindahl
1983).
There is a lot of evidence to suggest that PGs also play a role in myometrial contractility.
It is well accepted that this involves enhanced uterine activation as well as increased
levels of contractile stimulants. Several uterine activation proteins (UAPs) enhance the
ability of the myometrium to respond to contractile agonists and to develop and
propagate the depolarisation signal efficiently between smooth muscle cells (Olson
2003). These UAPs include the prostaglandin receptors, FP and EP1-4 and the
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stimulators include PGs. PGs are now recognised as a trigger of labour because the
myometrium contracts in response to exogenous PGs in vivo and in vitro (Crankshaw &
Gaspar 1992, Garrioch 1978, Senior et al 1991, Senior et al 1993, Senior et al 1992,
Wikland et al 1982, Wikland et al 1984, Word et al 1992). PG synthetic enzymes and
levels in tissues and fluids increase before or at the time of labour (Hirst et al 1998, Hirst
et al 1995, Mijovic et al 1999, Mijovic et al 1998, Slater et al 1995, Slater et al 1999),
and inhibitors of PG synthesis delay birth and prolong pregnancy (Challis & Olson
1988, Poore et al 1999).
1.4 Prostaglandin Receptors
1.4.1 Identification of Prostaglandin receptors
Prostanoid receptors are a family of seven-transmembrane G-protein coupled receptors
(GPCRs). These receptors have been cloned in humans and were first defined
pharmacologically as EP, FP, DP, IP and TP, which referred to the endogenous ligands
which activated these receptors: PGE2, PGF2a, PGD2, PGI2 and TxA2, respectively
(Coleman et al 1994, Pierce et al 1995). There is a lot of heterogeneity of the prostanoid
receptors due to the presence of genes encoding separate subtypes and also alternative
mRNA splicing. There is however, more homology with each other than for example,
with the histamine HI receptor, suggesting a common ancestral prostaglandin receptor.
Although each prostaglandin binds with the highest affinity to its cognate receptor,
cross-reactivity can be observed between a given prostanoid and other receptors within
the family (Breyer et al 2001). Table 1.2 shows inhibition constants (Ki) for ligands




ep1 ep2 ep3 ep4 fp dp ip tp
pge2 9.1 ± 1.5 4.9 ± 0.5 0.33 ± 0.79 + 119 ±12 307 ± >100000 29000 ±
0.3 0.07 106 6702
pgf2a 547 ± 964 ± 64 38 ±6 288 ± 27 3.2 ± 0.3 861 ± >100000 8700 ±
104 139 670
pgd2 5820 ± 2973 ± 421 ± 60 1483 ± 6.7 ± 0.5 1.7 ±0.3 >100000 6602 ±
1801 100 189 541
Iloprost 11 ± 1 1870 ± 56 ±6 284 ±9 619 ± 1035 ± 11 ± 1 6487 ±
176 105 171 29
u46619 28200 ± 12020 ± 13013 ± 2013 ± 241 ±8 3970 ± 53350 ± 35 ±5
3863 1617 2956 149 390 3950
Table 1.2: Binding and cross-reactivities between prostanoid receptors and their
ligands. Prostacyclin and thromboxane, the endogenous ligands for IP and TP are
unstable, so the most commonly used mimetics have been analysed in their place,
iloprost for prostacyclin and U46619 for thromboxane. Data obtained from Abramovitz
et al using human embryonic kidney cells (HEK293) expressing recombinant human
prostanoid receptors (Abramovitz et al 2000).
1.4.2 EP Receptors
There are 4 subtypes of the EP receptor; EP1, EP2, EP3 and EP4, which are products of
separate genes. These receptors use alternate, and in some cases opposing intracellular
pathways (Ashby 1998) (Figure 1.6). PGE2 interaction with EP1 mobilises intracellular
calcium and inositol triphosphate (EP3) via Gaq. Activation of EP2 and EP4 result in
stimulation of cAMP production via Gas (Narumiya et al 1999, Sugimoto et al 1993).
There are several splice variants of EP3 which are coupled to various signalling
pathways resulting in either a positive or negative cAMP response to PGE2 or an
increase in intracellular calcium mobilisation and accumulation of IP3. This depends on
the splice variant and the cell type in which PGE2 is acting. However, the nature of the
G-protein activated by a specific prostaglandin receptor may sometimes differ between
cell types. Although EP2 and EP4 have similarities in their functional coupling,
comparing the primary sequences of these cloned receptors shows that they share only
38 % amino acid identity in their transmembrane domains. This is not dissimilar from
the amino acid identity they share with EP1 (37 %) and EP3 (34 %). The cloned IP and
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DP receptors actually have more sequence similarity with EP2 (60%) (Toh et al 1995).
This suggests that second messenger coupling has more influence than ligand binding
specificity with respect to the overall primary sequence of these receptors. It is
surprising how dissimilar the signalling pathways for EP2 and EP4 are, given that EP2 is
358 amnio acids long, and EP4 is 488. EP4 also has 25 extra amnio acids in the third
intracellular loop compared to EP2 (Regan 2003). The longer C-terminal end of EP4
consists ofmany serine and threonine residues which are potential phosphorylation sites.
This C-terminal has been shown to be involved in short term agonist induced
desensitisation in EP4 which is absent in EP2 (Bastepe & Ashby 1997, Nishigaki et al
1996). However, these serine and threonine residues have been shown to not play a role
in internalisation (Desai et al 2000).
Figure 1.6: Prostaglandin receptors EP1-4 and FP structure and signalling. Adapted




There are 2 known different forms of FP; FPA and FPB resulting from alternative mRNA
splice variants. These splice variants are identical except for the carboxyl-terminal
domain, which is truncated in the FPB isoform and lacks the last 46 amino acids on the
C-terminal domain (Fujino et al 2002). Both isoforms of FP are coupled to Gaq and can
activate IP3 via activation of phospholipase C, intracellular calcium flux and activation
of protein kinase A. Also, both forms can activate Rho, one of the Ras-family of small
GTPases, which in turn leads to phosphorylation and activation of focal adhesion kinase
(FAK) associated with cell morphology (Pierce et al 1999).
1.4.4 Prostaglandin Receptors During Pregnancy and Parturition
EP1, 2, 3, 4, DP, FP and IP receptors have all been identified in the human pregnant
myometrium (Erkinheimo et al 2000, Leonhardt et al 2003, Matsumoto et al 1997b,
Myatt & Lye 2004, Senior et al 1993). It was found that EP3 and FP mRNA levels in the
myometrium were down-regulated during pregnancy, possibly playing a role in the
relaxation of the myometrium, thus aiding the maintenance of pregnancy (Matsumoto et
al 1997b). EP2 levels can also be seen to decrease with advancing gestational age,
implying that these too are involved in uterine quiescence (Leonhardt et al 2003). Brodt-
Eppley et al investigated preterm and term, labouring and non-labouring lower segment
human myometrial samples. They found EP2 mRNA levels were greater in preterm, no
labour samples, and that FP mRNA levels were greater in term labour (Brodt-Eppley &
Myatt 1999). These results are consistent with the theory that EP2 has a role in
maintenance of uterine quiescence, whereas FP has contractility effects. There is not a
lot of other published evidence of prostaglandin receptors in any other gestational tissue
besides the myometrium in the human, though FP has been detected in human amnion-
decidua complexes (Fukai et al 1984) and also in the human placenta (Vielhauer et al
2004).
Expression of prostaglandin receptors has been investigated in baboon chorion and
decidua during parturition (Smith et al 2001b). It was shown that there was a lower
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level of expression of the EP2 gene in decidua obtained from animals in spontaneous
labour to those which were not in labour. This suggests that an adenylate cyclase-
mediated effect may inhibit parturition-related processes in decidua in cells expressing
the EP2 receptor. This parallels decreased EP2 receptor expression in myometrium and
cervix (Smith et al 1998). In the chorion, a decrease in EP4 mRNA was also seen with
advancing gestational age (Smith et al 2001b). This suggests an adenylate cyclase-
mediated effect may inhibit changes in chorion which promote parturition. This is
similar to the myometrium, where adenylate-cyclase coupled receptors inhibit
myometrial contractility (Senior et al 1993).
EP receptor localisation has been investigated in the mouse uterus (Katsuyama et al
1997). Abundance and localisation of EP2 and EP4 mRNA changes considerably when
mice undergo pseudo-pregnancy by treatment with pregnant mare's serum
gonadotrophin (PMSG) and human chorionic gonadotrophin (hCG). EP2 mRNA is
barely detectable before stimulation and is expressed considerably in luminal epithelial
cells on stimulation, peaking after around 5 days then disappearing.
It has been shown that mice lacking the FP receptor have failure of parturition
(Sugimoto et al 1997). Although these mice showed no abnormality in the oestrous
cycle, ovulation, fertilisation or implantation, they did not respond to exogenous
oxytocin receptor (a proposed triggering event in parturition), and they did not show the
normal decline of serum progesterone concentrations that precedes parturition.
Ovariectomy restored induction of the oxytocin receptor and allowed successful delivery
in the FP-deficient mice. This shows that parturition is initiated when PGF2„ interacts
with FP in ovarian luteal cells of the pregnant mice to induce luteolysis, an essential
process in this animal model.
1.4.5 Nuclear Prostaglandin Receptors
It has become clear recently that, as well as activating cell surface receptors,
prostaglandins can activate nuclear receptors (Bhattacharya et al 1999, Bhattacharya et
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al 1998). This gives rise to the possibility of many intracrine (see section 1.5.1)
signalling pathways. As discussed previously, the PGT allows PG reuptake within the
cell, and this can provide intracellular access to nuclear membrane located PG receptors.
More evidence for the nuclear site of PG receptors comes from studies of the subcellular
localisation and compartmentalisation of enzymes of the biosynthetic pathway, many of
which have a perinuclear localisation (Gilmour & Mitchell 2001). The methods of action
of the nuclear PG receptors are under investigation. In the brain, the activated G-protein
coupled EP3 receptor can activate perinuclear Ca2+ dependent K+ channels, PI-3 kinase,
MAPK and NF-kB pathways (Gobeil et al 2002). It is not yet clear whether nuclear PG
receptors are present in gestational tissues (Helliwell et al 2004). Prostaglandins can also
act on other nuclear receptors, namely the peroxisome proliferator activated receptors
(PPARs). In fact the J series of prostaglandins is thought to not mediate its action via a
G-protein coupled receptor, but via PPARs (Miwa et al 2004). These will be discussed
in more detail in Chapter 3.
1.5 Signalling Pathways of the Prostaglandin Receptors
1.5.1 Endocrine, Paracrine, Autocrine and Intracrine Signalling
Signalling by extracellular secreted molecules can be subdivided into: endocrine,
paracrine and autocrine (Snyder 1985). In endocrine signalling, a molecule acts on target
cells different from their site of synthesis by cells of endocrine organs. Usually the
molecule is carried in the blood from the release site to its target. Paracrine signalling
involves the signalling molecules released by the cells only affecting target cells in close
proximity. Autocrine signalling involves cells responding to substances that they
themselves have released. Recently, a new term has been coined, namely 'intracrine'
which describes active hormones which exert their action in the same cells where
synthesis took place, without release into the pericellular compartment (Labrie 1991).




A signalling molecule acts as a ligand which binds to its site on its receptor inducing a
conformational change in the receptor causing reactions leading to the specific cellular
response (Alberts et al 1994). The function of the ligand is only to bind the receptor, it is
not metabolised or an intermediate product in a reaction, and it does not have enzymatic
properties. Target cells may modify or degrade the ligand, thus modifying or terminating
its response, or the response of neighbouring cells to the signal.
Hormones can be classified on their solubility and receptor location (Kahn 1976). There
are 3 categories, including small lipophilic molecules that diffuse across the plasma
membrane and interact with intracellular receptors. There are also hydrophilic or
lipophilic molecules that bind to cell surface receptors. Intracellular responses include
those of steroid hormones, progesterone, Cortisol, oestradiol and testosterone. Water
soluble molecules acting via cell surface receptors include insulin and glucagons, and
lipophilic molecules acting on cell surface receptors include eicosanoid hormones e.g.
prostaglandins.
1.5.3 Cell Surface Receptors
These can be roughly organised into 4 categories. There are G-protein coupled receptors
(GPCRs), receptor tyrosine kinases, tyrosine kinase linked receptors, and receptors
linked to other enzymatic activities. GPCRs comprise the largest family of all cell
surface receptors (see section 1.5.4). Receptor tyrosine kinases are the receptors for most
growth factors and have intrinsic enzymatic activity. Ligand receptor interaction leads to
receptor dimerization, which activates tyrosine kinase and phosphorylation of tyrosine
on one receptor tail by another (transphosphorylation). Phosphotyrosine recruits effector
molecules which are either enzymes or adaptors. Tyrosine kinase linked receptors lack
intrinsic catalytic activity. Ligand binding stimulates formation of a dimeric receptor
which interacts with and activates one or more cytosolic protein tyrosine kinase.
Receptors linked to other enzymatic activities include protein tyrosine phosphatases,
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protein serine/threonine kinases and guanylate cyclase. They are capable of
autophosphorylating residues in their own cytosolic domain and phosphorylating various
substrate proteins.
1.5.4 G-Protein Coupled Receptors
GPCRs are the largest family of cell surface receptors with over 100 members defined in
mammals so far (Gether et al 2002, Lameh et al 1990). They mediate the cellular
responses to a huge diversity of signalling molecules, including hormones and
neurotransmitters which are highly variable in structure and function. The same ligand
can activate many different family members. Despite this diversity, all of the GPCRs
known to date have a similar structure, involving seven transmembrane segments,
suggesting that they are evolutionarily related.
1.5.5 Trimeric GTP-Binding Proteins
Trimeric GTP-binding proteins (G-proteins) are GTPases and function as molecular
switches that can flip between 2 states: active, when GTP is bound, and inactive, when
GDP is bound (Bourne et al 1991, Hepler & Gilman 1992). When an extracellular
signalling molecule binds to a GPCR, the receptor changes its conformation and
switches on the trimeric G-proteins associated without causing them to exchange their
bound GDP for GTP. The G-protein then dissociates into Ga and Gpy subunits and it is
usually the Ga subunit that diffuses away, delivering its message downstream. The
switch is reversed when the G-protein hydrolyses its own bound GTP back to GDP.
Most GPCRs activate a chain of events altering the concentration of intracellular
signalling molecules known as the second messengers.
1.5.6 Second Messengers
Binding of a ligand to many cell-surface receptors leads to short lived increases and
decreases in the concentration of various second messengers e.g. cAMP, cGMP, DAG,
IP3 and Ca2+. These are generated in large numbers and rapidly act within the cell to
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broadcast the signal to other parts of the cell. This triggers rapid alteration in the activity
of one of more enzymes or non-enzymatic proteins.
1.5.7 Cyclic AMP (cAMP) Pathway
cAMP can activate protein kinase A (PKA), which in turn can activate transcription of
certain genes. Thus a high or low concentration of cAMP can switch on or off target
genes. cAMP is a nucleotide that is generated from ATP by adenyl cyclase in response
to stimulation of many types of cell-surface receptors. cAMP acts as an intracellular
signalling molecule by activating cAMP-dependent kinase, protein kinase A (PKA)
(Krebs 1989). Extracellular signals can cause changes of more than 20 fold in seconds.
This requires that rapid synthesis of cAMP is balanced by its rapid breakdown or
removal. It is hydrolysed to AMP by a phosphodiesterase. However, the extracellular
signal causes the increase in cAMP activity by an increase in the activity of adenyl
cyclase, not a decrease in the activity of phosphodiesterase.
Adenyl cyclase is a multipass transmembrane protein with its catalytic domain on the
cytosolic side. There are more than 8 isoforms in mammals and it is regulated by G-
proteins and Ca2+. All receptors that act via cAMP are coupled to stimulatory G proteins
(Gs) which activate adenyl cyclase, thus increasing cAMP. Inhibitory G proteins (Gi)
inhibit adenyl cyclase, by regulating ion channels, not by decreasing the cAMP content.
cAMP can directly activate certain ion channels, but most of its effect is activating PKA.
PKA catalyses transfer of the terminal phosphate group of ATP to specific
serines/threonines of the target protein, thereby regulating their activity.
CRE is the cAMP response element. It is found in the regulatory region of many genes
activated by cAMP. A binding protein, CREB recognises this sequence (Brindle &
Montminy 1992). When CREB is phosphorylated by PKA on a single serine residue, it
recruits a transcriptional co-activator, the CREB binding protein (CBP) which stimulates
transcription of the genes. Serine/threonine protein phosphatases rapidly reverse the
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effects of PKA. A summary of the events involved in the cAMP pathway are shown in
Figure 1.7.
ligand repeptor
Activation of adenyl cyclase

















Figure 1.7: Summary of events involved in the cAMP/PKA pathway. Binding of the
ligand to its receptor alters the receptor conformation, allowing binding of the Gs
protein. This weakens the affinity ofGsfor GDP in favour ofGTP. Once GTP is bound,
the a-subunit can dissociate, exposing its binding site for adenyl cyclase. The a-subunit
binds to adenyl cyclase, activating it to hydrolyse ATP to cAMP. cAMP causes a
conformational change in the regulatory subunit of PKA, causing dissociation of the
subunits which become active. Active PKA phosphorylates CREB, which recruits CBP




Agents, such as PGE2 and ^-adrenergic agents promote uterine quiescence via their
ability to increase intracellular cAMP levels (Price & Bernal 2001). Elevated
concentrations of cyclic AMP (cAMP) in the human myometrium may promote uterine
quiescence during pregnancy by PKA-mediated phosphorylation and subsequent
inactivation of myosin light-chain kinase, as well as by the phosphorylation and
activation of cAMP-dependent transcription factors (Bailey et al 2000). It has been
suggested that labour may be a result of the loss of this uterine quiescence. CREB has
been identified in the myometrium, and levels are lower in pregnant non-labouring, than
non-pregnant tissue (Bailey et al 2000). Adenyl cyclase has also been detected in both
non-pregnant and pregnant human myometrium and changes in isoform expression
identified during pregnancy. This consists of a shift from predominantly calcium-
calmodulin stimulated isoforms, to those regulated by G-proteins (Price et al 2000). As
well as its role in uterine quiescence, cAMP may also induce gene transcription of other
proteins involved in labour, such as the MMPs (Lyons et al 2002).
1.5.8 Mitogen Activated Protein Kinase (MAPK) Pathways
The MAPK pathways are major signalling pathways in all eukaryotes and are involved
in proliferation, differentiation and apoptosis (Kolch 2000, Kyosseva 2004). Ras
proteins belong to a large superfamily ofmonomeric GTPases (Alberts et al 1994). They
are signalling molecules and their activation is triggered by activated receptor tyrosine
kinases. This is a short-lived response. Ras inactivates itself by hydrolysing its bound
GTP to GDP via tyrosine specific protein phosphatases. When active, Ras activates a
downstream serine/threonine phosphorylation cascade that includes a mitogen activated
protein kinase (MAPK). Full activation ofMAPK requires phosphorylation of a tyrosine
and threonine residue. This is carried out by MAPK kinase (MEK) which is
phosphorylated by a MEK kinase (Raf). It is Raf which is activated by Ras. The
phosphorylated MAPK then relays the signal by phosphorylating proteins further
downstream, including other protein kinases and gene regulatory proteins, thus causing
regulation of gene expression and protein activity (Figure 1.8). There are 3 distinct
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MAPKs in mammals: the extracellular signal-regulated kinases (ERKs), the c-Jun NH2-
































Figure 1.8: The mitogen activated protein kinase (MAPK) pathway of intracellular
signalling. Phosphorylation of tyrosine activates Ras, which activates Raf a
serine/threonine kinase. This can phosphorylate MAPK kinase, MEK, which
phosphorylates MAPK which ultimately leads to the regulation ofgene expression and
protein activity. Figure adapted from Alberts, Bray et al. 1994.
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The MAPKs have been shown to play many roles in parturition. Studies show p38
MAPK is involved in the induction of COX-2 expression in the myometrium by IL-lp
(Bartlett et al 1999). p38 MAPK and ERK are involved in the regulation of COX-2
expression by phospholipase D (Park et al 2002) and sphingosine-1 phosphate in amnion
derived WISH cells (Kim et al 2003), respectively. p38 MAPK plays a role in decidual
function at parturition (Takanami-Ohnishi et al 2001), and ERK is involved in the
phosphorylation of myometrial caldesmon (an actin binding protein involved in smooth
muscle contraction (Marston & Lehman 1985)) during pregnancy and labour (Li et al
2003). Both ERK and p38 MAPK, though not JNKs, have also been shown to mediate
MMP-9 expression in vascular smooth muscle cells (Cho et al 2000).
1.5.9 Inositol Triphosphate Pathway
Some G proteins activate the inositol phospholipid signalling pathway by activating
phospholipase-C|3 (Michell 1992). Phospholipase-C(3 acts on an inositol phospholipid (a
phosphoinositide) called phosphatidylinositol 4,5-biphosphate (PIP2) which is present in
small amounts in the inner half of the plasma membrane lipid bilayer. Receptors acting
this way activate a specific trimeric G protein, Gq, causing the a-subunit to dissociate
and activate phospholipase-C(3 (Figure 1.9). The active phospholipase hydrolyses PIP2
to inositol 1,4,5 triphosphate (IP3) and diacylglycerol (DAG). The IP3 is a small water
soluble molecule which leaves the plasma membrane and diffuses rapidly into the
cytosol. There it releases Ca2+ from the endoplasmic reticulum by binding to IP3-gated
Ca2+ release channels (Berridge 1993, Streb et al 1983). The IP3 reponse is very short
lived and can be terminated by de-phosphorylating and thus inactivating IP3, and by
pumping out the Ca2+. The DAG has 2 potential signalling roles. It can be further
cleaved to release arachidonic acid, which can be used as a messenger (for example to
activate PKC (Blobe et al 1995), in a mechanism distinct from PKC activation by DAG
(see below)), or in the synthesis of eicosanoids. Also, it can activate a serine/threonine
protein kinase - protein kinase C (PKC) (Kishimoto et al 1980, Takai et al 1979). This is
Ca2+dependent, and it is thought that the initial rise in Ca2+ induced by IP3 causes it to
translocate from the cytosol to the cytoplasmic face of the plasma membrane. Here it is
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activated by DAG, Ca^+and phosphatidylserine and can phosphorylate cell proteins and
alter gene transcription.
Inositol phosphates are involved in signaling at labour. Cytokines, such as IL-6, activate
the IP3 signalling pathway in the myometrium, causing cytosolic calcium oscillations
that result in the development and maintenance of phasic myometrial contractions
(Phillippe & Chien 1998). This occurs via the PLCy isoform of PLC which is activated
by a receptor tyrosine kinase, as opposed to GPCR in the case of PLC(3. Oxytocin
increases IP3 levels and may influence labour by stimulating PGE2 production in amnion
through the IP3 pathway (Moore et al 1988). However, levels of IP3 receptor in the
human myometrium are similar in pregnant and non-pregnant tissue, and also remain























Figure 1.9: The 2 branches of the inositol phospholipidpathway. The activated receptor
couples to Gq protein causing the a-subunit to dissociate and activate phospholipase C-
Pwhich cleaves PIP2 to generate IP3 and diacylglycerol. The DAG, along with CcT ' and
phosphatidylserine, activate PKC. Figure adapted from Alberts, Bray et al. 1994.
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1.6 Matrix Metalloproteinases
Matrix metalloproteinases (MMPs) constitute a multigene family of secreted and cell
surface enzymes capable of degrading virtually every structural component of
extracellular matrix (ECM) (Hulboy et al 1997). Other targets include other proteinases,
proteinase inhibitors, clotting factors, chemotactic molecules, latent growth factors,
growth-factor binding proteins, cell surface receptors and cell-cell adhesion molecules
(Sternlicht & Werb 2001). They can thus regulate a wide variety of biological functions,
including playing a range of roles in the human reproductive system. During pregnancy
and parturition, there are many processes which involve extensive tissue remodelling,
including implantation, cervical dilation, and rupture of the fetal membranes. A lot of
this remodelling is influenced by the action of MMPs. MMP concentrations and activity
can be regulated by reproductive hormones, as well as by cytokines and growth factors
that participate in reproductive events. This section will deal with background
information about MMPs, MMP structure and regulation, and the role of MMPs in
reproductive processes and other biological events. The focus of MMP studies in this
thesis is on the gelatinases, namely MMP-2 and MMP-9.
1.6.1 Identification ofMatrix Metalloproteinases
Degrading extracellular proteins is essential for any individual cell to interact with its
surroundings and for multicellular organisms to develop and function normally and it is
extracellular proteinases that are responsible for this. In 1962 it was first shown that
diffusible enzymes produced by fragments of involuting tadpole tail could degrade gels
made of native fibrillar collagen by measuring degraded radioactive collagen (Gross &
Lapiere 1962). Since then, a family of related enzymes has been identified and
collectively named matrix metalloproteinases (MMPs) due to their dependence on metal
ions for catalytic activity, their potent ability to degrade structural proteins of the
extracellular matrix, and specific evolutionary sequence considerations that distinguish
them from other closely related metalloproteinases of the metzincin superfamily, such as
the astacins, serralysins and adamalysins (Stocker et al 1995). These metzincins are zinc
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endopeptidases and are all distinguished by a highly conserved motif containing three
histidines that bind zinc at the catalytic site. This signature motif is HEBXHXBGBXHZ
where (H) histidine, (E) glutamic acid and (G) glycine are fixed, B is a bulky
hydrophobic residue, X is a variable residue, and Z is a family-specific amino acid. The
subfamily identity is based on this specific amino acid, which is serine in all but a few
MMPs (Sternlicht & Werb 2001). In addition to cleaving proteins of the ECM, the
MMPs act upon cell surface molecules and other pericellular non-matrix proteins, thus
regulating cell behaviour in a number of ways (Sternlicht & Werb 2001). The MMPs
play a role in many diverse physiological and pathological processes, including aspects
of embryonic development, tissue morphogenesis, wound repair, inflammatory diseases,
and cancer (Nelson et al 2000, Stemlicht et al 2000).
1.6.2 Nomenclature and Classification ofMMPs
To date, around 25 MMPs have been identified in humans and other vertebrates in
addition to several non-vertebrate MMPs. They are generally referred to by their
common name or according to a sequential numeric nomenclature for the vertebrate
MMPs. They can be grouped as to their specific substrates also. These MMPs are
classified in Table 1.3.
1.6.3 Structure ofMMPs
Nearly a decade after collagenolytic activities were first discovered, it was found that
MMPs are synthesised and secreted as inactive zymogens (pro-MMPs) that require
activation (Harper et al 1971). This pro-domain contains a unique sequence, including a
cys, known as the cysteine switch, which ligates the catalytic zinc to maintain the
latency of pro-MMPs (Becker et al 1995, Van Wart & Birkedal-Hansen 1990). There is
a catalytic domain containing a zinc binding motif and a conserved methionine, which
forms a unique 'Met-turn' structure (Bode et al 1993). The domain consists of a five-
stranded (3-sheet, three a-helices and bridging loops (Dhanaraj et al 1996). These
backbones structures, including the Met-turn are similar to those of other
metalloproteinases (Bode et al 1993). The MMPs additionally have a structural zinc ion,
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Collagenases MMP-1 Interstitial 52 (42) Collagens I, II, III, VI, X,
collagenase gelatins
MMP-8 Neutrophil 75 (58) Collagens I, II, III,
collagenase aggrecan
MMP-13 Collagenase-3 60 (48) Collagens I, II, III
MMP-18 Collagenase-4 ?
Gelatinases MMP-2 Gelatinase-A 72 (66) Gelatins, collagens I, IV,
V, VII, X, XI, fibronectin,
laminin, aggrecan, Elastin,
MMP-9 Gelatinase-B 92 (86) Gelatins, collagens IV, V,
XIV, aggrecan, elastin,
Stromelysin MMP-3 Stromelysin-1 57 (45) Aggrecan, gelatins,
fibronectin, laminin,
collagen II, IV, IX, X
MMP-10 Stromelysin-2 57 (44) Aggrecan, fibronectin,
laminin, collagen IV
MMP-11 Stromelysin-3 51(44) Fibronectin, laminin,
collagen IV, aggrecan,
gelatins
Membrane- MMP-14 MT-MMP-1 63 (?) Collagens I, II, III,













MMP-12 Metalloelastase 54 (45/22) Elastin, plasminogen
MMP-19 RASI-1






Table 1.3: MMP classification (adaptedfrom Sternlicht and Werb 2001).
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and two to three calcium ions which are required for the stability and expression of
enzymatic activity. The gelatinases have three-repeats of fibronectin-type II in the
catalytic domain which interact with collagens and gelatin (Allan et al 1995, Steffensen
et al 1995). The catalytic domain shows cleavage specificity through its active site cleft,
through specificity sub-site pockets that bind amino acid residues immediately adjacent
to the scissile peptide bond, and through secondary substrate-binding exosites located
outside the active site itself (Overall 2001). A proline-rich linker peptide joins the
catalytic domain to the C-terminal hemopexin domain. The function of this is not known
although it may adopt a collagen-like conformation which can disturb the quaternary
organisation of the triple-helix in the collagenase-susceptible site (De Souza et al 1996).
The hemopexin domain is essential for collagenases to cleave triple helical interstitial
collagens (Bode 1995) although the catalytic domains alone retain proteolytic activity
towards other substrates (Clark & Cawston 1989). All MMPs have an N-terminal 'pre'
domain that is removed after it directs their synthesis to the endoplasmic reticulum.
Most MMPs are secreted, however, the membrane type MMPs have transmembrane
domains and are expressed as cell surface enzymes. A representation of the domain
structures of different MMP groups is shown in Figure 1.10. The gelatinases, MMP-2
and MMP-9 are distinguished from other MMPs by a fibronectin type II repeat insert
that mediates their ability to bind to and degrade gelatine and other components of the
ECM (Shipley et al 1996). The gelatinases have similar substrate specificities, but differ
in terms of their regulation at many levels.
1.6.4 Regulation ofMMPs
In order for MMPs to carry out their roles, they must be localised to the correct cell type
at the correct time and activated or inhibited suitably. Thus, MMPs are controlled at a
transcriptional and post-transcriptional level and at a protein level via secretion,
activation, inhibition, localisation and their removal (Sternlicht & Werb 1999).
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Figure 1.10: Domain structure of MMPs (adapted from Calbiochem "Extracellular









1.6.4.1 Transcriptional Control ofMMPs
With the exception of MMP-2, which is often constitutively expressed and controlled
through enzyme activation (Strongin et al 1995), and post-transcriptional mRNA
stabilisation (Overall et al 1991), MMPs are closely regulated at the level of
transcription by numerous stimulatory and suppressive factors that influence multiple
signalling pathways. The effectors include growth factors, cytokines, endocrine factors
such as steroids, chemical agents (e.g. phorbol esters which work by activating PKC as
they resemble DAG), extracellular matrix proteins, physical stress and changes in cell
shape (Kheradmand et al 1998). MMP-11 is only transcriptionally activated by retinoic
acid (Guerin et al 1997), or by stromal cell interactions with tumour cells (Ahmad et al
1997).
Activating Protein-1 (AP-1) sites, which bind the Fos and Jun families of transcription
factors, and Polyoma Enhancer A-binding Protein-3 (PEA-3) sites, which bind the Ets
family of transcription factors and are present in the promoters of inducible MMP genes.
These are essential for transcriptional activation. MMP-1 contains adjacent AP-1 and
PEA-3 sites that are proximal to the transcriptional start site, and these sites are required
for activation of the promoter by transforming oncogenes and tumour promoting phorbol
esters (Vincenti et al 1998). The proximal AP-1 site contributes to basal MMP-1
transcription, whereas a second AP-1 site, located further 5' in the promoter, mediates
transcriptional induction by phorbol esters (White & Brinckerhoff 1995). Other
transcription factors often contribute, particularly in response to growth factors and
cytokines. II^l transactivates the rabbit MMP-1 promoter through an NF-kB binding
site near the transcription start site, which cooperates with the proximal AP-1 site. This
cooperativity between NF-kB and AP-1 also activates the MMP-9 promoter in response
to TNF-a (Sato & Seiki 1993) or IL-1 (Yokoo & Kitamura 1996).
1.6.4.2 Post Transcriptional Regulation ofMMPs
Post transcriptional mechanisms are also a means by which regulation of many MMPs
occurs. It has been suggested that multiple transcripts of MMP-13, MMP-17 and MMP-
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20 probably result from alternative polyadenylation (Bartlett et al 1996, Freije et al
1994, Puente et al 1996). Also, a soluble and proteolytically active form of MT3-MMP
(SM3) is generated by alternative splicing (Matsumoto et al 1997a). MMP-1 and MMP-
3 mRNA are stabilised by phorbol esters and EGF, and MMP-13 transcripts are
stabilised by PDGF and glucocorticoids and destabilised by TGF-|3 (Delany et al 1995,
Vincenti 2001). AU-rich sequences are also required for regulated decay of MMP-1
transcripts (Vincenti 2001).
1.6.4.3 Secretion ofMMPs
Once translated, most MMPs are constitutively secreted, however some regulation does
occur at this level. MMP-8 and MMP-9 are synthesised by differentiating granulocytes
in the bone marrow, stored in the specific and gelatinase (tertiary) granules or circulating
neutrophils, respectively, and released following neutrophil activation by inflammatory
mediators (Hasty et al 1990). In macrophages, post-translational release of MMP-12
occurs in response to PKC activation downstream of a G-protein-coupled thrombin
receptor. This becomes activated after binding a ligand that is generated by its own N-
terminal thrombin-dependent cleavage (Raza et al 2000).
1.6.4.4 Localisation ofMMPs
Expression of some MMP genes is cell specific. For example, three interstitial
collagenases, MMP-1, MMP-8 and MMP-13 have similar substrate specificities in that
they all degrade collagens I, II, and III. However, their cellular expression is different,
suggesting that they play distinct roles in tissue remodelling. MMP-1 is most broadly
expressed, and can be induced in fibroblasts, chondrocytes, macrophages, endothelial
cells and keratinocytes (Vincenti et al 1996). MMP-8 is stored in neutrophils as granules
that are released upon cellular activation. MMP-13 was first cloned from human breast
carcinomas (Freije et al 1994) and has since been shown to be expressed in other
carcinomas (Johansson et al 1997).
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Localisation of MMP protein within the cell is also important. It appears that cell surface
localisation can control the activity of the MMP. The mechanisms for localising MMPs
to the cell surface and to specific cell surface subdomains include the expression of
membrane-bound MMPs, binding of MMPs to cell surface receptors, presence of cell
surface receptors for MMP-activating enzymes such as uPA, plasminogen, thrombin and
elastase, and the concentration of MMPs on pericellular ECM molecules. This
localisation can enhance MMP activation, limit access of MMP inhibitors, concentrate
MMPs within the vicinity of their targets, and limit the extent of proteolysis to discrete
pericellular regions (Sternlicht & Werb 2001). Cell surface docking is also important in
providing a mechanism to tether MMP activity to the regions of physical contact
between the cell and ECM, where ECM remodelling occurs. This provides a means to
control ECM degradation (Stamenkovic 2003). The localisation of the MMPs within the
ECM is also important.
1.6.4.5 Activation ofMMPs
Like other proteolytic enzymes, most MMPs are synthesised as inactive pro-enzymes.
The cysteine sulph-hydryl group in the propeptide domain acts as a fourth ligand for the
active site zinc ion, and activation requires that this cysteine switch be opened by normal
proteolytic removal of the pro-peptide domain, or by ectopic perturbation of the
cysteine-zinc interaction (Van Wart & Birkedal-Hansen 1990). Once displaced, the thiol
group is replaced by a water molecule that can then attack the peptide bonds of MMP
targets (Figure 1.11a). Secreted pro-MMPs can be activated in-vitro by proteinases and
by non-proteolytic agents such as SH-reactive agents, mercurial compounds, reactive
oxygen and denaturants. In vivo, most pro-MMPs are likely to be activated by plasma
proteinases or opportunistic bacterial proteinases.
Some MMP members are not secreted as inactive zymogens, including MMP-11, MMP-
27 and MT-MMPs. They contain a furin-like enzyme recognition motif between their
propeptide and catalytic domains. This allows them to be activated by intracellular
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Figure 1.11: (a) General activation ofmost latent MMPs. The latency of the proMMP is
maintained by an unpaired cysteine sulphhydryl group in the propeptide domain. The
sulphydryl group acts as a fourth ligand for the zinc in the catalytic domain. During
activation, this cysteine is displacedfrom the complex with removal of the propeptide
domain and is replaced by a water group, (b) Activation of latent MMP-2. A membrane
type MMP (MT-MMP) is inhibited by a tissue inhibitor ofmetalloproteinases (T1MP-2).
The hemopexin domain ofproMMP-2 then binds to the C-terminal portion of TIMP-2.
An uninhibitedMT-MMP then removes the propeptide domain. C = catalytic domain, PI
= hemopexin domain, P = propeptide domain, T = transmembrane domain. Figures
adaptedfrom Visse & Nagase 2003.
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(Pei & Weiss 1995). MMP-23, which lacks the cysteine switch of other MMPs which is
required for latency (Gururajan et al 1998), has a furin-susceptible cleavage site and is a
likely target of intracellular proprotein convertases. All other MMPs lack a furin-
susceptible insert and are thus activated outside the cell following secretion.
Activation of most MMPs can be initiated by already active MMPs or by serine
proteases which cleave peptide bonds within MMP pro-domains (Stemlicht & Werb
2001). Activation of MMP-2 is different (Figure 1.11b). It is activated at the cell surface
in a process involving MT-MMPs and TTMP-2 (Strongin et al 1995). During this
process, an active MT-MMP is inhibited by TIMP-2. The hemopexin domain of pro-
MMP-2 then binds to the C-terminal portion of TIMP-2 to form a tri-molecular
complex. A free, uninhibited MT-MMP then partially activates the pro-MMP-2 by
removing most of the propeptide. The remaining portion of propeptide is removed by a
separate MMP-2 molecule at the cell surface, giving fully active MMP-2. This can then
be released from the cell surface, or bind to another MMP-2 docking protein. It seems
that MT1-MMP is an efficient activator of MMP-2, whereas MT2-MMP and MT4-
MMP cannot activate MMP-2 (Stemlicht & Werb 2001).
1.6.4.6 Inhibition of MMPs
1.6.4.6.1 Tissue Inhibitors ofMetalloproteinases (TIMPs)
The activity of secreted MMPs is restricted by endogenous tissue inhibitors of
metalloproteinases (TIMPs). The TIMPs consist of at least 4 members which have been
identified in vertebrates to date (Gomez et al 1997) as shown in Table 1.4.
The TIMPs share between 37 and 51 % sequence homology and a conserved gene
structure. They have an N- and C-terminal domain of about 125 and 65 amino acids
respectively, each one containing three disulfide bonds (Murphy et al 1991, Williamson
et al 1990). The N-terminal domain folds into a separate unit and interacts with the
MMP catalytic site (Murphy et al 1991, Murphy & Willenbrock 1995). Mutational
analysis (Huang et al 1997, O'Shea et al 1992, Willenbrock & Murphy 1994) and
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TIMP Mass Extracellular Reported function
(kDa) location
TIMP-1 30 Soluble in ECM Inhibits all known MMPs, associates with pro-
and body fluids MMP-9, inhibits angiogenesis
TIMP-2 21/28 Soluble in ECM Inhibits all known MMPs, associates with MT1-
and body fluids MMP and MMP-2 at cell surface, regulates
MMP-2 activation
TIMP-3 24 (28) Bound to ECM Inhibits all known MMPs. Mutation linked with
Sorsby's fundus dystrophy
TIMP-4 29 Inhibits all known MMPs. Restricted expression
suggests tissue specific TIMP function
Table 1.4: TIMPs: classification, molecular weights and role in theECM.
peptide and anti-body blocking experiments (Bodden et al 1994) have helped to identify
which regions of the N-terminal are involved in MMP inhibition. Analysis by NMR first
identified the N-terminal domain structure of TIMP (Williamson et al 1994), then X-ray
crystallographic studies of TTMP-l-MMP-3 complexes (Gomis-Ruth et al 1997) and
TIMP-2-MT1-MMP (Fernandez-Catalan et al 1998) revealed the inhibition mechanism.
The TIMP molecule slots into the active cleft of an MMP molecule, much like a
substrate would. The TIMP and MMP bind with a 1:1 stochiometry and kinetic
experiments indicate that interactions first form a reversible intermediate complex,
followed by rearrangement to a stable inhibitory complex (Hutton et al 1998). Although
most inhibitory activity is in the N-terminal, both domains influence enzyme-inhibitor
binding (Willenbrock & Murphy 1994). The C-terminal domain of TIMP-1, for
example, binds more favourably to the hemopexin domain of MMP-9 than that ofMMP-
2, whereas the C-terminal of TTMP-2 prefers to bind the hemopexin domain of MMP-2
(Morgunova et al 2002, Murphy & Willenbrock 1995).
The high level of sequence divergence between the four TIMPs suggests that they
probably have different functional properties. Although they all bind tightly to most
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MMPs (Murphy & Willenbrock 1995), inhibitory abilities are variable. TIMP-2 and
TIMP-3 are good inhibitors of the MT-MMPs while TIMP-1 is not, and TIMP-3, but not
the others, is a good inhibitor of TNF-a converting enzyme (Amour et al 1998), and
other members of the ADAM family (a disintegrin and metalloproteinase) (Amour et al
2000, Kashiwagi et al 2001, Loechel et al 2000). TIMPs also vary in their patterns of
gene regulation and tissue distributions.
1.6.4.6.2 Other Endogenous Inhibitors
Another class of MMP inhibitors, the protein subdomains, have structural similarity to
the TIMPs. Proteolytic processing of the procollagen C-terminal proteinase enhancer
protein, PCPE, releases a C-terminal fragment (CT-PCPE) that has structural similarity
and MMP inhibitory activity to the N-terminal domain of the TIMPs (Mott et al 2000).
There are also sequence similarities between TIMPs and the noncollagenous C-terminal
domain of type IV collagen and functional analysis shows that this also has MMP
inhibitory activity (Netzer et al 1998) and can inhibit tumour growth and angiogenesis
(Petitclerc et al 2000). It is unclear whether MMPs are the main target of these domains,
despite CT-PCPE having a much higher inhibiting affinity for MMP than TIMP-2 (Mott
et al 2000).
1.6.4.7 Catabolism and Clearance
Although much progress has been made in understanding proteolytic processing of pro-
MMPs, relatively little is known about the further proteolysis of active MMPs. Some
cleavages inactivate MMPs, whereas others, for example a cleavage to specifically
remove the C-terminal, hemopexin domain can generate a truncated form of the enzyme,
which loses its ability to act on some substrates but not others. This can diminish their
affinity and ability to be inhibited by TIMPs (Itoh et al 1998). Removal of the
hemopexin domain also removes the ability of some MMPs to localise to the cell
surface. MT-MMPs can be secreted if they are cleaved at a juxtamembrane site before or
after they reach the cell surface (Imai et al 1996). So, factors which influence MMP
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degradation also alter the steady-state concentrations of MMPs, their substrate
specificities, their localisation and their ability to be activated and inactivated.
MMPs can also be regulated by direct clearance of intact enzymes. Most MMPs cleave
a2-macroglobulin, initiating a conformational change in it that irreversibly traps the
enzyme (Sottrup-Jensen & Birkedal-Hansen 1989). This physical entrapment keeps the
enzyme from acting on its substrates and eventually the complex of a2-macroglobulin
and the MMP is endocytosed and permanently cleaved.
1.6.5 Role of MMPs in Tissue Remodelling of the ECM During Pregnancy and
Parturition
MMPs play a key part in tissue remodelling of extracellular matrix of uterine and
gestational tissues throughout pregnancy and parturition. As discussed previously, they
are involved in tissue remodelling of the cervix during cervical ripening and dilation,
and rupture of the fetal membranes. A summary of the role of MMPs in tissue
remodelling and rupture of the membranes is shown in Figure 1.12. It is suggested that
an inflammatory cascade causes the ratio of MMP:TIMPs to increase by a combination
of MMP levels increasing, and TIMP levels decreasing. This increases degradation of
collagen, weakening the fetal membranes, leading to eventual rupture. MMPs are also
involved in tissue remodelling at the implantation stage of pregnancy, and establishment
of the placenta.
1.6.6 Roles ofMMPs in Other Biological Systems
MMPs are able to regulate numerous biological processes besides their effects in the
reproductive system. They may promote the initial stages of cancer development, but
may also decrease the severity of the ultimate malignancy (Coussens et al 2000, Pozzi et
al 2000). In arthritis, the loss of certain MMPs aggravates, rather than alleviates the
disease (Mudgett et al 1998). MMP-9 has also been implicated in p-amyloid degradation











Figure 1.12: Role ofMMPs and their inhibitors, TIMPs in tissue remodelling of the fetal
membranes and their contribution to rupture of the membranes.
1.7 Aims and Hypothesis
It is well known that the prostaglandins PGE2 and PGF2a play a role in many aspects of
labour. Previous studies have localised the enzymes involved in prostaglandin synthesis
and catabolism within intrauterine and gestational tissue. So far, receptors for PGE2 and
PGF2a have been identified in the human myometrium, and the decidua of the baboon.
There are no published reports of these receptors being localised in the fetal membranes,
decidua or placenta in the human. In this thesis, the presence and localisation of the EP2,
EP4 and FP receptors within these tissues will be investigated. Furthermore, samples
will be examined from preterm and term samples, in both spontaneous labour and non-























The signalling pathways via the EP2, EP4 and FP receptors have been well characterised
in other tissues, including the endometrium. EP2 and EP4 are coupled to stimulatory G-
proteins and activation causes elevation in cAMP levels and activation of the PKA
pathway. The FP receptor is coupled to a Gaq receptor and activation of this can elevate
IP3 levels via activation of phospholipase C, intracellular calcium flux and activation of
protein kinase A. EP2, EP4 and FP receptors are also linked to Ras and activation of the
MAP kinase pathway. This thesis deals with activation of the EP2, EP4 and FP receptors
within the human amnion and chorio-decidua and the intracellular pathways which are
stimulated. Specifically, the cAMP pathway, the MAPK pathway and the IP3 pathway
will be investigated. The JEG3 choriocarcinoma cell-line will also be used as a model of
chorion trophoblast cells to investigate specific intracellular signalling within these cells.
Activation of intracellular signalling pathways can influence transcription of certain
genes within the nucleus. Previous studies have shown that PGE2 and PGF2a can elevate
MMP-2 and MMP-9 levels, and activation of MMP-2 within the human fetal membranes
(McLaren et al 2000b, Ulug et al 2001). In this thesis, these findings of other research
groups will be further investigated. Furthermore, the JEG3 cell-line will be used as a
model of chorion trophoblast cells to investigate the effects of PGE2, PGF2a and IL-6, on
MMP-2 and MMP-9 production and activation.
The aims of this thesis therefore are to:
a) characterise the distribution of prostaglandin receptors in human uterine and
gestational tissue and investigate the effect of labour at term and preterm on this
distribution.
b) investigate the signalling pathways by which prostaglandins act via these
receptors.
c) examine the effects of prostaglandins on production and activation of MMPs.
The experimental work in this thesis aims to examine the hypothesis that EP2, EP4 and
FP receptors are located in the human fetal membranes and binding of PGE2 and PGF2a
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can activate intracellular signalling pathways by elevating cAMP, IP3 and MAPK. levels.
These influence events further downstream causing increases in transcription of the
genes for MMP-2 and MMP-9 {Figure 1.13). The resulting increase in MMP levels
contributes to rupture of the fetal membranes, thus demonstrating that PGE2 and PGF2a


















Figure 1.13: Hypothesised model for PGE2 and PGF2a actions in the fetal membranes.
PG; prostaglandin, cAMP; adenosine-35'-cyclic monophosphate, IP3; inositol






2.1.1 Fetal Membranes and Placental Tissue for Explants
Fetal membranes and placenta were collected from women with uncomplicated
pregnancies at term not in labour immediately after elective caesarean section. Tissue
was collected in DPBS containing 10 U/ml heparin. Women with clinical evidence of
infection, multiple pregnancy, dysfunctional labour, or women who had received
prostaglandin or artificial oxytocin were excluded. Collection of tissue was approved by
the Lothian Research Ethics Committee (LREC; LREC no. 2002/6/27). Written,
informed consent was obtained from all patients prior to tissue collection.
2.1.2 Tissue for Immunohistochemistry
At the time of delivery, the following tissues were collected from elective caesarean
sections and emergency caesarean sections during active labour (defined as a cervical
dilation of over 4 cm) for failure to progress: a cross-section of placenta from placental
plate to decidua basalis from a centrally located cotyledon; decidua parietalis from the
uterine aspect of the fundus; fundal myometrium; and fetal membranes from the fundal
region remote from the placental edge. A clip was attached to the membranes overlying
the internal os of the cervix allowing for orientation. Tissues were fixed in 10 % neutral-
buffered formalin (appendix 1.1.1) for 24 hours, washed in 70 % ethanol, followed by
100 % ethanol, before being embedded in paraffin.
2.2 Tissue Culture
2.2.1 Amnion, Chorio-decidua and Placenta Explant Culture Methods
Fetal membranes and placenta collected after delivery were washed 5 times with DPBS.
The amnion and chorion were then separated and these and the placenta steeped in
steeping buffer (appendix 1.1.2) for 30 min at room temperature. These were then
washed 5 times with DPBS. Discs of amnion (8 mm diameter) and chorio-decidua (6
mm diameter) were cut using a cork borer. Pieces of villous placental tissue were
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dissected from the middle central cotyledon (wet weight 30-50 mg). Explants were
placed on absorbent capillary matting in a 24-well plate and maintained in complete
serum-free RPMI 1640 (appendix 1.1.3) for 24 hours at 37 °C in 95 % water-saturated
air-5 % CO2 atmosphere. Culture media was harvested and frozen at -20 °C until
analysis.
2.3 Cell Culture
The JEG3 choriocarcinoma cell line (Figure 2.1) is one of 6 clones derived from human
cells implanted into a hamster cheek pouch and propagated on irradiated feeder layers of
human fibroblasts (Kohler & Bridson 1971). This cell-line secretes chorionic
gonadotrophin, somatomammotrophin (placental lactogen) and progesterone. It is also
able to transform steroid precursors to oestrone and oestradiol. There are no publications
involving the expression and function of prostaglandin receptors EP and FP in this cell
line. However, it has been shown that the receptor for 15-deoxy-A12'14-PGJ2, peroxisome
proliferator activated receptor-y (PPARy) is expressed and functionally active in these
cells (Marvin et al 2000). MMP-26 and TIMP-4 have been detected in these cells (Zhang
et al 2002) and also MMP-2 and MMP-9 (Mandl et al 2002). The MAPK pathway has
been investigated and found to be activated by fibronectin and vascular endothelial
growth factor (VEGF) in these cells (Zhang et al 2003). It is considered therefore that
these cells are a good model to investigate trophoblast cell function.
The JEG3 cell-line was maintained in complete DMEM with serum (appendix 1.1.4) in a
75 cm3 flask and split 1 in 4 twice a week when the cells had reached confluence. Old
medium was aspirated from the flask, the cells washed twice with 10 ml DPBS, then 1.5
ml of 0.5x trypsin/EDTA was added. When the cells became detached from the flask
wall, 15 ml DMEM containing serum was added to quench the action of trypsin. Cells
were then diluted 1 in 4 and put back in flasks to grow and maintain a stock. At this
stage, cells could also be counted and plated out for use in experiments. Cells were
counted using a haemocytometer, using trypan blue (appendix 1.1.5) to check the
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viability of the cells. They were then diluted accordingly and plated out at a
concentration of 2 x 105 cells/ml.
haematoxylin
cytokeratin
Figure 2.1: Image ofJEG-2 cells visualized with haematoxylin and cytokeratin. Positive
cytokeratin staining shows that the cells are ofepithelial origin. Both photomicrographs




Immunohistochemistry involves localisation of an antigen within tissue or cells by a
specific primary antibody. Here we used the standard avidin-biotin peroxidase (ABC) to
visualise specific staining (Figure 2.2). Primary antibody binds to the target antigen
within the sample. A biotinylated secondary antibody, which is specific to the species
the primary antibody was raised in, is then added which binds to the primary antibody.
Addition of an avidin-biotin and horseradish-peroxidase complex results in any free sites
on the avidin molecule binding to the biotin on the secondary antibody. When 3,3-
diaminobenzidine (DAB) is added, it becomes oxidised. The resulting colour change of
the chromagen causes an insoluble brown precipitate to form at the site of the protein of
interest.
Non-specific staining may occur due to a variety of reasons. The primary antibody may
bind non-specifically to other epitopes. If this is the case, the results can be compared to
those obtained for Western Blotting to ensure they are valid. Tissues may contain
endogenous peroxidase activity which can catalyse the DAB, causing brown staining to
appear at the site of this endogenous activity. To counteract this, a weak solution of
hydrogen peroxide was added to saturate any endogenous peroxidase, rendering it
inactive. The secondary antibody may too be non-specific. This can cause it to bind to
epitopes in the tissue mimicking those from species it was raised against, as well as the
primary antibody. To stop this, normal serum from the species from which the secondary
antibody was raised was added prior to addition of the primary antibody.
Inability of an antibody to detect a specific epitope must also be recognised as a
potential problem when using this technique. The appropriate concentrations of primary
antibody must be determined, and also the detection system validated. The epitope may
be masked, for instance, by fixation. Different fixatives may be tested, and also antigen
retrieval methods, for example boiling/microwaving sections or pre-treating with a
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Figure 2.2: Immunohistochemistiy using ABC and DAB detection. After blocking, the
primary antibody binds to a specific antigen in the tissue/cell. The biotinylated
secondary antibody then binds to this. A complex of peroxidase labelled avidin and
biotin will then bind to the biotin on the secondary antibody with its' vacant sites. When
DAB is added, the peroxidase enzyme causes a reaction which leaves a brown
precipitate at the site ofthe antigen.
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2.4.1 Cultured Cell Immunohistochemistry
Cultured cells were fixed for 30 min in 10 % NBF at room temperature then stored in 70
% ethanol until use. Fixed cells were re-hydrated in 50 % EtOH for 2 min then washed
in 1 % Triton-X-100 for 10 min. Plates were then washed in PBS (appendix 1.2.1) 3
times for 2 min then endogenous peroxidase activity blocked with 3 % H2O2 for 30 min.
The cells were washed in PBS twice for 5 min and H20 for 2 min before adding
haematoxylin (a blue non-specific nuclear stain) for 1 min. Scott's solution (appendix
1.2.2), which assists in colour development, was added for 1 min, followed by washing
in PBS twice for 2 min. The cells were blocked in 10 % goat serum (appendix 1.2.3) for
20 min then primary antibody added for 2 hours at 4 °C. This was followed by washing
in PBS twice for 2 min then the secondary antibody added for 1 hour. After another 2
washes in PBS for 2 min ABC reagent (appendix 1.2.4) was added for 1 hour. Then cells
were washed in PBS twice for 2 min then specific staining detected by DAB (appendix
1.2.5) for 4 min before being rinsed and left in tap water.
2.4.2 Immunohistochemistry on Tissue Sections
2.4.2.1 Slide Coating in 3-aminopropylmethoxy-silane (AAS)
Slides were coated with AAS in order for tissue sections to adhere to the slides. A rack
of blank slides was dipped in 2 % AAS in acetone 30 times then washed in 3 changes of
distilled water, 10 dips each. The slides were then left to dry in an incubator overnight.
2.4.2.2 Block Cutting
Blocks of fixed tissue were placed face down on an ice block for 30 min prior to cutting
as paraffin blocks section best when cool and moist. They were cut using a microtome
set to a thickness of 5 pm. When a ribbon of sections was cut it was transferred to a
water bath at 37 °C to flatten out the sections, which were then separated and mounted
on an AAS coated slide. The slides were incubated at 37 °C overnight.
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2.4.2.3 Immunohistochemical Procedure for Formalin Fixed Tissue
Slides were de-waxed in histoclear (2x5 min) and re-hydrated in graded ethanol (100 %
EtOH 20 s, 100 % EtOH 20 s, 95 % EtOH 20 s, 70 % EtOH 20 s, rinse in water).
Antigen retrieval was carried out by boiling the slides in 2 1 of citrate buffer (appendix
1.2.6) in a pressure cooker for 2 min at full pressure. The slides were then blocked in 3
% H2O2 for 20 min to block endogenous peroxidase activity, then rinsed in tap water and
washed in TBS (appendix 1.2.7)(2 x 5 min). The sections were then drawn around with a
wax pen (to contain fluid) and blocked in goat serum (appendix 1.2.3) for 30 min. The
slides were then drained and excess block wiped off, before adding the primary antibody
(100 pi per section) for an overnight incubation at 4 °C. The slides were then washed in
TBS (2x5 min) and wiped then the secondary antibody added (100 pi per section) for
30 min. Slides were again washed in TBS (2x5 min) and wiped before adding ABC
(appendix 1.2.4) for 30 min. Slides were washed in TBS (2x5 min) and wiped. The
positive staining was then detected by application of the peroxidase substrate, DAB
(appendix 1.2.5), which produces a brown stain. Colour development was monitored
microscopically and stopped by washing in H2O. Cells were lightly counterstained in
haematoxylin for approximately 8 min, washed in H20 then dipped very briefly in acid-
alcohol and rinsed immediately in H20. The slides were then dipped in Scott's solution
(appendix 1.2.2) to develop the blue colour and washed in H2O before being dehydrated
in graded ethanol (70 % EtOH 20 s, 95 % EtOH 20 s, 100 % EtOH 20 s, 100 % EtOH 20
s, histoclear 5 min, xylene 5 min) then mounted with coverslips using Pertex.
2.4.2.4 Haematoxylin and Eosin stain (H and E)
Tissue sections were de-waxed and re-hydrated as above then rinsed in tap water prior to
haematoxylin staining for 5 min. Then slides were rinsed briefly in acid-alcohol, Scott's
solution then Eosin for 20 s with a tap water rinse between each stage. Sections were
then dehydrated as above and Pertex mounted.
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2.5 Messenger RNA Extraction and Reverse Transcription
Polymerase Chain Reaction (RT-PCR)
Polymerase chain reaction (PCR) was the first practical system for in vitro amplification
of DNA, invented by Kary Mullis in 1983 (Mullis et al 1986, Shampo & Kyle 2002).
Two synthetic oligonucleotide primers, which are complementary to two regions of the
target DNA to be amplified (one for each strand), are added to the target DNA in the
presence of excess nucleotides and Taq polymerase, a heat stable DNA polymerase. In a
series of cycles, the target DNA is repeatedly denatured (around 90 °C), annealed to the
primers (around 60 °C) and a new strand extended from the primers (72 °C). The new
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Figure 2.3: DNA amplification by PCR. Each cycle consists ofDNA separation, primer
annealing and DNA synthesis.
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2.5.1 Messenger RNA extraction
For cell extraction, medium was pipetted off the cultured cells, which were then washed
in DPBS. Cells from 4 wells (identically treated) of a 24 well culture plate were
combined in 1 ml tri-reagent, a guanidine thiocyanate based reagent (Chomczynski &
Sacchi 1987). This was passed several times through a pipette to form a homogenous
lysate before being transferred to 1.5 ml nuclease-free tubes and kept on ice for the
remainder of the procedure. Tissue samples were either collected directly into tri-reagent
(1 ml for 50-100 mg tissue) or cultured samples were washed twice in DPBS then added
into tri-reagent. This was homogenised for 1 min to break up the tissue. To each 1 ml of
tri-reagent from tissue or cells, 200 pi of chloroform was added and the tubes shaken
vigorously for 15 seconds, then left to stand for 10 minutes before being centrifuged in a
biofuge at 4 °C, 10,000 g for 20 min. This removed the pink organic phase containing
protein and a white layer of DNA that became trapped beneath the gel layer. The top
colourless, aqueous phase, containing RNA was pipetted into 1.5 ml eppendorf tubes. To
each sample, 500 pi of isopropanol was added and tubes were inverted several times
then left on ice for 1 hr. Samples were then centrifuged at 4°C, 10, 000 g for 15 minutes
to precipitate out an RNA pellet. The isopropanol was pipetted off and 70 % ethanol
(prepared with nuclease-free water) added to each eppendorf. After a brief, gentle
vortex, the samples were centrifuged at 4°C, 10,000 g for 10 min. The ethanol was
removed from each tube, then the tubes left open for 10 min to dry. The pellets were
then suspended in 10 pi nuclease-free water.
The concentration of total RNA in the sample was then determined by spectroscopy
using GeneQuant Pro. This machine automatically calculates the concentration (A260)
and quality (A28o/26o) of RNA. If RNA is free of DNA the (A28o/26o) ratio should be > 1.7.
All samples were then diluted using nuclease-free water to a concentration of 1 pg/pl. If





To remove contaminating genomic DNA from the extraction process, messenger RNA
samples were DNAse treated in a 10 pi reaction consisting of 1 pi mRNA (of 1 pg/pl
stock), 1 pi deoxyribonuclease (1 U/pl stock), 0.1 pi RNAse inhibitor (20 U/pl stock), 1
pi lOx buffer, 6.9 pi nuclease-free water. This reaction mixture was incubated at 37 °C
for 30 min, 1 pi stop solution added then incubated for a further 10 min at 70 °C. DNAse
treated RNA was then stored at -70 °C.
2.5.3 Reverse Transcription of RNA
In order to obtain cDNA to assess specific genes of interest, DNAse treated mRNA
samples were reverse transcribed in a 20 pi reaction mix consisting of 2 pi mRNA (0.1
pg/pl DNase-treated stock), 2 pi dNTP's (10 mM stock), 1 pi RNAse inhibitor (40 U/pl
stock), 1 pi reverse transcriptase (50 U/pl stock), 1 pi random hexamers (5 pM stock),
2.4 pi MgCl2 (25 mM stock), 2 pi lOx buffer and 8.6 pi nuclease-free water. Samples
were incubated at room temperature for 10 min, 42 °C for 60 min then 95 °C for 10 min.
The cDNA was then stored at - 20 °C. A sample with nuclease-free water in place of
mRNA was prepared to use as a negative control for reverse transcription (RT).
2.5.4 RT-PCR
cDNA samples were tested for a house keeping gene, glucose-6 phosphate
dehydrogenase (G-6-PDH) to check the extraction and RT stage had been successful.
This is a suitable house-keeping gene as it is constitutively expressed and does not vary
with the added treatments. The RT negative control was included in the PCR, in the case
of any contamination, to aid the isolation of the source. A PCR negative was also
included in each run, with nuclease-free water in place of cDNA. Amplified PCR
products were run on a 1.5 % agarose gel (appendix 2.4/section 2.7.2.6) containing
ethidium bromide and visualised and photographed under UV light. A 100 bp DNA
ladder was also run to show product size. If no contamination was apparent, cDNA
samples were then amplified for the gene of interest. Primers were designed to amplify a
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region of the gene. Each 10 pi PCR mix consisted of the following: 1 pi lOx buffer, 0.6
pi MgCl2 (25 mM stock), 0.2 pi dNTPs (10 mM stock), 1 [xl each of forward and reverse
primers (5 pM stock), 4.7 pL nuclease-free water, 0.5 pi Taq DNA polymerase (5U/pl)
and 1 pi cDNA. The samples were optimised for annealing temperature using a gradient
PCR machine, and also MgCl2 concentration (the above shows 1.5 mM MgCl2, this can
be adjusted along with nuclease-free water to change the concentration). The samples





95 °C 5 min
95 °C 30 s
62 °C 30 s
72 °C 1 min 30 s
72 °C 10 min
2.5.5 Quantitative PCR using the Lightcycler
The Lightcycler (Roche) was used to amplify and quantify cDNA in a cyclic process of
DNA denaturation, specific primer annealing and primer extension to exponentially
increase the primer specified DNA fragment. cDNA sequences for target genes were
obtained from Genebank and primers were designed against a segment of sequence that
displayed low homology with other genes of the same family and where possible,
spanning an intron. This allowed identification of genomic contamination. If genomic
DNA remains in the sample even after DNAse treatment, 2 peaks with different melt
curves would be produced when using melt curve analysis, or 2 bands would be visible
on an agarose gel.
Real time quantification of this process allows cDNA synthesised after each PCR step to
be visualised by fluorescence of SYBR Green 1. This is a DNA binding dye, which by
binding to the minor groove of double stranded DNA, greatly enhances its fluorescence.
During the stages of PCR, different intensities of fluorescence are detected depending on
the amount of double stranded DNA present. After denaturation, all DNA present is
85
Chapter 2
single-stranded, hence no SYBR Green 1 is bound giving a low signal. During
annealing, primers hybridise to the target sequence resulting in small amounts of SYBR
Green 1 binding and a low fluorescence. During elongation as the primers are extended,
more SYBR Green 1 becomes bound hence an increase in the signal. At the end of
elongation, all DNA is double stranded and the maximum amount of dye is bound. The
fluorescence (530 nm) is recorded at this stage and increasing amounts of PCR product
can be monitored from cycle to cycle (Figure 2.4).
The quantification is based on calculations taking into account a housekeeping gene and
the gene of interest. Choice of the house-keeping gene is critical. It must be quantifiable
over the same range as the gene of interest and be amplified with the similar efficiency.
It must be constitutively expressed, being equal in all samples and not variable with
treatment, and optimally synthesised at the same primer annealing temperature as the
gene of interest, and with the same MgCl2 concentration. The primer annealing
temperature was optimised using a gradient PCR machine, and the MgCL concentration
optimised on the Lightcycler. MgCl2 is present in the SYBR Green1 master mix used for
reactions at a concentration of 1 mM, so additional MgCl2 can be added to optimise.
Each 10 pi reaction mix contains the following: 1 pi SYBR Greenl mastermix, 5.4 pi
nuclease free water, 0.5 pi each forward and reverse primers, 1.6 pi MgCl2 (of 25 mM
stock - this volume and water volume vary according to optimum MgCl2 concentration),
and 1 pi cDNA. The samples are run on the Lightcycler using a programme set up as
shown:
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At the start, the reaction mixture consists of
denatured DNA, primers, and dye. The
unbound dye fluoresces weakly, producing a
small background signal which is subtracted
during computer analysis
After annealing of the primers, some dye
molecules can bind to the double strand. This
increases the fluorescence of the sample.
During elongation, more and more dye
molecules bind to the newly synthesised DNA.
Monitoring the reaction continuously thus
shows real time increases in fluorescence.
Upon denaturation of the DNA for the next
heating cycle, the dye molecules are released
and the fluorescence signal falls.
Figure 2.4: Diagrams to show the binding ofSYBR Green dye throughout the stages of
PGR using the Lightcycler. Diagrams from www.lightcycler-online.com.
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Programme:
Stage 1: 95 °C 10 min
Stage 2: 95 °C 15 s
(45 cycles) 61 °C 5 s (annealing temperature is optimised for gene)
72 °C 15 s
87 °C 1 reading (measurement temperature is optimised for gene)
Stage 3: 95 °C 0
50 °C 15 s
50 -99 °C 0.1 °C/s
Cool: 40 °C 30 s
In order to identify a temperature to measure the fluorescence of specific product only,
avoiding non-specific double stranded DNA, for example primer dimers, melt curve data
was analysed (Figure 2.5a). The samples are cooled then gradually reheated with
constant fluorescence readings. The graph of fluorescence against temperature shows a
sharp drop in fluorescence when the specific DNA is denatured. There is also, at a lower
temperature, another drop in fluorescence as primer dimer pairs (if present) are
denatured. The temperature selected is between these 2 temperatures, so primer dimers
have denatured, but the DNA of interest will remain double stranded.
Relative quantification of specific DNA involves normalisation to a known relative
concentration of serially diluted standards. This should be reverse transcribed at the
same time as samples to reduce reverse transcription variation. The samples should be in
the same range as the standard curve, in which a graph of the cycle number versus the
log of concentration should have a gradient of approximately -3.3 (Figure 2.5b). To
reduce reaction variation, a master mix of reagents should be prepared and samples run
in duplicate. In each run on the Lightcycler, which is capable of holding 32 capillaries, 5
controls for the gene of interest and 5 controls for a house keeping gene are included.
This leaves space to run 5 samples in duplicate for the gene of interest and the
housekeeping gene. Results are given as a ratio of the gene of interest to the
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Figure 2.5: Graphs from Lightcycler. (a) Melt curve analysis. A primer dimer can be
seen in the negative control. It can be seen that the best temperature to take a
measurement in this case is 86 °C. (b) A standard curve is produced for each gene using
control standards. An ideal slope for this curve is -3.3. Here, the slope is -3.361. From





This protocol has been adapted from the original Lowry assay method (Lowry et al
1951). Standards were prepared using BSA diluted in distilled water. The standards
ranged from 5mg/ml to 0.078 mg/ml and 20 pi of each standard was used to give a
working range of 100 pg to 1.56 pg protein. 20 pi of each standard or sample (diluted in
water as required) was added to a 96 well plate followed by 100 pi solution A (appendix
1.4.1.5) to all wells. This was mixed on a plate shaker at room temperature for 10 min
before adding 10 pi Folin and Ciocalteu's Reagent (appendix 1.4.1.6) and mixed on the
plate shaker for a further 30 min before being read at 650 nm using the Softmax
programme. The Softmax programme will draw a standard curve according to
densitometric readings of the standards then calculate values for unknown samples using
this standard curve. A sample protein assay standard curve is shown (Figure 2.6a).
2.6.2 PGE2 Assay - Competitive ELISA
The PGE2 assay is an example of a competitive enzyme-linked immunosorbent assay
(ELISA). A competitive ELISA makes it possible to obtain an estimate of the amount of
a particular antibody or antigen, even when these cannot be isolated from the medium in
which they are found. Here, a plate is coated with purified donkey anti-rabbit IgG and
then blocked to remove non-specific binding (Figure 2.7). The sample containing the
substance to be measured is then added with anti-sera and a link (biotinylated PGE2).
The anti-serum, rabbit anti-PGE2, will bind to epitopes coating the wells. The anti-serum
can also recognise identical epitopes in the sample and in the link. If the sample being
measured contains a high concentration of the PGE2, then the majority of the anti-serum
will have become conjugated to it. However, if there is a low concentration, the anti-sera
will have bound to the link. The conjugate, streptavidin peroxidase, is then added which
binds to biotin in the link. Excess strepatavidin peroxidase is washed off. When the
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Figure 2.6: (a) Standard curve for protein assay by Softmax. This cui~ve fit is 4-
parameter with the formula: y = (A-D)/(l+(x/C)'B)+L). (b) and (c) Standard curves for



















Figure 2.7: PGEj ELISA, an example ofa competition ELISA reaction. Anti-serum binds
to donkey anti-rabbit epitopes in the wells. Then PGEi in the sample competes with the
biotin-labelled link for anti-serum binding sites. Streptavidin peroxidase then binds to
the biotin on the bound link and converts the substrate into a coloured product which
can be measured. The greater the level ofPGE2, the lower the concentration ofcoloured
product.
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converts the substrate into a coloured product, which can be measured. The amount of
the substance being measured in the original samples can be calculated by comparing
values obtained by using a standard curve.
This method has been adapted from one previously described (Kelly et al 1989). On
collection, samples were treated 1:1 with methyloximating solution (MOX) (appendix
1.4.2.1) overnight at 4 °C to stabilise PGE2 and prevent conversion to the PGA form.
This treatment causes chemical derivitisation of the prostaglandin via the ketone link,
forming a methoxime at C9 in place of the oxo group. 96-well plates were coated with
purified donkey anti-rabbit (DAR) serum using the direct binding procedure. Briefly,
100 pi purified DAR serum diluted 1:200 with PBS was added to each well and sealed
and left over night at 4 °C. The contents were then flicked out and 300 pl/well Dry Coat
solution (appendix 1.4.2.2) was added and incubated for 1 hr at room temperature. The
contents were flicked out and wells washed 4 times in wash buffer (appendix 1.4.2.3)
before use.
Standards were prepared at a range from 10240 - 20 pg/ml using 25% MOX buffer
(appendix 1.4.2.5). 100 pi standard was added per well. 50 pi samples + 50 pi buffer
containing Tween (appendix 1.424) and no MOX, bringing the MOX concentration to
25 % as the standards. Additionally in the wells, there was 50 pi antiserum (diluted in
ELISA buffer + Tween to 1 in 50,000) + 50 pi link (diluted 1 in 3 million with
phosphate buffer, appendix 1.4.2.6). Wells were also prepared containing only buffer +
25% MOX with (B0) and without (NSB) antiserum. Quality control wells were also set
up with a standard concentration of 200 pg/ml. The link increases the sensitivity of the
assay via proline coupling to a PG, making it more antigenic. This enables the free PG
in the sample to displace the biotin-labelled link for antiserum binding sites. The above
is left overnight at 4 degrees and is followed by washing 4 times in wash buffer,
including once for 30 s on a plate shaker. Streptavidin was diluted in buffer with no
tween to a concentration of 0.125 U/ml and 100 pi pipetted into all wells. This was
93
Chapter 2
shaken for 25 min at room temperature then washed 4 times as previously. TMB
substrate (appendix 1.4.2.7) is then added at 200 pi per well. Plates were then left for
approximately 10 minutes before being quenched with 50 pi 2N sulphuric acid and read
on a plate reader at 450 nm within 30 min of quenching. Results were analysed and
quantified using Assay Zap and Microsoft Excel. Assay Zap is a programme which will
use an optical density measurement to draw a standard curve for the standards, and then
calculates a value using this curve for the unknowns. A sample standard curve for a
PGE2 assay is shown (Figure 2.6b).
2.6.3 Cyclic AMP Assay
The cAMP assay was carried out using an enzyme-immunoassay (ELA) system kit. This
assay is based on the ELISA method described above. However, instead of a labeled link
being added, peroxidase labeled cAMP was added to compete for anti-sera binding with
the cAMP in the samples. Standards were prepared by serial dilution to a range of 12.5 -
3200 fM by diluting a stock standard (3200 fM) in lysis reagent IB. The kit comes with
a 96-well plate coated with donkey anti-rabbit IgG. This was washed 4 times with wash
buffer prior to use. Into each well, the following was added: 100 pi lysis reagent IB
(NSB and 0 standard wells)/100 pi standard/100 pi sample and 100 pi lysis reagent 2B
(NSB only)/100 pi antiserum. This was covered and left at 4 °C for 2 hours. Then 50 pi
cAMP-peroxidase conjugate was added into all wells and the plate covered and
incubated at 4 °C for 60 min. The wells were then aspirated and washed 4 times with
wash buffer. Then 150 pi enzyme substrate was dispensed into each well and mixed on a
plate shaker at room temperature for 60 min. Following this, the reaction was quenched
by addition of 100 pi 1 M sulphuric acid and the optical density determined at 450 nm
within 30 min. Results were analysed and quantified using Assay Zap and Microsoft
Excel. A sample standard curve for a cAMP assay is shown in Figure 2.6c.
94
2.7 Electrophoresis Based techniques
Chapter 2
2.7.1 Sample Preparation for Electrophoresis
2.7.1.1 Freeze Drying
A known volume of culture medium was collected in a 2 ml Sarstedt tube and covered
with parafilm with small holes pierced in the top and frozen at -70 °C before use. The
samples were placed in the freeze drier and vacuum pump apparatus on a suitable rack
and freeze-dried at a pressure of 6-8 mbar until dry (about 6 hr for 1 ml). When dry, the
pressure was released and samples stored capped at -20 °C until reconstituting in a
known volume of distilled water.
2.7.1.2 Dialysis
Some samples require a dialysis step to "clean" them up for electrophoresis. The dialysis
tubing used here was capable of retaining proteins 12 kB or larger. This also allows
removal of salts in the culture medium and salts associated with the folded protein,
which stops them interfering with the complex separation procedure of electrophoresis.
Tubing was cut to the required length (10 cm for 1 ml sample) and added to very hot
water for 5 min prior to use to render it pliable. A clip was placed on one end of the
tubing and the other end opened and the sample pipetted in. The tubing was then sealed
with another clip. Samples were immersed in distilled water and dialysed overnight at
5 °C stirring very slowly on a magnetic stirrer. When completed, the samples were
retrieved and stored at -20 °C and freeze-dried as appropriate.
2.7.1.3 Homogenisation ofCultured Tissue Samples
Samples collected in lysis buffer (appendix 1.511/2) were frozen at -20 °C or -70 °C
until homogenisation. Using the Polytron PT 3100 with the 7 mm probe, the sample was
homogenised for 2 x 30 sec on ice at the highest setting. The probe was cleaned with
DPBS between samples. The samples were then centrifuged at 10,000 g for 20 min at
4 °C. The supernatant was collected and stored at - 20 °C before use (samples used for
the cAMP assay were stored at -70 °C for 10 days maximum before use). The samples
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used to measure ERK phosphorylation were sonicated for 10 min prior to the
centrifugation step. This breaks up nucleotides in the sample making it less 'gooey' and
easier to use.
2.7.2 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
2.7.2.1 Principles of SDS-PAGE
SDS-PAGE is a separation technique commonly used to separate proteins by molecular
weight. The relative mobility of a protein in an SDS-PAGE gel is related to its molecular
weight. A standard curve is constructed with proteins of known molecular weight by
plotting the logarithms of their molecular weights against the relative mobilities of the
proteins. The relative mobility of an unknown protein is then fitted to the curve to
determine its molecular weight. Polyacrylamide gels are formed by co-polymerisation of
acrylamide and bis-acrylamide, which is initiated by TEMED and ammonium
persulphate. SDS is added to dissociate proteins into their individual polypeptide
subunits and gives a uniform net charge along each denatured polypeptide. The
percentage of acrylamide in the gel can be varied to visualise a range of protein
molecular weights, as proteins migrate faster through a lower percentage gel.
Ammonium persulphate is very hygroscopic so the gel is degassed prior to pouring and
the ammonium persulphate solution is prepared freshly before making a gel.
2.7.2.2 General Electrophoresis Method
The discontinuous system used here (Figure 2.8) involves a resolving gel with a
stacking gel on-top in which the proteins are loaded. Using the Biorad minigel system,
resolving gel (see appendix 2) was prepared and left to set topped with sec-Butanol to
create a level top on the gel. This was then washed off and the gel left overnight to
equilibrate, topped with stacking gel buffer (diluted 1 in 5 with water). This buffer was
washed off and stacking gel was then poured on-top with the chosen spacers to form
wells. This was left for 1.5 hr to set. The gel apparatus was then filled with running tank
buffer and the samples loaded into wells. Molecular markers were always also loaded.
Broad range markers of roughly 30 - 210 kDa were used on 7.5 % gels, and low range
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markers of around 20 - 120 kDa were used for 10 and 12 % gels. Gels were run at a
constant voltage of 100 V for an appropriate length of time.
glass plates sample wells buffer
Figure 2.8: Assembly ofgel apparatus for the discontinuous gel electrophoresis system.
The resolving gel is prepared and left to equilibrate overnight before being over-lain
with stacking gel using combs to create wells where the sample is loaded before being
electrophoresed.
2.7.2.3 Western Blotting
Western blotting detects the presence of proteins in a sample. Samples are separated by
SDS-PAGE and then the proteins on the gel are transferred by electrophoresis onto a
thin sheet such as nitro-cellulose membrane (Figure 2.9). The proteins bind to this





Figure 2.9: Assembly ofa "gel sandwich "for Western blot transfer. The layers are kept
moist with transfer buffer at all times and rolled with an autoclaved glass pipette to
remove all bubbles and to ensure layers are in contact in all places.
The method used for Western Blotting has been adapted from the original method by
Towbins et al. (Towbin et al 1979). Gels were prepared (appendix 2.1) and loaded with
samples mixed 1:1 with sample application buffer (appendix 1.5.1.3). They were
electrophoresed in running tank buffer (appendix 1.5.1.4) for 2 hours at 100 V.
Following this, gels were equilibrated in transfer buffer (appendix 1.5.1.5) for 30 min.
Nitro-cellulose membranes and filter paper were also steeped in transfer buffer for 30
min and 10 min respectively, prior to use. The "gel sandwich" was constructed and
electrophoresed with a Bio-Rad Ice Cooling unit at 100 V for 60 min. Gels could then be
stained using Coomassie Blue (appendix 1.5.2.9) for 60 min to check protein transfer.
Membranes were then blocked in 5 % BSA (appendix 1.5.1.8) in TTBS solution
(appendix 1.5.1.7) overnight at 5 °C, prior to adding the primary antibody for 2.5 hours.
Membranes were then washed in TTBS (lx 15 min, 2x 5 min) then a horse radish
peroxidase (HRP) linked secondary antibody was added for 1 hour. The membranes
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enhanced chemiluminescence (ECL). This method is based on the luminescent
properties of luminol. In the presence of H2O2, HRP on the nitrocellulose membrane
catalyses the oxidation of cyclic diacylhydrazides, such as luminol. Oxidation causes
luminol to become excited. It then slowly decays to the ground state, with a half life of
60 min, by emitting light. This light is detected by exposing the membranes to
autoradiography film. A strong enhancement of the light emission is achieved by
enhancers, such as phenolic compounds (Thorpe & Kricka 1986, Thorpe et al 1985,
Whitehead et al 1979). After exposure, membranes were developed in a processor or by
hand. Membranes were then stripped for 45 min using stripping solution (appendix
1.5.1.9), washed (2x 5 min) in TI BS and then either stored at 5 °C for future use, or re-
blocked and probed.
2.7.2.4 Gelatin Zymography
Gelatin zymography detects the activity of latent and active forms of the gelatinases,
MMP-2 and MMP-9 using a method previously described (Rawdanowicz et al 1994).
The resolving gel contains gelatin which is a substrate for the gelatinases. The proteins
are visualised as a site of enzymatic activity, identified by a white band when the gel is
stained blue. The latent forms of the gelatinases are also seen as SDS present in the gel
activates them via a conformational change to expose the active site, as well as
dissociating active forms from their inhibitors. A sample zymogram is shown in Figure
2.10(a). A dimer of the latent form of MMP-9, and a complex of MMP-9 and lipocalin
are also visualised on the zymograms (Kolkenbrock et al 1996).
Gels were prepared (appendix 2.2) and samples mixed 1:1 with sample application
buffer (appendix 1.5.2.1) loaded into the wells. A sample of characterised amniotic fluid,
containing active and latent forms of both MMP-2 and MMP-9 was also run as a control.
Gels were electrophoresed in running tank buffer (appendix 1.5.2.2) at 100V for
approximately 90 min. Gels were washed twice with Triton-X wash buffer (appendix
1.5.2.5), twice using TBS wash buffer (appendix 1.5.2.3), then incubated in zymography
digestion buffer (appendix 1.5.2.6) for 18 hours at 37 °C. Gels were then washed twice
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with TBS wash buffer, immersed in staining solution (appendix 1.5.2.9) for 3 hours at
room temperature, then de-stained using de-staining solution (appendix 1.5.2.8) to reveal
discrete bands where gelatin has been hydrolysed by gelatinase activity. The zymograms


















Figure 2.10: Example of (a) a zymogram and (b) a reverse zymogram. A= amniotic fluid
control, 1+2 = TIMP-1 and -2 standard, 3 = TIMP-3 standard.
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2.7.2.5 Reverse Zymography
Reverse zymography detects activity of TTMPs. Samples were separated by SDS-PAGE,
using gels containing gelatin and an MMP preparation (from BHK-21 cells that
constitutively express proMMP-2; University Technologies Inc). This method has
previously been described (Hampton et al 1995).
Gels were prepared (appendix 2.3) and loaded with samples mixed 1:1 with sample
application buffer (appendix 1.5.2.1), then run for approximately 90 min at 100V. The
gels were washed in Triton-X wash buffer (appendix 1.5.2.4) then incubated in reverse
zymography digestion buffer (appendix 1.5.2.7) for 17 hours at 37 °C. The gels were
stained (as for zymography) for 3 hours using staining solution then de-stained with de-
staining solution. The presence of TIMPs was detected by their discrete inhibition of
MMP activity, seen as a dark band on a lighter background {Figure 2.10b). TTMPs were
identified and characterised by comparison with molecular weight markers, with control
standards of conditioned medium containing mouse TIMP-1, -2 and -3 expressed by
transfected BHK cells and recombinant TIMP-2. This human TIMP-2 standard shows
different mobility to the mouse form (observed at 21 kDa by reverse zymography under
non-reducing conditions and 26 kDa by Western Blot under reducing conditions)
2.7.2.6 Agarose Gels
Agarose gels are commonly used to separate nucleic acids. Agarose is a neutral, linear
polysaccharide in agar, consisting of repeating galactose and 3,6-anhydrogalactose.
Powdered agarose was mixed with electrophoresis buffer (appendix 2.4) and boiled then
poured into a gel tank with a suitable comb to create wells and allowed to cool. Ethidium
bromide was added to the hot solution (in a fume hood) as this binds to nucleic acids and
fluoresces under UV light allowing visualisation of the genetic material. Samples which
had undergone PCR were mixed with a loading dye and loaded into wells in the gel
along with a DNA ladder (consisting of 11 double-stranded DNA fragments with sizes
100-1500 bp to serve as a reference indicator). The gels were electrophoresed for 1 hr in
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TAE buffer (appendix 1.3) at 100V and then examined and photographed under UV
light using a transilluminator.
2.8 Statistical Analysis
All statistical analysis was carried out using Microsoft Excel. The significance values
were calculated using a paired student T-test. Significance was indicated when p < 0.05
or p < 0.01.
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Chapter 3: Prostaglandin Receptors in Human
Uterine and Gestational Tissue at Parturition
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3.1 Introduction and Aims
Prostaglandins have many roles within the human uterus during pregnancy and
parturition. These roles are likely to be mediated via specific prostaglandin receptors
(see section 1.3). The receptors, EP1, 2, 3, 4, DP, FP and IP have all been identified in
the human pregnant myometrium (Duckworth et al 2002, Erkinheimo et al 2000,
Leonhardt et al 2003, Matsumoto et al 1997b, Senior et al 1993). There is not a lot of
published evidence of prostaglandin receptors in any other tissues involved in pregnancy
besides the myometrium in the human. FP has been detected in human amnion-decidua
complexes (Fukai et al 1984) and also in the human placenta (Vielhauer et al 2004).
In the myometrium, the prostaglandin receptors can be split into 2 groups - relaxant, and
contractile, by their effect on smooth muscle cells. DP, EP2, EP4 and IP are relaxant and
act by increasing the intracellular cAMP concentration, and EP1, EP3, FP and TP can be
considered contractile and act by either decreasing cAMP concentrations or increasing
intracellular Ca2+ concentrations (Coleman et al 1994). The interaction between the
release of prostaglandins and their specific receptors might therefore participate in
maintenance of uterine quiescence during gestation, and uterine contractions during
labour at term and preterm. Comparing the receptor expression and distribution levels
between non-labouring and labouring myometrial samples could indicate if this plays a
role in uterine quiescence and contractility.
Prostaglandins have also been implicated in regulation of MMP expression and
activation in human fetal membranes and decidua (McLaren et al 2000b, Ulug et al
2001), thus affecting extracellular membrane degradation which is involved in rupture of
the fetal membranes at term and preterm. This regulation is likely to occur via
prostaglandin receptors. To establish the location of the receptors within these tissues
would test this hypothesis. A similar mechanism is likely to explain placental
detachment from maternal tissues at labour. Collagenase activity in the placenta has
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been found to increase during labour (Rajabi et al 1990), particularly MMP-9 (Xu et al
2002) and prostaglandins may be involved in inducing this.
Nuclear prostaglandin receptors have also been identified, though as yet there is no
evidence for any in gestational tissues. However, prostaglandin signalling may still
occur in the nucleus without these receptors. Other targets for the actions of
prostaglandins within the nucleus are peroxisome proliferator activated receptors
(PPARs), of which several isoforms have been identified in gestational tissue and JEG3
cells (Helliwell et al 2004, Keelan et al 1999b).
The control by which prostaglandins exert their effects via their receptors depends on an
intricate balance of receptor and ligand expression. It follows that regulation of a
combination of prostaglandin receptor levels and expression, and enzymes involved in
prostaglandin metabolism all contribute to balance the levels to which prostaglandins
exert their specific effects during labour. The aim of this chapter is to detect and localise
PG receptors in human uterine and gestational tissue at term and preterm, using samples
from patients in labour and not in labour. The receptors that are focused on in this
chapter are EP2, EP4 and FP. PGDH will also be immunolocalised to compare the sites
of prostaglandin metabolism to their sites of action.
3.2 Methods
3.2.1 Identification of PG Receptor mRNA by PCR
For this experiment, n=6 for each of amnion, chorio-decidua, placenta and JEG3
samples. RNA was extracted according to section 2.5.1-2.5.3. The tissue samples were
collected directly into tri-reagent, cell samples were plated out at 2xl05 cells/ml, 1
ml/well on 24 well culture plates and maintained in complete DMEM with serum for 48
hours prior to washing and extraction using tri-reagent.
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PCR was carried out on the cDNA, as in section 2.5.4 after optimizing for MgCl2
concentration and temperature. These conditions are shown in Table 3.1. The sequences
and product size of the primers used are shown in Table 3.2.
Primers Annealing temperature MgCl2 concentration
EP2 57 °C 1.1 mM
EP4 57 °C 1.1 mM
FP 63 °C 1.6 mM
Table 3.1: Optimum annealing temperature andMgC^ concentration for EP2, EP4 and
FP receptorprimers.
















Table 3.2: Sequence andproduct size forprostaglandin receptorprimers.
The programme was run for 35 cycles. Products were electrophoresed on a 1.5 %
agarose gel at 100 V for 60 min and bands were visualized under UV light and
photographed. Plasmid pcDNAI/Amp, containing human EP2, EP4 or FP receptor
cDNA (generously donated by Mark Abramovitz, Merck Frosst, Canada Ltd, Kirkland,
Quebec, Canada) was used as a positive control.
3.2.2 Localisation of PG Receptors and PGDH in the Human Fetal Membranes,
Decidua, Placenta and Myometrium at Parturition
The receptors were localised by immunohistochemistry using specific polyclonal
antibodies for the receptor of interest. Tissue was collected and fixed as in section 2.1.2,
and cells as in section 2.4.1. The tissue groups used were term active labour and elective
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caesarean section for fetal membranes, decidua, myometrium and placenta. Preterm
tissue was also used, which was a kind gift from Dr. Inass Osman, Glasgow Royal
Infirmary. This tissue consisted of fetal membranes and myometrium in non-labouring
and labouring groups. n=5 for every group investigated. The tissue was immunostained
using the antibodies as shown in Table 3.3:
Primary Antibody Type Secondary Antibody
EP2 rabbit polyclonal donkey anti-rabbit IgG
EP4 rabbit polyclonal donkey anti-rabbit IgG
FP rabbit polyclonal donkey anti-rabbit IgG
PGDH rabbit polyclonal donkey anti-rabbit IgG




Messenger RNA for the EP2 receptor was detected in none of the amnion, chorio-
decidua, placenta or JEG3 cell samples. EP4 mRNA was found in chorio-decidua and
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Figure 3.1: RT-PCR gels photographed under UV light showing the presence of
prostaglandin receptors EP2, EP4 and FP rnRNA in: JEG3 cells (J): amnion (A);
chorio-decidua (C); placenta (P). D: DNA ladder, +; positive control.
3.3.2 Localisation of PG Receptors and PGDH in the Human Uterus at
Parturition
This immunohistochemistry detected the presence of EP2, EP4, FP and PGDH in the
fetal membranes, decidua, placenta, myometrium and JEG3 cells (see Figures 3.1-3.7
for representative photomicrographs). The immunolocalisation of all three receptors and
PGDH was highly consistent throughout all of the samples. There appeared to be no
obvious differences in localisation of the receptors between labour and non-labouring
samples, and between term and preterm samples. The predominant staining of the
receptors was found on the plasma membrane in most cell types. Some nuclear
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localisation of the receptors was also obvious from the experiments. There also appeared
to be cytoplasmic staining in some cells.
Fetal membranes: The three prostaglandin receptors and PGDH were all localised to
the amnion epithelium, with some staining also in cells of the amnion fibroblast layer. In
the chorion, they were predominantly found in the trophoblast layer. Staining here of the
receptors was clearly mainly in the plasma membrane with some also in the cytoplasm.
The receptors and PGDH were also found in cells of fibroblast like morphology in the
reticular layer. The same pattern of distribution and localisation was found in term
(Figure 3.2) and preterm (Figure 3.3) fetal membrane tissue sections, except that in the
amnion epithelium, FP receptor was not present in preterm samples (labouring or non-
labouring), and the EP4 receptor was not present in labouring preterm samples.
Decidua: EP2, EP4, FP and PGDH were found in the glandular epithelial cells of the
decidua and also decidual stromal cells and vascular endothelial cells (Figure 3.4).
There is no evidence of any staining in leukocytes seen in the vessels.
Placenta: The three receptors and PGDH were predominantly visualised in the
syncytiotrophoblasts of the placenta (Figure 3.5). Cytotrophoblasts appear negative for
the receptors and PGDH, as do the endothelial and fibroblast cells of the villous core
tissue, with the exception of some PGDH positive staining of stromal core tissue.
Extravillous trophoblast cells also appear negative. Fetal and maternal leukocytes
appeared negative.
Myometrium: Receptors and PGDH were located in the smooth muscle cells of the
myometrium in term (Figure 3.6) and preterm (Figure 3.7) samples. The staining for
EP2, EP4 and FP in these cells appears to be principally localised to the nuclear
membrane, except for FP in preterm samples.
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Figure 3.2: Immunolocalisation by DAB detection ofEP2, EP4 and FP in sections of
fetal membranes with adherent decidua, collected from term active labour births and
elective caesarean sections, am, amnion; ch, chorion; dec, decidua; r, reticular layer of
chorion; t, trophoblast layer of chorion. All photomicrographs are taken at the same
magnification. The scale bar represents 50 urn. Top right shows representative negative
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Figure 3.3: Immunolocalisation by DAB detection of EP2, EP4 and FP receptors in
sections offeted membranes collectedfrom preterm labouring and non-labouring births.
All photomicrographs are taken at the same magnification. The scale bar represents 50
urn.
Ill
elective caesarean section active labour
Figure 3.4: Immunolocalisation by DAB detection ofEP2, EP4 and FP in sections of
decidua collected from term active labour births and elective caesarean sections. All
photomicrographs are taken at the same magnification. The scale bar represents 50 pm.
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elective caesarean section active labour
Figure 3.5: Immunolocalisation by DAB detection ofEP2, EP4 and FP in sections of
placenta collected from term active labour births and elective caesarean sections, s =
syncitiotrophoblast All photomicrographs are taken at the same magnification. The
scale bar represents 100 am.
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Figure 3.6: Immunolocalisation by DAB detection of EP2, EP4 and FP in section of
myometrium collected from term active labour births and elective caesarean sections.









Figure 3.7: Immunolocalisation by DAB detection of EP2, EP4 and FP receptors in
sections ofmyometrium collected from preterm labouring and non-labouring births. All




JEG3 choriocarcinoma cells: EP2, EP4, EP and PGDH were all detected in these cells
(Figure 3.8). All receptors were chiefly located in the plasma membrane, with some









Figure 3.8: Immunolocalisation by DAB detection ofEP2, EP4, FP and PGDH in JEG3
cells. Inset, -ve control staining. All photomicrographs are taken at the same




In summary, the EP2, EP4, FP receptors and PGDH were localised to the amnion
epithelium and fibroblast layer, the chorion reticular and trophoblast layers, glandular
epithelial, vascular endothelial, and stromal cells of the decidua, syncitiotrophoblasts of
the placenta, and smooth muscle cells of the myometrium. From this, it can be
understood that these are the sites of prostaglandin action and their direct effect within
these tissues.
It is unclear why the PCR results and the immunohistochemistry results do not reflect
each other. It is possible that the mRNA levels of some of the receptors were too low for
detection by standard PCR in the samples in which they were not detected. Other
experiments in the laboratory involving Taqman quantitative RT-PCR did detect the
presence of EP2 in JEG3 cells. As shown in the next chapter, these cells elicit responses
through the EP4 and FP receptors implying that they are present, and the amnion shows
a response through the EP2 receptor, which has not been detected by PCR here either.
Western blotting was also carried out to try and clarify the presence of the receptor
proteins in tissue and cell samples. However, the antibody used proved unspecific, and
was therefore deemed unsuitable. That the receptors have all been detected in the tissue
and cell-line using immunohistochemistry does indicate their presence in these samples.
Although the receptors are transmembrane, it is possible that they are being detected in
the cytoplasm at their site of synthesis, in endoplasmic reticulum, golgi apparatus, or in a
vesicle during their trafficking to the cell membranes. The staining viewed in the
cytoplasm could also possibly be non-specific. To further clarify the localisation of the
prostaglandin receptors, in-situ hybridisation studies to examine receptor mRNA with
the tissue sections used, would have been useful. Also, although no detectable changes
in levels of prostaglandin receptors was observed between the different groups in the
immunohistochemistry studies, to be sure of this the receptor levels would actually have
to be quantified. The relative receptor mRNA levels could have been analysed using
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Taqman quantitative PCR, had preterm tissue, and tissue from term spontaneous labour
been available at the time to extract RNA and create a comparative study. If the Western
blotting had proved successful, this could have also been used to quantify receptor
protein extracted from tissue in the various groups.
Inter-species differences and limitations in the suitability of animal models restrict
research into this area, though there have been results published with regard to
prostaglandin receptors in species other than the human. In the baboon, EP2 receptor has
been detected in the myometrium, decidua and cervix (Smith et al 1998, Smith et al
2001a, Smith et al 2001b). EP2 and EP4 have also been detected in the mouse uterus
(Katsuyama et al 1997). Recently, it was shown that EP2 and FP, but not EP4 were
present in bovine fetal membranes (Arosh et al 2004).
The studies in this chapter showed few gestational or labour induced changes in
prostaglandin receptor distribution. However, it was seen that the FP receptor was not
detected in the amnion epithelium or myometrial nuclear membrane in preterm tissue,
whereas it was in term samples. It is possible that the FP receptor is up-regulated with
gestational age in these cells. The EP4 receptor was not seen in the amnion epithelium of
preterm labouring samples, while it was observed in preterm non-labouring tissue and
term samples. A reason for this is not clear. Other literature indicates gestation and
labour associated changes in prostaglandin receptor expression occur. It was found that
EP3 and FP mRNA levels in the human myometrium were down-regulated during
pregnancy, possibly playing a role in the relaxation of the myometrium, thus aiding the
maintenance of pregnancy (Matsumoto et al 1997b). EP2 levels can also be seen to
decrease with advancing gestational age, implying that these too are involved in uterine
quiescence (Leonhardt et al 2003). In the baboon decidua, EP2 expression decreased
with labour, which suggests an adenylate-cyclase-mediated effect may inhibit
parturition-related processes in decidua (Smith et al 2001b). This parallels decreased
EP2 receptor expression in myometrium and cervix (Smith et al 1998).
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There was positive nuclear staining of prostaglandin receptors observed from the
immunolocalisation studies. This suggests a role for intracrine prostaglandin signalling
mechanisms in the nucleus. As well as GPCRs, PPARs are also presumed to be targets
of prostaglandins and other eicosanoid hormones. PPARs are members of the nuclear
receptor superfamily of transcription factors that include steroid receptors. Three
subtypes have been identified - a, 8, and y. PGE2 and PGF2a are both naturally occurring
ligands for PPARa (Forman et al 1997), and PGE2 also binds to PPARy (Ferry et al
2001). There is little information to date on the role of PPARa in pregnancy and
parturition. PPARa deficient mice have normal fertility (Lee et al 1995) so this receptor
apparently does not have a major role in normal reproductive function. The finding of
PPARa mRNA in term amnion, chorio-decidua and placenta (Eykholt et al 2004,
Helliwell et al 2004) (Wang et al 2002) suggests there is a role for this receptor in
gestational tissue, however what this is remains unclear. PPARy has been found to be
important in placental development (Barak et al 1999). It is expressed in human
placental tissues at various stages of gestation (Helliwell et al 2004) and has been
immunolocalised to the nuclei of the syncytiotrophoblast, cytotrophoblast and
endothelial cells of the term placenta (Schaiff et al 2000). It has also been identified in
human chorio-decidua and JEG3 cells (Keelan et al 1999b, Marvin et al 2000). There
were also small amounts of PPARy in a few amnion samples (Marvin et al 2000). Recent
data has detected PPARy in term labouring and non-labouring amnion, chorio-decidua
and placenta, and shown that PPARy levels with the onset of labour, as COX-2 levels
increase, and a positive feedback mechanism of prostaglandin action during parturition
through this receptor has been suggested (Dunn-Albanese et al 2004).
The localisation of the prostaglandin receptors correlates well with the sites of
prostaglandin metabolism. Immunolocalisation of PGDH, has shown that the tissue
distribution of this enzyme is the same as these receptors, with a prominent location in
the chorion trophoblast cells. This corresponds to previous reports on the distribution of
PGDH which shows the enzyme in amnion, chorion and decidua with the order of
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activity as follows: chorion > decidua > amnion (Okazaki et al 1981). Other groups have
also shown high chorion PGDH levels, with localisation to the trophoblast layer
(Cheung et al 1990, van Meir et al 1997). COX enzymes are expressed in the amnion,
chorion and decidua, with highest levels being in the amnion (Cheung et al 1990, Gibb
& Sun 1996, Okazaki et al 1981, Rose et al 1990, Teixeira et al 1994). The amnion is
thus the primary site of PG synthesis, synthesizing principally PGE2. So, overall, PGE2
and PGF2a output is greater in the amnion, than in the chorion and decidua (Cheung et al
1990). Only very small amounts of these prostaglandins will cross the fetal membranes
without being metabolized (Roseblade et al 1990). COX enzymes and PGDH were also
found in the placenta (Cheung et al 1990, Greystoke et al 2000, Jarabak 1972, Macchia
et al 1997, Schoof et al 2001) and myometrium (Giannoulias et al 2002, Moonen et al
1984).
Changes in expression of the enzymes involved in prostaglandin biosynthesis occur with
advancing gestational age and labour. Two isoforms of the COX enzyme - COX-1 and
COX-2 are known to be involved in catalyzing the production of prostaglandins. COX-1
is constitutively expressed, and COX-2 is known to be inducible (Morita 2002). COX-2
mRNA increases at the onset of labour in the amnion and chorion in coordination with
one another implying a concerted mechanism of regulation in the fetal membranes at
both term and preterm (Mijovic et al 1999, Mijovic et al 1997). There are no reported
COX changes in the decidua with labour (Hirst et al 1998, Mijovic et al 1999), however
COX-2 mRNA has been shown to be up-regulated in chorio-decidual tissue with labour
(Slater et al 1998). Evidence suggests that although PGDH levels do not change in the
amnion and decidua (Skinner & Challis 1985), in the chorion, mRNA expression and
activity of PGDH decrease in human labour, at term and preterm (Patel & Challis 2002,
Sangha et al 1994). The combination of increase in synthesis and decrease in
degradation of prostaglandins during labour gives rise to overall higher intrauterine
prostaglandin levels at term and preterm.
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In the placenta, reports of COX-2 expression increasing with gestation have been
published, with no changes in COX-1 levels, and no labour induced changes in either
COX isoform in sheep (Gibb et al 1996, Rice et al 1995). In the human placenta, PGES
activity decreases with the onset of labour - suggesting that PGE2 has been maintaining
uterine quiescence and its degradation is associated with initiating labour (Alfaidy et al
2003). Placental PGDH mRNA levels increase during pregnancy, implying a role in
delaying prostaglandin induced uterine contractions presumably by degrading PGF2a
(Schoofet al 2001).
In the human myometrium, COX-1 and COX-2 levels are greater in the pregnant
compared to the non-pregnant state (Moonen et al 1984), although labour associated
changes are not clear. They have been reported to increase (Erkinheimo et al 2000),
decrease (Zuo et al 1994) and stay the same (Giannoulias et al 2002, Moore et al 1999).
A significant decrease in PGDH protein levels and activity is found in the myometrium
with labour at term and preterm (Giannoulias et al 2002). Also, in the cervix, PGDH
expression was found to be higher in the unripe than ripe condition, irrespective of
gestation time. COX-1 and COX-2 expression did not differ. This suggests that
increased levels of prostaglandin output are associated with cervical ripening at term and
preterm (Tomblom et al 2004).
Putting together the observed changes in prostaglandin biosynthesis and catabolism, and
receptor expression in uterine and gestational tissue during pregnancy and labour can
give an indication of proposed prostaglandin target sites at these times. The amnion
produces large quantities of prostaglandins, particularly PGE2, with production
increasing during labour. The EP2, EP4 and FP receptors are present at term and preterm
labour in labouring and non-labouring amnion. Thus, the amnion is a likely target site
for prostaglandin action. The chorion trophoblast represents a target site also, as the
receptors are expressed here, and the chorion also is a place of prostaglandin
degradation. This paracrine and autocrine action of prostaglandins on the fetal
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membranes may lead to their rupture at term or preterm by stimulating production and
activation of MMP-2 and MMP-9 (McLaren et al 2000b, Ulug et al 2001).
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Chapter 4: Signalling Pathways via Prostaglandin
Receptors in Term Human Fetal Membranes
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4.1 Introduction and Aims
Prostaglandin ligand-receptor interactions play a key role in many reproductive
functions, including parturition. The intracellular pathways which these receptors trigger
when activated have been investigated (Ashby 1998) as discussed in section 1.4. Once
activated, these intracellular pathways can activate transcription factors and control gene
expression, and they can also activate various proteins via mechanisms such as
phosphorylation. The prostaglandins have effects on various factors during pregnancy
and parturition, for example cytokines and MMPs. These effects are mediated through
their receptors by activating intracellular pathways.
There is little published data on the involvement of PG stimulated pathways in the
regulation of cytokines or MMPs in human uterine and gestational tissue. More roles of
intracellular mediators have been reported in animal models however. Levels of MMP-2
and MMP-9 have been found to be regulated in part by a PGE2-cAMP dependent
mechanism in the rat uterus and cervix (Lyons et al 2002), with prostaglandins
stimulating MMP-2 and MMP-9 in labouring tissues. cAMP has also been shown to play
a role in uterine quiescence (Price & Bemal 2001). Further to this, it has been found that
Gas subunit expression in the human myometrium is greater in the pregnant compared to
non-pregnant state and so is its associated increase in adenyl cyclase activity. However,
upon spontaneous labour, levels fall back to the non pregnant state. This suggests that
cAMP contributes to prolonged relaxation of the uterus during gestation and down-
regulation of Gas would decrease the relaxing effect exerted by cAMP and may be a
triggering mechanism for the initiation of labour (Europe-Finner et al 1994).
There is a lot of evidence for a role of inositol phosphates in myometrial contractions.
Phosphoinositide breakdown is thought to be important in regulating a variety of
transmembrane signal transduction events in the action of oxytocin during smooth
muscle contraction. Oxytocin, PGE2 (Okawa et al 1993) and PGF2a (Maka et al 1993,
Okawa et al 1993) have all been found to stimulate IP production in pregnant and non-
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pregnant rabbit myometrium. Contradictory to this, PGE2 and PGF2a have both been
found to have no effect on phosphoinositide hydrolysis in human smooth muscle, though
they were shown to stimulate arachidonic acid release contributing to prostaglandin
production, and Ca2+ which is involved in contraction of the myometrium (Schrey et al
1988). Another study showed PGE2 and PGF2a stimulated cAMP generation and inositol
phosphate release in rabbit myometrium and that PLC activation was coupled not only to
PGF2a but also to PGE2 receptors and could be correlated with contractions induced by
PGF2a and PGE2 (Goureau et al 1992).
MAPKs have been shown to mediate MMP-9 expression in rat arterial smooth muscle
cells (Cho et al 2000). It is not known whether a similar control is exerted in myometrial
smooth muscle and if this can be activated by prostaglandins. It is evident that MAPK
plays a role in uterine quiescence. In the rat myometrium, PGF2a can activate the MAPK
cascade through the (3y subunit of a G-protein which possibly involves a receptor
tyrosine kinase, and ultimately leads to cell contraction (Ohmichi et al 1997).
Having now localised the prostaglandin receptors, EP2, EP4 and FP within human fetal
membranes, decidua, placenta, myometrial tissue and JEG3 cells, the aims of this
chapter are to investigate the signalling pathways which are activated upon
prostaglandin binding to these receptors. As EP2 and EP4 are linked to Gas, changes in
cAMP levels will be examined on treatment with PGE2. The FP receptor is Gaq linked,
so total inositol phosphate levels will be monitored upon addition of PGF2ct. Both
receptors have been shown to activate the MAPK pathway so phosphorylation of MAPK
will be determined following treatment with PGE2 and PGF2a. Selective inhibitors of
MEK, PLC and EGFR kinase will also be added to further elucidate the pathways
involved in prostaglandin synthesis. Specific antagonists of the EP2, EP4 and FP
receptors will also be utilised to clarify the receptors involved in these signalling





Figure 4.1: Proposed mechanisms ofprostaglandin signalling via EP2, EP4 and FP
receptors. AC; adenyl cyclase, PKA; protein kinase A, PKC; protein kinase C, PLCft;
phospholipase Cf, DAG; diacylglycerol, PIP2; phosphatidylinositol 4,5-hiphosphate,
IP3; inositol 1,4,5-triphosphate, ERK; extracellular signal regulated kinase, MEK; ERK
kinase, GTP; guanosine triphosphate, GDP, guanosine diphosphate, GEF; guanine




4.2.1 PGE2 Effect on cAMP Production
4.2.1.1 Fetal Membrane Time Course Study
Fetal membranes were collected as in section 2.1.1 and cultured as in 2.1.2. Prior to
cutting, tissue was steeped in steeping buffer (appendix 1.1.2) containing 10 pM
indomethacin for 2 hours. After cutting, explants of amnion and chorio-decidua were
mounted and incubated in 24 well plates in complete RPMI (appendix 1.1.3) containing
10 pM indomethacin (a COX inhibitor) and 1 mM 3-isobutyl-l-methylxanthine (IBMX)
(a phosphodiesterase inhibitor) for 1 hour. Following this, PGE2 was added into the
wells to a final concentration of 100 nM for 0, 5, 10 or 15 minutes. The PGE2was mixed
in by swirling. After the treatment time, the tissue was removed using forceps and
dipped briefly into DPBS twice to wash. Then it was put into 0.5 ml ice cold lysis buffer
IB (cAMP assay kit) in an eppendorf tube and kept on ice until being homogenised
(section 2.7.1.4) and frozen at -70 °C until assaying. For this experiment, n=4 patients,
and each treatment group was replicated 3 times for each patient.
4.2.1.2 JEG3 Cell Time Course Study
JEG3 cells were diluted to a concentration of 2 x 105 cells/ml and plated out into 6 well
plates with 3 ml/well. They were left to adhere for 24 hours, and then the medium was
aspirated and replaced with serum free DMEM containing 10 pM indomethacin for a
following 24 hours. The medium was then aspirated and replaced with serum free
DMEM containing 10 pM indomethacin and 1 mM IBMX for 1 hour. After this, PGE2
was added and mixed into the wells to a final concentration of 100 nM over a time
course of 0 to 35 min. The medium was then aspirated and the cells washed twice with
DPBS before adding 300 pi lysis reagent IB (cAMP assay kit) to each well. The plates
were then rocked on ice for 10 min, then the cells scraped and the contents of each well
pipetted into an eppendorf tube. This was centrifuged at 10, 000 g for 20 min at 4 °C, the
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supernatant removed and kept frozen at -70 °C until a cAMP assay was carried out. For
this experiment, n=2 and within each individual experiment, 3 replicates were used of
each treatment.
4.2.1.3 Amnion Antagonist Study
Amnion was collected and treated as in section 4.2.1.1 until the IBMX incubation stage.
Here, at this step, in addition to IBMX, the tissue was incubated with or without
selective receptor antagonists. Antagonists were: 10 pM AH6809 (for EP2); and 300 nM
ONO-AE2-227 (for EP4) added. Following this, PGE2 was added into the wells to a
final concentration of 100 nM for 10 min. The treatment groups were: control (vehicle
(DMSO) + no PGE2), vehicle + PGE2, EP2 antagonist + PGE2, EP4 antagonist + PGE2,
and EP2 + EP4 antagonists + PGE2. The tissue was then washed and homogenised as in
section 4.2.1.1 and a cAMP assay carried out. For this experiment, n=3 patients, and
each treatment group was replicated 3 times for each patient.
4.2.1.4 JEG3 Cell Antagonist Study
The protocol for this experiment was the same as section 4.2.1.2, except selective
receptor antagonists were added in addition to IBMX as in section 4.2.1.3. For this
experiment, n=2 and within each individual experiment, 3 replicates were used for each
treatment.
4.2.1.5 cAMP ELISA
The samples of amnion, chorio-decidua and JEG3 cells prepared as above were assayed
for intracellular cAMP content using an enzyme-immunoassay (section 2.6.3). Samples
were defrosted to room temperature before use. Amnion samples were used undiluted,
chorion samples diluted 1 in 2 and JEG3 cell samples diluted 1 in 10 in lysis buffer IB
to fit into the range of the assay. Each sample was assayed in duplicate and a standard




A protein assay (section 2.6.1) was carried out for every sample which was assayed for
cAMP so as to express the cAMP levels in pg/mg of protein. The cAMP levels were
then expressed as a percentage of the control (time 0, no PGE2 treatment). This allowed
for variation between patients.
4.2.2 PGE2/PGF2a Effect on ERK1/2 Phosphorylation
4.2.2.1 Fetal Membrane Time Course Study
Amnion and chorio-decidua were collected as in section 2.1.1 and cultured as 2.1.2.
Prior to cutting the explants, tissue was steeped in steeping buffer containing 10 pM
indomethacin for 2 hours. After explants were cut and mounted, they were steeped in 1
ml complete RPMI plus either PD98059 to a final concentration of 50 pM, U73122 to a
final concentration of 10 pM or the same volume of DMSO as a control, as these
inhibitors are diluted in DMSO. After 1 hour incubation, tissue was treated with either
100 nM PGE2 or 100 nM PGF2a for 5, 10 or 15 min, or left untreated (time 0). After this
treatment, the tissue was washed twice in DPBS and then added to 500 pi NP40 lysis
buffer (appendix 1.5.1.2). It was then homogenised, centrifuged and sonicated (section
2.7.1.4). The supernatant was kept at -20 °C until protein assay and Western blot
analysis. (n=4 different patients, with every treatment replicated 3 times for each
patient).
4.2.2.2 JEG3 Cell Time Course Study
Cells were diluted to 2 x 105 cells/ml and plated out in 5 ml volumes into Petri dishes.
They were left 24 hours, then the medium was replaced with serum free DMEM plus 10
pM indomethacin for a further 24 hours. The medium was aspirated and replaced with
serum free DMEM +/- PD98059 to a final concentration of 50 pM, U73122 to a final
concentration of 10 pM, or DMSO as a control for 1 hour. Cells were then treated with
either PGE2 or PGF2a to a final concentration of 100 nM for 5, 10 or 15 minutes, or left
untreated (time 0). Following this, the medium was aspirated and cells washed twice
129
Chapter 4
with DPBS, before adding 300 pi NP40 lysis buffer. Cells were then scraped and the
dish contents collected into a tube and centrifuged and sonicated (section 2.7.1.4) and
the supernatant kept at -20 °C until protein assay and Western blot analysis. (n=3
separate and independent experiments).
4.2.2.3 JEG3 Cell Receptor Antagonist Study
The protocol for this study is as section 4.2.2.2, except instead of adding inhibitors for 1
hour prior to PG treatment, receptor antagonists were added. These antagonists were:
EP2 (AH6809); EP4 (ONO-AE2-227); and FP (AL8810) added to final concentrations
of 10 pM, 300 nM and 100 pM respectively. Samples were then treated with 100 nM
PGE2 or PGF2a for 10 min. Treatment groups were control (vehicle (DMSO) + no PG),
vehicle + PGE2, EP2 antagonist + PGE2, EP4 antagonist + PGE2, EP2+EP4 antagonists
+ PGE2, vehicle + PGF2a and FP antagonist + PGF2a. (n=2 experiments with 2 repeats
for each treatment).
4.2.2.4 JEG3 Cell EGFR Kinase Inhibitor Study
The protocol for this study is as section 4.2.2.2, with pre-treatment being with or without
100 nM AG1478. This compound is an inhibitor of EGFR kinase, preventing EGFR
from becoming tyrosine phosphorylated, dimerising, and signalling. Treatments were
100 nM PGE2 or PGF2a for 10 min. (n=2 experiments with 2 repeats for each treatment).
4.2.2.5 Protein Assay
Every sample collected underwent protein assay (section 2.6.1) prior to Western blotting
to ensure equal loading of all samples into the gels.
4.2.2.6 Western Blot Analysis for ERK Phosphorylation
Gel electrophoresis was carried out for all samples as described in section 2.7.2.3. 20 pg
protein was loaded for each sample. After transfer, and blocking the membranes with
BSA, they were incubated in primary antibody (P42/P44 ERK-P) overnight. After
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washing, secondary antibody binding and further washing, proteins were detected using
ECL (see section 2.7.2.3). The photographic film was exposed to the membrane until
sharp, clear bands were observed on developing (approximately 10 min exposure). The
bands were then analysed by densitometry using Biorad Quantity One software and
levels of phosphorylation expressed relative to control levels (no PG treatment, same
inhibitor treatment as sample being compared). Normalising the data like this allowed
for any slight background differences between autoradiographs and differences between
patients.
4.2.3 IP3 Pathway
JEG3 cells were diluted to 2 x 105 cells/ml and plated out into 24 well plates at 1
ml/well. They were left overnight before the medium was aspirated and replaced with
DPBS plus tritium (myo-[3H]-inositol at 1 pCi/well). This was left for a further 24
hours, then the medium aspirated and washed once with Buffer A (appendix 1.4.3). Then
500 pi buffer A + 10 mM LiCl was added for 30 min at 37 °C gently shaking. The
medium was aspirated and treatment added for 1 hour. Treatments were 10 nM or 100
nM PGF2a diluted in buffer A, with buffer A as a control. This was then aspirated and
replaced with 500 pi formic acid on ice and incubated at 4 °C for 30 min. This was then
removed from the well and added to a tube and 500 pi Dowex resin added, mixed and
allowed to settle. The top layer was aspirated, and the remaining washed with 1 ml
water. This was mixed, allowed to settle, the top aspirated and 1 ml 60 mM ammonium
formate/5 mM sodium tetraborate added and mixed. After letting this settle and
aspirating the top layer, 1 ml of 1 mM ammonium formate/ 0.1 M formic acid was added
and mixed and allowed to settle. 0.8 ml of the top layer was transferred to a scintillation
tube, scintillation fluid added and the associated radioactivity determined by liquid
scintillation counting for 1 min. (n=2 separate and independent experiments, with




4.3.1.1 PGE2 increases cAMP production in amnion and not chorio-decidua
Cyclic AMP production in response to PGE2 treatment in amnion tissue (Figure 4.2a)
increased significantly after 5, 10 and 15 minutes, with a peak after 10 min. The baseline
(control) level of cAMP was 5.23 ± 0.06 pmol/mg protein. The cAMP levels relative to
the control were as follows: 5 min = 270 ± 7 %; 10 min = 302 ± 45 %; 15 min - 192 ± 7
%. These results were all significant when compared to time 0. The baseline level of
cAMP in the chorio-decidua was 13.93 ± 2.69 pmol/mg protein. cAMP levels also
increased in chorio-decidua (Figure 4.2b), with changes as follows: 5 min = 140 ± 29 %;
10 min = 154 ± 49 %; 15 min = 136 ± 29%. However, none of these results were found
to be significant when compared to the control.
4.3.1.2 PGE2 increases cAMP production in JEG3 cells
In the JEG3 cell-line, cAMP levels were found to increase on stimulation with PGE2
treatment (Figure 4.3). This increase in cAMP was in a time-dependent manner, with a
slight reduction in cAMP levels observed after 15 and 30 min. The baseline cAMP level
was 56.23 ± 3.27 pmol/mg protein. The cAMP relative to control levels was as follows:
2 min =145 ± 8 %; 5 min = 150 ± 17 %; 10 min = 179 ± 9 %; 15 min = 134 ± 12 %, 20
min = 243 ± 22 %; 25 min = 293 ± 15 %; 30 min = 260 ± 27 %; 35 min = 302 ± 37 %.
These increases were all significant.
4.3.1.3 EP2 antagonist inhibits PGE2 stimulation of cAMP in amnion
Addition of an EP2 antagonist totally inhibited the cAMP stimulation in response to
PGE2 treatment after 10 min (Figure 4.4a) in amnion tissue. An EP4 antagonist had no
effect on this response, however a combination of both EP2 and EP4 receptor
antagonists totally inhibited the response like EP2 alone. The cAMP levels relative to
the control were: no antagonist: 174 ± 28 %; EP2 antagonist = 105 ± 7 %; EP4
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antagonist = 179 ±31 %; EP2 + EP4 antagonist = 106 ± 10 %. The rise of cAMP with
PGE2 and with PGE2 in combination with the EP4 antagonist were significant when
compared with the control, and the EP2, and combined EP2 + EP4 antagonist effects







































PGE2 treatment time (min)
15
Figure 4.2: cAMP levels after treatment with 100 nMPGE2 for 0, 5, 10 and 15 min in
(a) amnion and (b) chorio-decidua. * denotes a significance value ofp < 0.05, ** is
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Figure 4.3: cAMP levels in JEG3 cells after treatment with 100 nMPGE2for 0, 2, 5, 10,
15, 20, 25, 30 and 35 min. * denotes a significance value ofp < 0.05, ** is p < 0.01


































Figure 4.4: cAMP levels after treatment with 100 nM PGE2 for 0 and 10 min in the
presence or absence ofEP2 and EP4 antagonists in (a) amnion and (b) JEG3 cells. *
denotes a significance value ofp < 0.05, ** isp < 0.01 compared to the samples with no
antagonist. n=3 patients, with 3 replicates of each treatment.
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4.3.1.4 EP4 antagonist inhibits PGE2 stimulation of cAMP in JEG3 cells
The cAMP levels in response to PGE2 and EP2 and EP4 antagonists were as follows:
PGE2 alone = 179 ±9 %; PGE2 + EP2 antagonist = 226 ± 11 %, PGE2 + EP4 antagonist
= 92 ± 9 %; PGE2 + EP2 + EP4 antagonist = 77 ± 10 % (Figure 4.4b) This shows that
the EP4 receptor antagonist is inhibiting the rise in cAMP seen in response to a 10 min
stimulation with PGE2. The combination of EP2 and EP4 receptors is also inhibiting
this. These 2 inhibitory actions are significant (p < 0.01) when compared to PGE2
treatment with no antagonist. Addition of an EP2 antagonist alone appears to cause a
stimulation of cAMP production which is significant when compared to PGE2 treatment
with no antagonist (p < 0.05).
4.3.2 MAPK results
4.3.2.1 PGE2 and PGF2a do no affect ERK1/2 phosphorylation in fetal membranes
The results of a time course experiment involving treatment of amnion and chorio-
decidua with PGE2 and PGF2a and PD98059 and U73122 inhibitors and measuring
ERK1/2 phosphorylation is shown in Figure 4.5. The graphs show ERK1
phosphorylation levels relative to a control that had not been treated with PG.
Administration of either PG caused no change to ERK1 phosphorylation, results that
were mirrored with ERK2 phosphorylation. Further to this, neither PD98059 nor
U73122 inhibitors caused a change to ERK phosphorylation.
4.3.2.2 PGE2 and PGF2a increase ERK1/2 phosphorylation in JEG3 cells
Treating JEG3 cells with both PGE2 and PGF2a for 10 min caused an increase in ERK
phosphorylation (Figure 4.6). ERK1/2 phosphorylation occurred in a time-dependent
fashion with a slight stimulation after 5 min PGE2 treatment, a significant (p < 0.05)
stimulation after 10 min, and further stimulation after 15 min. With PGF2a treatment,
ERK phosphorylation increased significantly after 10 min (p < 0.05) and further after 15
min. Pre-treatment with PD98059 inhibited this stimulation after both treatments and at
all time points, however this was only significant after 10 min with both PGs (p < 0.05
compared to control after 10 min). U73122 appeared to partially inhibit the PGE2
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Figure 4.5: Relative ERK1 phosphorylation levels, as determined by densitometric
analysis ofWestern blots, on treatment with PGE2 ((a) and (c)) and PGFja ((b) and (d))
in the amnion ((a) and (b)) and chorio-decidua ((c) and (d)). The effects ofpre-treatment
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Figure 4.6: Western blot ofERKl/2 in JEG3 cells upon time course treatment with 100
nM PGE2 (a) and 100 nM PGF2a (b). Effects of treatment ofPD98059 and U73122 are
shown. Densitometry analysis of the Western blot for relative ERKl phosphorylation is
shown in (c) for PGE2 and (d) for PGF2a■ (a = p < 0.05 compared to time 0 values and
b = p < 0.05 compared to un-inhibited samples). n=3.
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4.3.2.3 EP4 and FP antagonists inhibit PG induced ERK1/2 phosphorylation in
JEG3 cells
Pre-treatment with an EP4 or an FP receptor antagonist inhibited the PGE2/PGF2a
increase in ERK phosphorylation (Figure 4.7). Relative ERK1 phosphorylation levels
were as follows: for PGE2 treatment - no antagonist - 290 ± 15 %; EP2 antagonist - 430
± 69 %; EP4 antagonist - 203 ± 10 %; EP2+EP4 antagonists - 204 ± 7 %; for PGF2a
treatment - no antagonist - 264 ± 0.5 %; FP antagonist - 141 ± 13 %. These changes
were mirrored in the ERK2 phosphorylation levels. EP2 receptor antagonist treatment
increased ERK phosphorylation after 10 min PGE2 treatment compared to a control with
no antagonist. An EP4 receptor antagonist, and a combination of EP2 and EP4
antagonists inhibited the response to PGE2 significantly (p < 0.05) compared to a control
with no antagonist. FP antagonist significantly inhibited the PGF2a response after 10 min
(p < 0.05 compared to PGF2a control with no antagonist).
4.3.2.4 An EGFR kinase inhibitor does not affect PG stimulation of ERK1/2
phosphorylation in JEG3 cells
Pretreatment with AG1478 had no significant effect on the PGE2 or PGF2a stimulation
of ERK1/2 phosphorylation. The graph in Figure 4.8 shows these results for ERK1
phosphorylation. The same pattern was observed for ERK2 phosphorylation.
4.3.3 Inositol phosphate release by JEG3 cells is not affected by addition of PGF2ot
No changes in release of total inositol phosphate from JEG3 cells occurred upon
treatment with either of the administered doses of PGF2a (Figure 4.9).
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Figure 4.7: Effect ofEP2, EP4 and FP receptor antagonists on ERK1 phosphorylation
in JEG3 cells. Treatments consisted of 100 nMPGE2 and 100 nMPGF2afor 10 minutes
with or without antagonists. * denotes a significance value ofp < 0.05 compared to the












Figure 4.8: Relative ERK1 phosphorylation, as determined by densitometric analysis of
Western blotting, showing the effect of AG1478, an EGFR inhibitor. Treatments
consisted of 100 nM PGE2 and 100 nMPGF^afor 10 minutes with or without AG1478.
** denotes a significance value ofp < 0.01 and * = p < 0.05 compared to untreated
cells. AG1478 had no significant effect on the increase in ERK1 phosphorylation caused
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Figure 4.9: Relative total inositol phosphate release in JEG3 cells treated with 10 nMor





During parturition, PGE2 and PGF2a exert many different effects on human uterine and
gestational tissue such as stimulating myometrial contractions, ripening of the cervix and
rupture of the fetal membranes. These actions are mediated via specific GPCRs. In the
previous chapter, it was shown that receptors for these ligands, EP2, EP4 and FP are
expressed in human amnion and chorio-decidua and in JEG3 cells. The results in this
chapter show that PGE2 and PGF2a can cause phosphorylation of ERK1/2 via a MEK
dependent pathway mediated through EP4 and FP receptors in JEG3 cells. This pathway
is not PLCp dependent, as shown by lack of inhibition with U73122. It is also clear that
PGE2 is acting via the EP2 receptor in human amnion, and the EP4 receptor in JEG3
cells to provide signalling via the cAMP pathway. These results and are summarised in
the diagram in Figure 4.10 which shows a model of the signalling cascades activated by
prostaglandins in the JEG3 cells.
Measuring cAMP generation in response to PGE2 assessed functional signalling of the
EP2 and EP4 receptors, which are both coupled to stimulatory G-proteins. Through the
use of selective receptor antagonists, it was shown that PGE2 can activate the
cAMP/PKA pathway via the EP2 receptor in human amnion, and via the EP4 receptor in
JEG3 cells. The pattern of response in both the JEG3 cells and the amnion tissue was
with a peak after 10 minutes, and a slight reduction compared to this after 15 min. The
time scale was extended in the JEG3 cells experiments and this pattern was similar after
a further 15 min. This trend could be due to cAMP degradation within the cell, or cAMP
release from the cells during this time course. No significant cAMP response to PGE2
was observed in the chorio-decidua samples, although a small elevation was seen in a
similar pattern and time-scale to that seen in the amnion and JEG3 cells. Due to the
number of cell types in these samples, a positive response in one cell type may be being
masked by another. For example, while the trophoblast cells contain the EP2 and EP4
receptors which are couple to a stimulatory G protein, it is possible that these cells, and
also the cells in the reticular layer contain an isoform of the EP3 receptor which is
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coupled to an inhibitory G protein. Thus, while in some cell types, PGE2 may be
elevating cAMP, in others, it may be inhibiting cAMP production, these effects
cancelling each other out, showing no overall changes. The JEG3 trophoblast cells did
show a response, so it is possible that the trophoblast cells of the chorion, which have
















Figure 4.10: Proposed mechanism ofprostaglandin intracellular signalling in the JEG3
cells. AC; adenyl cyclase, PKA; protein kinase A, ERK; extracellular signal regulated
kinase, MEK; ERK kinase, GTP; guanosine triphosphate, GDP; guanosine diphosphate,
GEE; guanine exchange factor, GAP; GTPase activating protein.
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In the JEG3 cells, the small but significant increase in cAMP generation and the slight
(though not significant) increase in ERK phosphorylation after treatment with PGE2 and
an EP2 antagonist was surprising. A possible explanation is that, in the presence of the
EP2 antagonist, there is more PGE2 available for stimulating the EP4 receptor, which
has been shown to be functional in cAMP and ERK signalling in these cells. This is
supported by the fact that a combination of EP2 and EP4 antagonists inhibits the cAMP
generation and ERK phosphorylation to the same level as that seen with an EP4
antagonist alone. It is also possible that the EP2 antagonist is having agonist effects,
possibly on the EP4 receptor, or the EP1 or EP3 receptors. To fully understand this
system of PGE2 signalling, analysis of EP1 and EP3 receptors would also have to be
carried out.
It is not known what role this elevation of cAMP in response to PGE2 specifically does
in human fetal membranes. It has been shown that PGE2 induced elevations of cAMP in
pregnant rat uterine and cervical tissue can regulate MMP levels (Lyons et al 2002). In
this study, the authors found that in uterine and cervical tissues, PGE2 up-regulated
cAMP significantly in term and preterm pregnant tissue, but not in non-pregnant tissue.
MMP-2 and MMP-9 levels were also elevated in response to PGE2 in the same
circumstances (except uterine MMP-9 levels were unchanged in term tissue). As cAMP
has been shown to induce MMP-2 mRNA transcription (Hasan & Nakajima 1999), the
authors suggested that the PGE2 effect on MMP levels is being mediated via the cAMP
pathway in these rat tissues. It has also been suggested that the PGE2 induced elevation
in cAMP levels play a role in functional progesterone withdrawal in myometrial cells at
labour by increasing the progesterone receptor (PR)-A/PR-B expression ratio. (Madsen
et al 2004a). PGE2 and PGF2a both increased progesterone receptor expression. Addition
of a cAMP analogue, 8-Br-cAMP activated the PKA pathway, as well as increasing PR-
A and PR-B expression, without altering the PR-A/PR-B ratio. Activation of PKC
however, increased expression of only PR-A, and not PR-B, thus increasing the PR-
A/PR-B ratio. This shows that in the myometrium, a PGE2 induced cAMP elevation
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does not facilitate functional progesterone withdrawal, however, PGF2a activation of the
PKC does.
The MAPK pathways are a key signalling mechanism in cells and are a potent regulator
of cell growth, differentiation and development (Lewis et al 1998). MAPK signalling
can be activated by RTKs, GPCRs via activation of small G-proteins such as Ras and
Raf, or by PKA via activation of Rapl (Stork 2003).
From the results in this chapter, activation of the ERK pathway by both PGE2 and PGF2a
in JEG3 cells indicates functional receptor signalling in choriocarcinoma trophoblast
cells. Phosphorylation of ERK1/2 is inhibited by pre-treatment of JEG3 cells with the
MEK inhibitor, PD98059. However, no decrease in PGE2 or PGF2a. induced
phosphorylation of ERK1/2 was observed with U73122, indicating that ERK1/2
phosphorylation is not mediated via PLC(3. As with the PGE2 induced cAMP elevation,
the ERK1/2 phosphorylation was shown to be mediated via the EP4 receptor. However,
addition of this antagonist, or a combination of the EP2 and EP4 antagonists, only
partially inhibited the PG mediated ERK1/2 phosphorylation. This suggests that other
receptors, such as EP1 and EP3 may also be functionally active in these cells and
mediating PG induced ERK1/2 phosphorylation.
MAPK/ERK phosphorylation is usually a consequence of activation of tyrosine kinase
receptors (RTKs). Activation of the MAPK pathway via the FP receptor, which is Gaq-
coupled, can be explained by activation of PLC(3 and PKC and subsequent
phosphorylation of Raf (MAPK kinase kinase). Data has suggested that GPCRs, in
addition to activating G-proteins, also activate MAPK kinase cascades (Faure et al 1994,
Lewis et al 1998). However, the way in which signals are transduced from GPCRs to the
MAPK cascade has been a matter of debate for years. Recent advances suggest that RTK
transactivation is an important pathway that links these GPCRs and the MAPK pathway
(Wetzker & Bohmer 2003). This was first seen when several GPCR agonists were
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shown to have an effect on the EGF receptor in fibroblasts (Daub et al 1996). This link
between RTKs and GPCRS has been seen in at least 3 RTKs: EGF, PDGF and IGF-1 all
become tyrosine phosphorylated after GPCR activation (Luttrell et al 1999).
There are a few models for the transactivation of RTKs by GPCR, one of these being a
'triple-membrane-passing-signalling mechanism' (TMPS). This was first proposed when
it was found that GPCR-dependent stimulation of EGFR involved stimulation of the
matrix metalloproteinases, which in turn induce the extracellular release of heparin
binding-EGF (HB-EGF) from its latent membrane spanning precursor form in the
plasma membrane (Prenzel et al 1999). Similar findings have been shown by others
since (Fujiyama et al 2001, Pierce et al 2001). A diagram of this model is shown in
Figure 4.11a. Different mediators of the Scr-family kinases are involved, as are Ca2+
and PKC. Additional pathways of EGFR transactivation that do not involve
metalloproteinase-mediated HB-EGF release have also been identified. One mechanism
involves the GPCR-triggered recruitment of RTK in a complex with cytoplasmic TKs,
for example Src and Pyk2 (Figure 4.11b). Both of these kinases interact with the EGFR
(Biscardi et al 1999, Keely et al 2000) and Src has also been shown to directly
phosphorylate and activate the EGFR (Biscardi et al 1999). Another model suggests that
GPCR activation may lead to the production of H202 through the activation of NAPDH
oxidases (Figure 4.11c). Protein tyrosine phosphatases (PTPs), which negatively
regulate RTK activity are very sensitive to oxidation, are transiently inactivated (Cys-SH
oxidised to Cys-SOH) by H202, thus inhibiting the deactivation of RTK signalling (Rhee
et al 2000, Wetzker & Bohmer 2003).
Prostaglandin transactivation of RTKs has been observed. In human endometrial
adenocarcinomas, PGF2a binding to the FP receptor has been shown to induce
transactivation of EGFR (Sales et al 2004b), as has PGE2 via the EP2 and EP4 receptors
(Sales et al 2004a). Thromboxane can activate the ERK pathway through its TP receptor,
















Figure 4.11: Possible mechanisms for transactivation of receptor tyrosine kinases
(RTKs) by G-protein coupled receptors (GPCRs). (a) the triple-membrane-passing-
signalling pathway (TMPS); (b) a mechanism involving the recruitment of cytoplasmic
tyrosine kinases: and (c) a route through the activation ofNADPH oxidases and the
subsequent oxidation and inactivation ofprotein-tyrosine phosphatases (PTPs). Figure
adaptedfrom Wetzker and Bohmer 2003.
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The JEG3 cells express both plasma membrane bound EGFR (Cao et al 1994, Fulop et
al 2001) and nuclear EGFR (Cao et al 1995). To ascertain whether the observed
stimulation of the ERK pathway with both PGE2 and PGF2a is linked to the EGFR, cells
were preincubated with an inhibitor of EGFR kinase, AG1478, prior to stimulation with
PGE2/PGF2a. No inhibition of the PGE2/PGF2ct induced stimulation of ERK1/2
phosphorylation was observed upon addition of AG1478. It may be that another RTK,
such as PDGF is transactivated by the prostaglandin receptors, to activate the ERK
pathway. It is also possible that GPCR-dependent stimulation of the ERK/MAPK
cascade does not involve RTKs. For example, non-receptor tyrosine kinases, such as
focal adhesion kinase (FAK) may be involved. FAK is activated by cell binding to ECM
components, and by several agonists acting on GPCRs, such as vasopressin, bradykinin
and endothelin (Igishi et al 1999, Salazar et al 2003). FAK recruits other non-receptor
tyrosine kinases and can activate the ERK/MAPK cascade. The FP receptor has also
been shown to be coupled to Rho, a small G-protein which is upstream of FAK
phosphorylation (Pierce et al 1999). Further experiments using tyrosine kinase inhibitors
of other RTKs, or small G-proteins and adaptor molecules would improve our
understanding of the intracellular signalling events involved in prostaglandin stimulation
of their receptors in JEG3 cells.
The role of prostaglandin induced MAPK pathway stimulation in human uterine and
gestational tissues is unclear. G-proteins have been shown to play a pivotal role in
smooth muscle activation and relaxation by coupling cell membrane receptors to effector
enzymes and ion channels. Clearly, the activation of various transcription factors via this
pathway may play a role in regulation of expression of mediators involved in pregnancy.
Activation of other proteins by phosphorylation may also play a role.
No evidence of levels of inositol triphosphate changes are evident upon treatment of
JEG3 cells with PGF2a indicating that this ligand does not activate the inositol
triphosphate signalling pathway in these cells. Further evidence for this pathway not
being activated comes from a lack of inhibition of PLC(3 by U73122 in ERK1/2
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phosphorylation. If the IP3 pathway had been stimulated, it would be expected that PKC
would have been activated and henceforth the MAPK phosphorylation cascade. If this
was the case, ERK1/2 phosphorylation would be expected to be inhibited by inhibitors
of this pathway. This suggests that ERK1/2 phosphorylation via PGF2a activation of the
FP receptor is dependent on transactivation of RTK.
Taken together, the results from this chapter show that the EP2 receptor is functionally
active in human amnion and that in this tissue, PGE2 stimulation of cAMP occurs via
this receptor. In the JEG3 cells, PGE2 is acting via the EP4 receptor to elevate cAMP
production, and via EP4 and FP to mediate PGE^ PGF2a stimulated phosphorylation of
ERK1/2. The chorio-decidua showed no response to PGs with regards to either of these
pathways which were activated in JEG3 cells. Although JEG3 cells are derived from
human trophoblast cells, they are an immortalised cell line, and exhibit different
receptor-ligand interactions. The chorio-decidua explants used contain a variety of cell
types, giving rise to different paracrine signalling mechanisms. Unless specific chorion
trophoblast cells were isolated for this experiment it will not be known whether the same
effect occurs in this human tissue as in the JEG3 cells.
It has been shown that MMP expression and activation can be increased by PGE2 and
PGF2a (McLaren et al 2000b, Ulug et al 2001) and this regulation may be occurring via
intracellular signalling pathways such as the MAPK cascade, or the cAMP/PKA
pathway. It has been suggested that ERK1/2 regulates MMP-2 production in JEG3 cell
culture (Andrassy et al 2004). These relationships will be further examined in the next
chapter.
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Chapter 5: MMP Production and Regulation in
Human Fetal Membranes and Placenta
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5.1 Introduction and Aims
Extracellular matrix (ECM) remodelling is found in many processes during human
parturition at term and preterm. These include cervical ripening, fetal membrane rupture,
and placental detachment from the maternal uterus (Bryant-Greenwood & Yamamoto
1995, Rajabi et al 1988, Tsatas et al 1999). Matrix metalloproteinases (MMPs) are the
main mediators of ECM degradation, particularly the gelatinases, MMP-2 and MMP-9
have been implicated in parturition (Riley et al 1999a, Stygar et al 2002, Vadillo-Ortega
et al 1995, Xu et al 2002). The activity of MMPs is regulated by their physiological
inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), inhibition occurring by
the formation of a 1:1 MMP:TIMP complex.
It has been found that levels of certain MMPs are present and elevated in uterine and
gestational tissues at labour. MMP-9 production in the rat amnion is induced prior to
labour (Lei et al 1995). Similar changes are seen in the human. MMP-9 production is
elevated in amnion, chorion, decidua and placenta (Goldman et al 2003, McLaren et al
2000a, Tsatas et al 1999, Uchide et al 2000, Xu et al 2002) with the activity increasing
in the amnion at the onset of labour (Goldman et al 2003, Maymon et al 2000a, McLaren
et al 2000a, Vadillo-Ortega et al 1995). MMP-2 production is also elevated in amnion,
chorion, decidua and placenta (Goldman et al 2003, McLaren et al 2000a, Xu et al
2002). Activity of MMP-2 is increased in decidua with labour, with no changes seen in
amnion, chorion or placental samples (Goldman et al 2003, Xu et al 2002). MMP-2 and
MMP-9 production both increase in human cervical tissue at term, implicating both
these enzymes in the process of cervical ripening (Stygar et al 2002). Decreases in levels
of TIMPs and an increase in the balance of the MMP:TIMP ratio have also been
implicated in labour (Riley et al 1999b, Vadillo-Ortega et al 1996).
Prostaglandins and cytokines may be among the regulatory factors responsible for the
increased levels of MMP expression and activity in the fetal membranes associated with
rupture, and may also be involved in cervical ripening. In fact MMP-9 secretion from
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human cervical fibroblasts (Sato et al 1996), trophoblasts (Shimonovitz et al 1996) and
endometrial stromal cells (Huang et al 1998) are stimulated by hormones and cytokines.
Intrauterine infection has been associated with higher MMP-9 concentrations in
amniotic fluid, whether or not rupture occurred (Athayde et al 1998, Draper et al 1995,
Vadillo-Ortega et al 2002). MMP-9 is stimulated by IL-ip and TNF-a in human amnion
but not chorion (Arechavaleta-Velasco et al 2002). In the rhesus monkey, bacterial and
IL-lfl induced preterm labour and spontaneous labour are preceded and accompanied by
progressive increases in amniotic fluid MMP-9 levels (Vadillo-Ortega et al 2002). Thus,
amniotic fluid MMP-9 may be a good clinical marker for onset of both preterm and term
labour. The role of MMP-9 as a clinical marker for preterm labour and intra-amniotic
infection has been investigated and was found to be a potentially valuable tool
(Locksmith et al 1999). Cytokine effects on human myometrial smooth muscle MMP
production have also been studied. IL-ip and TNF-a both induced MMP-9 production,
though 17(3-oestradiol and progesterone did not (Roh et al 2000). Progesterone did not
decrease the cytokine mediated stimulation of MMP-9 either, despite it having been
shown to be a physiological suppressor of MMP-9 (Roh et al 2000). In human
trophoblast cells, MMP-9 is suppressed by progesterone (Shimonovitz et al 1998), which
also occurs in rabbit cervical fibroblasts (Imada et al 1997), and progesterone also
increases TIMP-2 expression in these cells (Imada et al 1994).
Various prostaglandin effects on MMPs have been reported. PGE2 has been linked to
elevated MMP-9 production by cultured human fetal membranes (McLaren et al 2000b).
This PG has also been shown to elevate plasma, uterine and cervical MMP-2 levels in
preterm and term pregnant rats, and to induce MMP-9 in preterm plasma and uterus in
term pregnant rats (Lyons et al 2002). PGF2a elevates MMP-2 and MMP-9 production,
and MMP-2 activation and decreases TIMP-1 levels in human term decidua, with no
effect on these proteins in fetal membrane samples (Ulug et al 2001). Prostacyclin has
been shown to be concerned with inhibiting MMP-9 production in human cultured
mesangial cells (Kitahara et al 2001), although no role has been found in tissues
involved in labour. COX-2 promotes the release of MMP-2 and MMP-9 in fetal rat
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hepatocytes (Callejas et al 2001), but again there is no evidence for involvement of this
process in labour.
In this chapter, the effect of prostaglandins, PGE2 and PGF2a on the production and
activation of MMP-2, MMP-9 and TIMPs in cultured human fetal membranes and
placenta, and the JEG3 choriocarcinoma cell line will be examined. The effect of a pro¬
inflammatory cytokine, IL-6 on MMP-2 in the JEG3 cell-line will also be investigated.
5.2 Methods
5.2.1 Effect of PGE2 and PGF2ct on MMP-2 and MMP-9 Production and
Activation in Human Fetal Membranes
Amnion and chorio-decidua were collected and cultured as in section 2.2.1. Treatments
added to the 1 ml culture medium for a 24 hr incubation were 100 nM, 10 pM and 100
pM PGE2 and PGF2a and a control with no treatment. Background samples were also
taken which consisted of 1 ml media without tissue or treatment. Culture medium
harvested from these wells was freeze dried and amnion samples were reconstituted in
100 pi water, chorio-decidua samples in 50 pi water. 5 pi samples were mixed with an
equal volume of zymography sample application buffer (appendix 1.5.2.1) and
zymography carried out. The zymograms were analysed by densitometry and values
expressed as a percentage of the control. Reverse zymography was also carried out on
the same samples with 7.5 pi sample mixed with 7.5 pi reverse zymography application
buffer. n=5 patients, and each treatment was carried out in quadruplicate.
5.2.2 Effect of PGE2 and PGF2a on TIMP Production in Human Fetal
Membranes
Reverse zymography, to detect TIMP activity, was also carried out on all the samples
above, with 7.5 pi sample mixed with 7.5 pi sample application buffer loaded into the
gels. This allows identification of TIMP-2, an unglycosylated form of TIMP-3, and a
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band at the molecular weight of TIMP-1, 4 and a glycosylated version of TIMP-3. To
further clarify these bands, Western Blot analysis was carried out. Equal volumes of
each of the 4 quadruplicates were pooled (to provide enough volume of sample) and 20
pi sample mixed with 20 pi Western sample application buffer (appendix 1.5.1.3) and
loaded into a well. The gels used were 12 % acrylamide. The procedure was carried out
as in section 2.7.2.3. The primary antibody incubation time was 2.5 hr. Exposure time
was dependent on the blot. The primary antibodies for TIMP-l, 2, 3 and 4 were all
human anti-rabbit monoclonal antibodies and used at a dilution of 1:1000 from the
stock. The secondary antibody was a donkey anti-rabbit. Reverse zymograms and
Western Blots were analysed by densitometry using Quantity One.
5.2.3 Indomethacin Effect on PGE2 in Amnion and Chorio-decidua
Samples of amnion, chorio-decidua and placenta were collected and divided into 3
categories: no indomethacin treatment, indomethacin pre-treatment, and indomethacin
pre-treatment and treatment. The first group were treated as previously, with a 2 hr
incubation in steeping buffer. The second and third groups had additionally 10 pM
indomethacin added at this stage. The third group had 10 pM indomethacin added to the
wells, along with the prostaglandins for the 24 hr incubation. The control samples with
no prostaglandin also received indomethacin. After the 24 hr incubation, medium was
treated 1:1 with methyloximating solution and a PGE2 assay carried out. The tissue was
also removed and fixed (section 2.1.2) and H and E staining carried out (section 2.4.2.4).
In this experiment, n=3 patients.
5.2.4 Effect of PGE2 and PGF2a on MMP-2 and MMP-9 with Indomethacin Pre-
treatment
Amnion, chorio-decidua and placenta were collected as previously described. They were
treated in steeping buffer containing 10 pM indomethacin prior to being cut and explants
placed in wells. They were then treated with either 100 nM PGE2 orlOO nM PGF2a or
not treated as a control, with 6 wells of a 24 well plate for each treatment. Treatments
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were left for 8 or 24 hr, upon which medium was collected (500 pi each combined to 1
ml from 2 duplicate wells, leaving 3 samples of 1 ml for each treatment). Medium was
frozen at - 70 °C before being freeze dried, and amnion samples reconstituted in 50 pi,
chorio-decidua and placenta samples in 100 pi. 7 pi of each sample, combined with 7 pi
sample application buffer was loaded into gels and zymography performed. n=4 patients
with each treatment being carried out in triplicate.
The same experiment was also performed using JEG3 cells. These were plated out as in
section 2.3 and left for 2 days to stick down and reach confluence. At this stage, medium
was aspirated and replaced with serum free medium with 10 pM indomethacin for 24 hr.
This was aspirated and treatments (control, 100 nM PGE2 or PGF2„ and also 0.5 nM IL-
6) added for 2, 8, 12 and 24 hr. 1 ml of medium was collected, freeze dried and
reconstituted in 50 pi water. Zymography was performed on these samples, as above.
5.2.5 Effect of PGE2 and PGF2a on TIMP Production with Indomethacin Pre-
treatment
Using the samples from section 5.2.4, TIMP production was also analysed. The
triplicates (same treatment) of the samples from each patient were pooled and dialysed
before being freeze dried and run on a gel and Western blotted for TIMPs 1-4, as in
section 5.2.2. The samples were also analysed by reverse zymography.
5.2.6 Cellular MMP-2 and MMP-9 Content in JEG3 Cells
JEG3 cells were also homogenised after aspiration of the medium to examine
intracellular levels of MMP. Here, cells were plated out in 75 cm3 flasks with 25 ml of
cells at 2 x 105 cells/ml, left to reach confluence, then left with serum free medium for
24 hr. The medium was then removed, and the cells trypsinised. 5 ml medium with
serum was then added and the cells spun down at 10,000 g for 5 min. The medium was
then aspirated from this and the pellet frozen at -20 °C. They were then resuspended in
0.5 ml homogenisation buffer (appendix 1.5.1.1) on ice, and homogenised using the
156
Chapter 5
Polytron on high power for 30 s. They were then centrifuged at 10, 000 g at 4 °C for 15
min. A Western blot was then run, using 20 pi of the homogenised sample and
immunoblotted for MMP-2 and MMP-9. These antibodies are both human anti-mouse
monoclonal antibodies, used at a dilution of 1:1000 from the stock and detected with
sheep anti-mouse secondary antibody. The samples were also analysed by zymography.
For this experiment, n=10 individual flasks of cells.
5.2.7 Effect of PGE2 and PGF2a on MMP-2 and MMP-9 mRNA
Using the same samples as above, at the time when the medium was aspirated, tissue and
cells were treated with tri-reagent and RNA extracted (section 2.5.1-2.5.4). The samples
were then analysed using the Lightcycler for changes in MMP-2 and MMP-9 mRNA
levels (see section 2.5.5 for use of the Lightcycler). G-6-PDH was used as the control
gene for both MMP-2 and MMP-9 quantification reactions. The sequences for the
primers used are shown in Table 5.1. Annealing temperature and MgCl2 concentration
were optimised for MMP-2 and MMP-9 and are shown in Table 5.2.
Control samples were tested at these conditions to check the standard curve was linear
for the MMP and G-6-PDH genes. Then the melt curve was analysed to find the best
temperature to make a reading each cycle. These were found to be 87 °C for MMP-2 and
86 °C for MMP-9. Once these reaction conditions were optimised, samples were all run
on the lightcycler, in duplicate, to quantify MMP-2 and MMP-9 mRNA.
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Product Primer Sequence 5' - 3' Product size
G-6-PDH forward
reverse
CGG AAA CGG TCG TAC ACT TC




ATG ACA GCT GCA CCA CTG AG




TTG ACA GCG ACA AGA AGT GG
GCC ATT CAC GTC GTC CTT AT
179 bp
Table 5.1: Primer sequence andproduct size for G-6-PDH, MMP-2 andMMP-9
primers.
Primers Annealing temperature MgCl2 concentration for lightcycler
MMP-2 61 °C 5mM
MMP-9 63 °C 4 mM
Table 5.2: Optimised annealing temperature andMgCh concentration for use ofMMP-
2 andMMP-9primers with the lightcycler.
5.3 Results
5.3.1 Effect of PGE2 and PGF2a on MMP-2 and MMP-9 Production and
Activation in Amnion and Chorio-decidua
Figure 5.1 shows a sample zymogram for each of amnion, chorio-decidua and placenta.
The latent forms of MMP-2 and MMP-9 have been detected in all three of the tissue
types. It is this latent form of these MMPs that has been analysed. The effects of PGE2
and PGF2a are shown in 4 graphs in Figure 5.2. In the amnion, 1 pM PGE2 has slightly
but significantly increased MMP-2 levels (p < 0.05). 100 nM PGF2a has significantly (p
< 0.01) increased MMP-2 levels slightly and MMP-9 levels to about 250 % of control
levels. 1 pM PGF2a has significantly (p < 0.05) increased MMP-2 levels, and 10 pM
PGF2a has significantly (p < 0.01) increased MMP-9 levels to almost 200 % of the
control. In the chorio-decidua, 10 pM PGE2 has slightly (p < 0.01) but significantly












Figure 5.1: Sample zymograms for amnion, chorio-decidua and placenta showing their
production ofactive and latent forms ofMMP-2 andMMP-9. The amnioticfluid (AmFl)
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Figure 5.2: The effects of incubation with 100 nM, 1 /jM, or 10 pM PGE2 (a and c) and
PGF2a (b and d) for 24 hr on MMP-2 andMMP-9 production in amnion (a and b) and
chorio-decidua (c and d) explants as determined by densitometric analysis of
zymograms. * and ** denote significance values ofp < 0.05 and p < 0.01 respectively




5.3.2 Effect of PGE2 and PGF2a on TIMP Production in Amnion and Chorio-
decidua
Figure 5.3 shows a sample reverse zymogram for each of amnion, chorio-decidua and
placenta. TIMPs activities at 21, 24 and 27-30 kDa have been detected in all three of the
tissue types. Results of reverse zymogram analysis are shown in Figure 5.4. It appears
that in the amnion, 100 nM PGE2 has caused over a than 50 % reduction in levels of
TIMP with a molecular weight of between 27-30 kDa and 24 kDa. 1 pM PGE2 has also
reduced 27-30 kDa TIMP levels to around 50 % that of controls. 10 pM PGF2a has
caused a reduction in a 21 kDa TIMP. No effect of PGs on TIMP levels was shown in
the chorio-decidua. The same samples analysed by Western Blot show large standard
error of the mean (Figure 5.5). No effects were identified in amnion samples, however,
these results showed that PGF2a decreased the production of TIMP1 to less than 50 %
that of controls.
5.3.3 Indomethacin Effect on PGE2 in Amnion and Chorio-decidua
It was thought that endogenous protaglandins may be masking effects of the treatments
given to tissue. Addition of indomethacin, a dual COX enzyme inhibitor, inhibits
endogenous prostaglandin biosynthesis. Levels of PGE2 were measured before and after
treatments with indomethacin to estimate the degree to which it was being inhibited and
to compare endogenous levels to doses given as treatments. Endogenous levels in media
from untreated tissue in amnion, chorio-decidua and placenta were 1.36 ± 0.66, 0.15 ±
0.04 and 3.51 ± 1.17 ng/ml, respectively (Figure 5.6a). This is far lower than the lowest
dose of PGE2 given, which at 100 nM is equivalent to 35 ng/ml. Indomethacin treatment
for 2 hours prior to a 24 hr incubation reduced PGE2 levels to 0.22 ± 0.05 ng/ml in the
amnion, 0.10 ± 0.001 ng/ml in the chorio-decidua and 0.77 ± 0.27 ng/ml in the placenta.
Levels were further decreased after treatment with indomethacin for the 24 hr incubation
(0.20 ± 0.08, 0.08 ± 0.001 and 0.09 ± 0.005 ng/ml in the amnion, chorio-decidua and
placenta, respectively). A similar pattern of decreasing PGE2 concentration with
indomethacin treatment was observed with the PGE2 treatment for 24 hr (Figure 5.6b),
















Figure 5.3: Sample reverse zymograms for amnion, chorio-decidua and placenta
showing their production of TIMPs with activities of 27-30 kDa, 24 kDa and 21 kDa.
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Figure 5.4: The effects of incubation with 100 nM, 1 /uM, or 10 juM PGEi (a and c) and
PGF2a (b and d) for 24 hr on TIMP production in amnion (a and b) and chorio-decidua
(c and d) explants as determined by densitometric analysis of reverse zymograms. * and
** denote significance values ofp < 0.05 and p < 0.01 respectively when compared to
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Figure 5.5: The effects of incubation with 100 nM, 1 juM, or 10 pM PGE? (a and c) and
PGF2a (b and d) for 24 hr on T1MP production in amnion (a and b) and chorio-decidua
(c and d) explants as determined by densitometric analysis of Western blots. * denote











































Figure 5.6: Effect of indomethacin on PGE2 output in amnion, chorio-decidua and
placenta explants in (a) samples with no PGE2 treatment and (b) samples with 100 nM
PGE2 administeredfor 24 hours before assayingfor PGE2. n=3 patients.
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In order to check that this indomethacin treatment had no adverse effects on the
histology of the tissue, H and E staining was performed on fixed tissue blocks at
different stages of the indomethacin treatment. The result of this immunohistochemical
analysis is shown in Figure 5.7. No apparent differences were observed between tissue
before and after exposure to a 2 hr indomethacin pre-treatment or a further 24 hr
indomethacin treatment. As a consequence of this and the prostaglandin assay results, it
was decided that a 2 hr indomethacin pre-treatment of tissue would be sufficient to
inhibit endogenous prostaglandins to levels low enough that they would not mask the
effects of PG treatment.
5.3.4 Effect of PGE2 and PGF2a on MMP-2 and MMP-9 with Indomethacin Pre-
treatment
Results of zymogram analysis are shown in Figure 5.8. Graphs are presented with values
as a percentage of the control at the relevant time. Levels of MMPs were higher after 24
hours compared to 8 hours, due to accumulation of the MMP in the media. In the
amnion, PGE2 treatment for 24 hr has caused MMP-2 levels to increase very slightly
though significantly. In the chorio-decidua, PGF2a has slightly but significantly
increased MMP-9 after 8 hr and MMP-2 production after 24 hr treatment.
In JEG3 cells, it is mainly MMP-2 being produced (Figure 5.9a). A third band suspected
to be another form of MMP-2 is visible below the latent and active forms of MMP-2 on
the zymogram. This was confirmed to be a form of MMP-2 after it was detected by a
specific MMP-2 primary antibody using Western blotting (Figure 5.9b). MMP-9 is
being produced but at such low levels that detection is barely possible by zymography
analysis, thus it is MMP-2 that has been analysed for the following experiments. After
just 2 hr, PGF2a significantly stimulated MMP-2 production to 135 % of control levels,
and after 24 hr, PGE2 raised MMP-2 levels to 125 % of the controls. A significant
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Figure 5.7: H&E staining to show effects of indomethacin pretreatment on histology of
amnion, chorio-decidua andplacenta samples. Treatments are (a) control samples after
2 hr steep with no indomethacin (b) after 2 hr incubation in indomethacin (c) after 2 hr
with no indomethacin, then 24 hr without (d) after 2 hr with indomethacin then 24 hr
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Figure 5.8: MMP-2 and MMP-9 production by (a) amnion (b) chorio-decidua and (c)
placenta after preincubation with indomethacin, then incubation with 100 nM PGE2 or
PGF2afor 8 or 24 hr, as determined by densitometric analysis ofzymograms. * and **
denote significance values ofp < 0.05 and p < 0.01 respectively when compared to















Figure 5.9: Representative zymogram (a) and Western blot (b) to show presence of
latent and active forms ofMMP-2 in cultured JEG3 cells.
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Figure 5.10: MMP-2 production in JEG3 cells after preincubation with indomethacin,
then a time course of incubations with (a) 100 nM PGE? or PGF2a end (b) 0.5 nM IL-6
as determined by densitometric analysis of zymograms. * and ** denote significance
values of p < 0.05 and p < 0.01 respectively when compared to control untreated
samples. n=3 separate experiments with treatments carried out in triplicate.
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5.3.5 Effect of PGE2 and PGF2a on TIMP Production with Indomethacin Pre-
treatment
The results of the analysis of TIMP production are shown for reverse zymography
{Figure 5.11) and Western blotting {Figure 5.12). No significant alterations in TIMP
levels are observed on addition of either prostaglandin. Due to antibody problems, levels
of TTMP3 could not be measured.
5.3.6 Cellular MMP-2 and MMP-9 Content in JEG3 Cells
The latent form of MMP-2 was found in a zymogram of homogenised JEG3 cell
samples {Figure 5.13). The same samples analysed showed trace levels of MMP-9 and
also the active form of MMP-2 in addition to the latent form of MMP-2. All were
expressed at lower levels than that seen in analysed media from these cells after 24 hr,
suggesting most MMP-2 is secreted.
5.3.7 Effect of PGE2 and PGF2a on MMP-2 and MMP-9 mRNA
Results from lightcycler analysis of MMP-2 and MMP-9 mRNA in amnion, chorio-
decidua and placenta stimulated with of PGE2 and PGF2a are shown {Figures 5.14 and
5.15). According to statistical analysis, none of the treatments produced any significant
changes in MMP-2 or MMP-9 mRNA levels, however, a few changes are evident. In the
amnion, after 8 hr treatment with PGF2a, MMP-2 and MMP-9 mRNA levels were
elevated 160 % and 150 % respectively, compared to controls. In the chorio-decidua
after 8 hr, of PGE2 and PGF2a had increased production of MMP-9 to 130 % that of
controls. After 24 hr, these prostaglandins also elevated both MMP-2 and MMP-9
mRNA, for PGE2 treatment to 170 % that of control and PGF2a treatment to 150 % that
of controls. In the placenta, MMP-2 mRNA production was almost doubled on addition
of PGF2ct for 8 hr.
In JEG3 cells, MMP-2 mRNA production has been significantly stimulated by 4 hr































Figure 5.11: TIMP production by (a) amnion (b) chorio-decidua and (c) placenta after
preincubation with indomethacin, then incubation with 100 nMPGE2 or PGFia for 8 or
24 hr, as determined by densitometric analysis of reverse zymograms. n=4 patients with
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Figure 5.12: TIMP production by (a) amnion (b) chorio-decidua and (c) placenta after
preincubation with indomethacin, incubation with 100 nMPGE2 or PGF2afor 24 hr. as
determined by densitometric analysis ofWestern blots. Sample Western blots for TIMPs
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Figure 5.13: Representative zymogram (a) and Western blots (b) to show cellular

























































Figure 5.14: MMP-2 rnRNA levels in (a) amnion (b) chorio-decidua and (c) placenta
after preincubation with indomethacin. then a time course ofincubations with 100 nM
PGEi or PGF2a as determined by quantitative PGR using the Lightcycler. n=3 patients

























































Figure 5.15: MMP-9 mRNA levels in (a) amnion (b) chorio-decidua and (c) placenta
after preincubation with indomethacin, then a time course of incubations with 100 nM
PGEi or PGF2a as determined by quantitative PGR using the Lightcycler. n=3 patients
with treatments carried out in triplicate.
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controls, respectively (Figure 5.16). After 24 hours, PGE2 and PGp2a significantly
increased MMP-2 mRNA levels by 175 % and 190 % that of controls.
Figure 5.16: MMP-2 mRNA levels in JEG3 cells after preincubation with indomethacin,
then a time course of incubations with 100 nM PGE2, 100 nM PGF2a and 0.5 nM 1L-6,
as determined by quantitative PCR using the Lightcycler. * and ** denote significance
values of p < 0.05 and p < 0.01 respectively when compared to control untreated




Degradation of fetal membranes and the adjacent decidua are essential processes for
rupture of the fetal membranes at term and preterm. The gelatinases, MMP-2 and MMP-
9 digest collagen in these tissues and are thus implicated in rupture of these membranes.
It has been suggested that prostaglandins play a role in up-regulating the production of
MMP-2 and MMP-9 in gestational tissues, and decreasing the production of the TIMPs,
the endogenous inhibitors of MMPs (Ulug et al 2001). The results presented in this
chapter show evidence that PGE2 and PGF2a can up-regulate the gelatinases and inhibit
TIMP production in amnion, chorio-decidua and JEG3 cells. They have also
demonstrated a prostaglandin stimulated up-regulation of MMP-2 mRNA production in
JEG3 cells.
These experiments were designed using tissue from patients with term pregnancies who
were not in labour and undergoing elective caesarean section. This was because it was
assumed that this tissue would be "un-primed" by prostaglandins whose levels are
known to increase in the fetal membranes and placenta during labour (Challis et al 2000,
Thorburn 1991, Van Meir et al 1997). The addition of prostaglandins in theory then
creates in vivo the conditions which prostaglandins contribute to during labour. It would
have been interesting to compare spontaneous labour tissue, and also preterm patients,
but due to ethical and practical considerations, these experiments could not be
performed. To investigate the effect of prostaglandins on MMP and TIMP production, it
was decided that a preincubation of indomethacin would be necessary to obliterate the
effects of endogenous prostaglandins which may mask the effects of the treatments. It
was unclear whether the results from experiments with no indomethacin pre-treatment
would be a true representation of the effect of prostaglandin stimulation on MMPs.
Indomethacin is a commonly used non steroidal anti-inflammatory drug (NSAID). It is a
non-selective COX-inhibitor, so it reduces prostaglandin synthesis. It appears from these
results to not have any damaging histological effects on the tissue, and to reduce
endogenous PGE2 levels to much lower than the doses used, so it was considered an
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effective step in the experiment. In similar studies, indomethacin has been found to
reduce the secretion of latent MMP-2 and MMP-9 in fetal membranes but not decidua,
and increase the production of TIMP- in fetal membranes but not decidua, suggesting
the reduction in prostaglandins levels is reducing the prostaglandin stimulation of MMP
production (McLaren et al 2000b, Ulug et al 2001).
MMP-2 and MMP-9 have been shown to be released by human fetal membranes and
placental tissue. Analysis of JEG3 cells show that these produce predominantly MMP-2,
with small amounts of MMP-9 and that most MMP is secreted and not stored within the
cell. Any large changes in MMP and TIMP production upon prostaglandin treatment
have not been obvious from the experiments in this chapter. It appears that, with the
indomethacin pre-treatment, the only significant effect is a very small stimulation of
MMP-2 by PGE2 after 24 hours, PGF2a stimulating MMP-9 production after 8 hours,
and MMP-2 production after 24 hours. In these same samples, TIMP levels are
unaffected by the addition of PGE2 and PGF2a. The results of the JEG3 experiments
showed small but significant changes in MMP-2 production after 2 hours with PGF2a
and 24 hours with PGE2. MMP-9 production within these cells was minimal so any
measurement using quantification of zymography would have been inaccurate. TIMP
measurements by reverse zymography and Western blotting with indomethacin
pretreatment showed no changes with prostaglandin treatment. The reverse zymography
experiments with no indomethacin pretreatment suggest that PGE2 is inhibiting TIMP
activities at 27-30 kDa and 24 kDa in the amnion. However, these results were not
consistent with Western blotting of the same samples, so the true nature of PGE2 and
PGF2a regulation of TIMPs in fetal membranes remains unclear. TIMPs in the JEG3
cells were expressed at such low levels that they were barely detectable by Western
blotting or reverse zymography, so quantification was not possible. Analysis of TIMP
mRNA by PCR could have given a useful insight into this study.
These results go alongside results from recent experiments, in which PGE2 was found to
stimulate MMP-9 secretion in cultured fetal membranes in a dose dependent manner,
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with significant increases being at 1, 10 and 100 nM PGE2, where over 2-fold increases
in MMP-9 secretion are observed (McLaren et al 2000b). PGF2a had a similar effect in
cultured decidual samples, causing around a 2-fold increase in MMP-2 and MMP-9
production, a large significant increase in the active form of MMP-2, and a 70 %
reduction in TIMP-l levels (Ulug et al 2001). These authors found that PGF2a had no
effect on the gelatinases and TIMP-l in the amnion and chorio-decidua.
It is possible that the culture model used in this chapter may have not been effective in
allowing MMP protein stimulation with the prostaglandins. There may have been some
limiting factor or inhibition mechanism within the culture set-up, such as the
composition of nutrients in the media, which did not allow for the intracellular pathways
required to occur, or for translation to take place. So, as well as protein levels, MMP-2
and MMP-9 mRNA levels were monitored upon treatment with prostaglandins. In the
amnion, chorio-decidua and placenta, the prostaglandins had no effect on MMP-9
mRNA production. However, MMP-2 mRNA levels were increased slightly by PGF2ot
after 8 hr in amnion and placenta culture, and by PGE2 and PGF2a after 24 hr in chorio-
decidua, though these results were not statistically significant. Both PGE2 and PGF2a
significantly stimulated MMP-2 mRNA production after 4 and 24 hr treatments in JEG3
cells.
IL-6 effects on MMP-2 and MMP-9 production were investigated in JEG3 cells. Here,
latent MMP-2 production was stimulated nearly 2-fold after 12 hours of incubation with
0.5 nM IL-6. IL-6 also stimulated MMP-2 mRNA levels by nearly 2-fold after only 4
hours. Using the JEG3 cells as a model of chorion trophoblast cells, this suggests that
IL-6, and possibly other proinflammatory cytokines may be involved in the rupture of
fetal membranes and placental detachment by stimulating the degradative MMP
enzymes.
The distribution of MMP-2 and MMP-9 within uterine and gestational tissues is quite
distinct. MMP-2 is localised to the amnion mesenchyme, the chorion trophoblast, the
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decidua parietalis and blood vessels in the placental villi. MMP-9 is detected in amnion
epithelium, chorion trophoblast, decidua parietalis and placental syncitiotrophoblasts
(Xu et al 2002). This variation may be due to the different collagen components of these
cell layers. Both MMP-2 and MMP-9 degrade collagen IV, but only MMP-2 digests
collagen I, which is found in the amnion mesenchyme layer (Bryant-Greenwood 1998).
These differential localisations of MMP-2 and MMP-9 may be important for the rupture
of the fetal membranes and placental separation.
MMP-2 and MMP-9 production and activation are also regionally controlled within the
fetal membranes. A zone of altered morphology (ZAM) has been identified as a
restricted area of the fetal membranes after their spontaneous rupture (Malak & Bell
1994b). This area is structurally weaker due to degradation of ECM. Similar alterations
have been identified in the fetal membranes in the lower uterine segment overlying the
cervix (McLaren et al 1999). Here, pro-MMP-9 levels are higher prior to labour
compared to fetal membrane tissue examined from the midzone and the placental edge,
whilst pro-MMP-2 levels are not different. With the onset of labour, the pro and active
forms of both MMP-2 and MMP-9 increase in all regions (McLaren et al 2000a). The
authors propose that before labour, the increase in pro-MMP-9 may provide a store of
potential activity that, if activated, possibly by the actions of labour it self, will
preferentially weaken the membrane to increase its susceptibility to labour. Prior to
delivery it is weakened by the generalised increased activity of MMPs and represents the
initial site of rupture that is identified as the ZAM. Changes in control of this mechanism
of MMP-9 action could result in preterm premature rupture of the membranes.
Little is known about the contribution of TIMPs to tissue remodelling during labour. The
technique of zymography by which most research groups detect active and latent forms
of MMP, only detects MMPs which are unbound. Thus, the true enzymatic activity may
not be measured using this technique, if the active form of the enzyme is bound and
inhibited by a TIMP. A precise balance of TIMPs and MMPs is necessary to control
actual enzymatic activity. TIMPs 1-4 have all been detected in amniotic fluid and
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amnion, chorion, decidual and placental tissue (Fortunato et al 1998, Riley et al 1999b),
although TIMP-4 was expressed at very low levels in amniotic fluid. Levels of TIMPs 1-
3 were significantly higher in elective caesarean section amniotic fluid samples than
those from spontaneous labour, showing a decrease in levels with the onset of labour
(Riley et al 1999b). There were relatively low levels of TIMPs in the amnion compared
with the other tissues mentioned, suggesting the amnion is not the source of TIMPs in
the amniotic fluid.
A change in the precise balance of MMP and TIMPs has been implicated in preterm
premature rupture of the fetal membranes (PPROM). Elevated amniotic fluid
concentrations of MMP-9 were found to be higher in PPROM compared to preterm
labour (Romero et al 2002) and PROM compared to term labour (Vadillo-Ortega et al
1996). MMP-2 and MMP-9 latent and TTMP-free active forms were both elevated in
amniotic fluid in PPROM compared to preterm and term labour (Fortunato et al 1999).
Furthermore, TIMP-1 levels were found to be lower in amniotic fluid from term PROM
than term labour (Vadillo-Ortega et al 1996). In amniochorion membranes,
lipopolysaccharide can elevate the expression and release of both gelatinases, and
decrease TIMP-2 levels, shifting the ratio in favour of gelatinase activity (Fortunato et al
2000). Shifting this balance increases membrane degradation by the MMPs,
predisposing the individual to PPROM.
The incidence of preterm birth and PPROM differs among ethnic groups with the risk of
preterm birth for African Americans being more than twice that of Caucasians (Hoffman
& Ward 1999). PPROM is also more likely to precede spontaneous labour in African
Americans (Ventura et al 2001). This suggests genetic factors are involved in PPROM.
MMP-9 expression is primarily regulated at the transcription level. Several
polymorphisms have been identified in the MMP-9 gene, and these are postulated to
play a role in PPROM due to the effects of MMP-9 on fetal membranes (Ferrand et al
2002). This group have investigated two polymorphisms in the proximal promoter: a
variable CA repeat, and a single nucleotide polymorphism (SNP). In African American
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women, the presence of a 14 CA-repeat displayed significantly increased activity in
isolated amnion epithelial cells compared to a 20 CA-repeat. The 14 CA-repeat is more
common than any other variation and is more represented in neonates from pregnancies
complicated by PPROM than others. Despite this, this allele is less common in African
Americans than Caucasians (St Jean et al 1995), so cannot be used to explain the higher
incidence of PPROM in these women.
Other MMPs may also be involved be involved in parturition, and may also be affected
by prostaglandins and cytokines. MMPs -1, -7 and -8 have all been implicated in
PPROM (Maymon et al 2000a, Maymon et al 2000b, Maymon et al 2000c). MMP-1 is
present in amniotic fluid and increases in this were associated with PPROM, in the
presence and absence of intrauterine infection, though no changes in MMP-1 were
associated with term or preterm labour. MMP-7 concentrations in the amniotic fluid
increase with advancing gestational age. Preterm gestations showed an increase in
MMP-7 with microbial invasion of the amniotic cavity. MMP-8 concentrations in
amniotic fluid increased with spontaneous labour at term and preterm. Spontaneous
rupture of the membranes was also associated with elevations of MMP-8 in preterm but
not term gestations. MMP-13 has been shown to be present in amniotic fluid and
constitutively expressed in fetal membranes, and not to be associated with PPROM
(Fortunato et al 2003).
An extracellular matrix metalloproteinase inducer (EMMPRIN) has been discovered and
characterised and is shown to be a glycoprotein and a member of the immunoglobulin
superfamily (Biswas et al 1995). As well as playing a role stimulating MMP production
in cancer systems, EMMPRIN has recently been implicated in parturition (Li et al 2004).
EMMPRIN was detected in term placenta and fetal membranes in three forms: 40 and
65 kDa (glycosylated protein) and 30 kDa (nonglycosylated). While there were no
changes in total EMMPRIN, the relative amount of the 65 kDa form significantly
increased in term labour amnion and chorio-decidua compared with non-labour. This
shows that MMP production can be stimulated in the fetal membranes and placenta,
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which could lead to facilitation of fetal membrane rupture and detachment of the
placenta and fetal membranes from the maternal uterus at the time of parturition. Also,
glycosylation could be important for functional activity of EMMPRIN at parturition.
In conclusion, MMP-2 and MMP-9 have been suggested to be involved in rupture of the
fetal membranes, and PGE2, PGF2a and IL-6 have been implicated in the up-regulation
of these enzymes at the time of this rupture. Indomethacin has been shown to diminish
the prostaglandin levels in gestational tissues. These mechanisms are likely to be
important in PROM at term and preterm, and indomethacin could be a useful agent to
delay premature rupture of the fetal membranes.
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Chapter 6: General Discussion
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6.1 Synopsis of Findings Presented in this Thesis
These studies have highlighted some of the pathways by which PGE2 and PGF2« can
regulate production and activation of MMP-2 and MMP-9, which are implicated in the
rupture of the fetal membranes at term and preterm. These findings are described in a
















Figure 6.1: Regulation ofautocrine and paracrine PGE2 and PGF2a signalling via EP
and FP receptors in JEG3 cells, and their effects on MMP-2. RTK; recetor tyrosine
kinase, PGT; prostaglandin transporter, COX; cyclo-oxygenase, ERK; extracellular
signal regulated kinse, MMP; matrix metalloproteinase.
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The mRNA for the prostaglandin receptor EP4 was detected in amnion, chorio-decidua
and placenta, and FP mRNA found in chorio-decidua and placenta samples.
Interestingly, mRNA for EP2 was undetected in fetal membranes and placenta. EP2,
EP4, FP, and also PGDH, were immunolocalised to the amnion epithelium and
fibroblast layers, the reticular and trophoblast layers of the chorion, decidual glandular
epithelial cells, stromal cells and vascular endothelial cells, syncytiotrophoblasts of the
placenta, myometrial smooth muscle cells, and JEG3 cells. Immunostaining of EP2, EP4
and FP was seen predominantly in the plasma membrane, with nuclear staining of
myometrial cells. EP2 was also visualised on JEG3 cell nuclear membranes.
Signalling pathways occurring via EP2, EP4 and FP in human fetal membranes and
JEG3 cells were also investigated. It was shown that PGE2 stimulates the cAMP/PKA
pathway via the EP2 receptor in amnion tissue, and via the EP4 receptor in JEG3 cells,
with no effect on chorio-decidua samples. The ERK pathway was found to be activated
by PGE2 and PGF2a in JEG3 cells, but not in amnion or chorio-decidua samples. The
PGE2 effect was mediated via the EP4 receptor, and the PGF2a effect occurred via the
FP receptor. An inhibitor of MEK inhibited the activation of the pathway, though
inhibitors of PLCp and an EGFR kinase did not, showing that this pathway is not
activated via PLCp or by transactivation of the EGFR. Furthermore, the IP3 pathway
was not stimulated by PGF2ot in JEG3 cells.
The effect of prostaglandins, PGE2 and PGF2a on MMP-2 and MMP-9 mRNA, and the
latent and active forms of the protein, and also TIMP levels and activity, was studied in
term fetal membranes and placenta, and in JEG3 cells. In the fetal membranes and
placenta, there were no clear prostaglandin related changes in MMP-2 and MMP-9
production or activation, or in TIMP production. There were also no reported changes in
MMP-2 or MMP-9 mRNA levels with this treatment. However, in the JEG3 cells, the
latent form of MMP-2 was significantly up-regulated by PGF2a after 2 hr, and by PGE2
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after 24 hr. PGE2 and PGF2a both also increased MMP-2 mRNA production after 8 and
24 hr.
6.2 Clinical Relevance of Findings Presented in this Thesis
Premature rupture of the fetal membranes (PROM) is defined as rupture of the
membranes before the onset of labour. Preterm premature rupture of the membranes
(PPROM) is defined as rupture of the membranes before 37 weeks gestation. PPROM
occurs in around 5-10 % of all pregnancies, and accounts for 30-40 % of all preterm
deliveries (Parry & Strauss 1998). It is associated with increased risk of infection, when
the time between rupture and delivery is delayed. Infection has also been implicated as a
cause of PROM and PPROM.
Rupture of the membranes was once attributed to physical stress, however there is
evidence to date suggesting that membrane rupture may also be due to biochemical
processes, including degradation of the collagen within the ECM of the fetal
membranes. The MMP family of proteinases are capable of degrading virtually every
component of ECM, and have thus been associated with rupture of the membranes
(Fortunato et al 1999, Vadillo-Ortega et al 1995, Vadillo-Ortega et al 1990). The
collagens in the fetal membranes are of both the interstitial types, I, III and V, and type
IV collagen which is the major component of the basement membrane (Aplin et al 1985,
Bryant-Greenwood & Yamamoto 1995). This basement membrane is associated with the
amnion epithelium and chorion trophoblast layers particularly, and also the reticular
layer of the chorion. These collagens are particular substrates for the gelatinases, MMP-
2 and MMP-9 (Lei et al 1999). Levels of MMP-2 and MMP-9 in the fetal membranes
and amniotic fluid have been shown to increase during the process of labour and PROM,
and levels of their endogenous inhibitors, the TIMPs, to decrease (Arechavaleta-Velasco
et al 2002, Fortunato et al 1999, Fortunato et al 2000, Goldman et al 2003, Locksmith et
al 1999, Maymon et al 2000c, McLaren et al 2000a, Riley et al 1999b, Romero et al
2002, Uchide et al 2000, Vadillo-Ortega et al 1995, Vadillo-Ortega et al 1996, Vadillo-
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Ortega et al 2002, Xu et al 2002). Prostaglandins, particularly PGE2 and PGF2a have
been implicated in labour, and reduced potential for prostaglandin degradation has been
seen in the fetal membranes overlying the lower uterine segment, prior to labour (Van
Meir et al 1997). Prostaglandins have been shown to stimulate the production of MMPs
in fetal membranes and decidua (McLaren et al 2000b, Ulug et al 2001).
The results of the immunolocalisation studies in this thesis indicate potential sites of
action of the prostaglandins. These sites correlate to the sites of prostaglandin synthesis,
as shown by studies of COX expression and PG release, and metabolism, as shown from
the PGDH immunolocalisation performed here, and also from an extensive series of
studies by others (see section 3.4). EP2, EP4 and FP were all present in the fetal
membranes prior to and during labour at term. The only apparent differences in
distribution of any of these prostaglandin receptors, was the absence of FP in the amnion
epithelium of preterm samples, and the absence of EP4 in preterm labouring samples.
The appearance of FP in the amnion epithelium at term could represent a site of action
of PGF2a at term, though it most likely would not influence PROM. The absence of EP4
in amnion epithelium in preterm labouring samples is not clear, due its presence in term
labouring and non-labouring samples. These studies only clarify the distribution and
localisation of the receptors, and do not actually quantify receptor levels, so it is not
clear whether levels are up-regulated at labour or term. Increased concentrations of
prostaglandins available to act on their receptors could be the key to increased
prostaglandin action at labour, or PROM. The presence of the EP2, EP4 and FP in the
placenta and myometrium suggest that these are sites for PG action also. It is well
known that PGE2 and PGF2a are involved in the processes of cervical ripening and
dilatation and myometrial contractility, respectively (Calder 1994, Carbillon et al 2001,
Winkler 2003), and prostaglandins have also been implicated in placental separation
(Gross et al 1987) so the localisation of the prostaglandin receptors here is expected. The
presence of the receptors on the nuclear membrane in myometrial smooth muscle cells
suggests that intracrine signalling may play a role in prostaglandin action on these cells.
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However, further experiments would have to be carried out to test the functionality of
these receptors and the intracellular signalling pathways mediated via them.
Examining the signalling pathways elucidated via EP2, EP4 and FP in gestational tissues
indicated whether the receptors were functionally active in these tissues. The results
showed that EP2 was functionally active in amnion, and both EP4 and FP were in JEG3
cells. Stimulation of cAMP production in the amnion and JEG3 cells shows a
prostaglandin mediated activation of the cAMP/PKA pathway, which can affect
transcriptional activity of target genes within the nucleus. The ERK pathway was also
activated by PGE2 and PGF2a in JEG3 cells. This can also influence gene transcription
and activation of proteins by changes in phosphorylation state. This pathway would have
been expected to be activated in the human fetal membranes as well. However, no
changes were identified in ERK phosphorylation after treatment with PGE2 and PGF2a,
indicating that prostaglandins do not activate the ERK pathway in this tissue.
The downstream effects of these intracellular signalling pathways have not been
clarified in the fetal membranes. cAMP/PKA and ERK can act on several gene
regulatory proteins and transcription factors to target transcription and activation of
many proteins. However, it is likely that MMPs are one of these targets. Previous studies
have shown that PGE2 induced activation of the cAMP pathway can up-regulate MMP-2
and MMP-9 production (Lyons et al 2002). ERK1/2 phosphorylation has been shown to
up-regulate MMP-2 production in JEG3 cells (Andrassy et al 2004), and the studies in
this thesis have shown that PGE2 and PGF2a stimulate ERK1/2 phosphorylation and
MMP-2 production in these cells. Putting these together, it follows that PGE2 and PGF2a
exert their stimulatory effect on MMP-2 via EP4 and FP and phosphorylation of the
ERK pathway (Figure 6.1). This pathway is likely to be involved in PROM. Use of
receptor antagonists to the EP4 and FP receptor, which inhibit the PG induced activation
of the cAMP/PKA and ERK pathways could be of potential use in blocking the PG
induced activation of MMP-2 as a treatment to prevent PROM.
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6.3 Models used in this Thesis for Investigating Parturition
As discussed in section 1.2.4, there are no ideal animal models for the studies of
parturition. Several methods of non-invasively investigating parturition in humans have
been derived. In this thesis, tissue explants of fetal membranes and placenta have been
collected and cultured, alongside work carried out in a cell-line. The benefits and
advantages of these models are discussed in this section.
6.3.1 Tissue Explant Model
The in vitro tissue explant model used in the thesis has been described before (Brennand
et al 1995) and similar methods have also been used (Fortunato et al 1994, Mitchell &
Powell 1984). Mounting the primary tissue explants on capillary matting allows the
tissue to remain oriented as it would in vivo, retaining the arrangement of all cell types
within the tissue. This maintains all the autocrine and paracrine relationships within the
tissue, without it rolling up, creating new cell-cell interactions within the culture. It also
allows tissue to remain histologically similar for up to 72 hours. It is also simple,
allowing for easy aspiration and replacement of culture medium. Isolating primary cells,
such as chorion trophoblast cells, and culturing them is another means by which
investigations could have been carried out.
6.3.2 JEG3 Cells as a Model of Chorion Trophoblast
The JEG3 choriocarcinoma cells are derived from human trophoblast cells. The cells
stain positive for cytokeratin, indicating that they are of epithelial origin, as expected.
They can be used as a model of chorion trophoblast cells with respect to parturition
(Marvin et al 2000, Moise et al 1986), the use for which has been described in this
thesis. To ascertain if they function in a similar manner to trophoblast cells from human
chorion at parturition, these cells would have to be isolated and experiments carried out
to compare the intracellular pathways and functional responses. In this thesis,
experiments show that the actions in these cells are not the same as that of chorio-
decidua explants. This is likely due, at least in part, to the variety of cell types in the
191
Chapter 6
human chorion layer, and in these explants with a small amount of adherent decidua. As
discussed in chapter 4, opposing intracellular signalling pathways may be being
activated via different receptors in these different cells. The PGE2 stimulation of cAMP
production seen in JEG3 cells was not observed in chorion explants and that could be
due to co-expression of EP receptors with opposing effects. These cells are derived from
a choriocarcinoma, so they are different from chorion trophoblast cells is some aspects
of cell function, for example the control of the cell cycle pathway. They have also been
stored and maintained in culture through multiple passages, which may also alter their
functionality. The explant is more representative of the tissue as a whole due to all cell
types and cell-cell interactions being the same as in vivo, however, to pinpoint a certain
cell type to a function or a response, it is useful to isolate individual cells or to be able to
use an appropriate cell-line. Other trophoblast cells lines which could be used to
investigate trophoblast cell function, and extrapolate the findings to parturition include
JAR and BeWo cells (Johansen et al 2000).
An amnion cell-line, WISH, is useful for in vitro study of amnion pathophysiology
(Pavan et al 2003). Prostaglandin and cytokine production in these cells have been
characterised (Harris et al 1988, Keelan et al 1997), and prostaglandin stimulation of
cytokines and its postulated role in promoting membrane rupture has been examined
(Keelan et al 2000). It was also planned to test the hypothesis of this thesis in WISH
cells. However, serious doubt was expressed about the origin of the cells, and they were
revealed to actually be HeLa cells (Kniss et al 2002).
6.4 Relevance of the Findings to Other Biological Systems
The prostaglandin stimulation ofMMP production reported in this thesis is a mechanism
which occurs in many cell types over a wide range of biological systems. Progression
and metastasis of cancer is one of those areas into which a lot of research has been
carried out recently. COX-2 up-regulates MMP-2 production, increasing tumour cell
proliferation in renal cell carcinomas (Miyata et al 2003). PGE2 also up-regulates the
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production of MMP-2 in rhabdomyosarcomas. Using selective and non-selective
inhibitors of COX-2 can inhibit the progression of this cancer through reducing MMP-2
production (Ito et al 2004). COX-2 inhibition has also been shown to suppress tumour
cell growth and invasion in colorectal cancer, by inhibiting MMP-2 and MMP-9
production. This also inhibited the formation of liver metastasis (Yao et al 2004). A
cooperative inhibition of MMP-2 and COX-2 has been shown to reduce colon
adenomas, and the cooperative inhibition allows a lower does of each inhibitor to be
used, reducing the side effects of such treatments (Wagenaar-Miller et al 2003).
Cooperative COX-2 and MMP-2 inhibition has also been shown treat many solid
tumours, such as osteosarcomas (Dickens & Cripe 2003). Another disease in which
prostaglandin stimulation of MMP production plays a role is periodontal disease. PGE2
has been shown to mediate IL-ip induced synthesis of MMP-1 (Sakaki et al 2004) and
MMP-3 (Ruwanpura et al 2004) in gingival fibroblasts. Furthermore, higher
concentrations of PGE2 and MMP-9 have been detected in gingival crevicular fluid from
Down syndrome compared to control patients exhibiting gingival infection (Tsilingaridis
et al 2003). In myocardial infarction and ischemic stroke, digestion by MMPs causes
rupture of atherosclerotic plaques. Production of macrophage MMP-2 and MMP-9 is
induced by COX-2 and PGE2 synthesis. A polymorphism in the COX-2 gene is
associated with a decreased risk of myocardial infarction and ischemic stroke, by
reducing COX-2 expression, and production of MMP-2 and MMP-9 (Cipollone et al
2004). IL-ip has also been shown to induce MMP-2 via a PGE2-dependent mechanism
in human chondrocytes. This causes degradation of collagen in cartilage (Choi et al
2004).
6.5 Suggestions for Future Study
These studies have demonstrated the immunolocalisation of EP2, EP4, FP and PGDH
within fetal membranes, decidua, placenta, and myometrium. It would be useful to
validate this data by using Western blotting, in situ hybridisation and PCR. It would also
be interesting to examine other prostaglandin receptors, such as EP1 and EP3, as PGE2
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is also likely to be mediating its effects through these receptors as well as EP2 and EP4.
It would also be valuable to look at localisation of enzymes involved in prostaglandin
synthesis, such as COX-1, COX-2 and PGES alongside the studies of PGDH.
Quantatative PCR could also have been used to examine the effects of prostaglandins on
the mRNA levels of the prostaglandin receptors, to establish if any positive or negative
feedback cascades are being activated by addition of these prostaglandins.
Intracellular signalling via EP2, EP4 and FP has been investigated in fetal membranes
and JEG3 cells. To investigate the actions upon receptor activation in the myometrium
would be interesting to assess the various relaxant and stimulatory effects of
prostaglandins in this tissue. Using preterm and term tissue would also be useful, as
would comparing tissue from subjects in labour and not in labour to see if any
differences occur across these groups. For example, non-labouring samples may act to
increase more relaxant intracellular pathways, as discussed in chapter 3, to maintain
uterine quiescence. In this thesis, the effect of PGF2« on the IP3 pathway was analysed in
JEG3 cells. No effect was observed, but it would be interesting to look at this pathway in
the human fetal membranes also to see if any stimulation is occurring in these. Further
clarification of the action of PGE2 via its receptors using antagonists for EP1 and EP3
receptors, alongside the antagonists already used would give more of an insight into how
the cAMP and ERK pathways are stimulated. Also, the way in which the prostaglandins
stimulate the ERK pathway remains unclear. Whether this is happening by
transactivation of a RTK other than EGFR, or by a non-receptor tyrosine kinase remains
to be discovered.
The effects of PGE2 and PGF2a on MMP-2, MMP-9, and TIMPs were investigated in
term non-labouring human fetal membranes and placenta, and also in JEG3 cells.
Comparing preterm tissue with this term tissue, and also tissue from patients in labour
would be interesting to see if these regulatory factors are different. It would also be
interesting to link these studies to the intracellular pathways activated by the
prostaglandins. This could be carried out by stimulating the cells and tissue with a
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cAMP analogue, such as dibutyryl cAMP, or ERK and investigating any changes in
MMP production or activation. Also, the IL-6 effect on MMP-2 was examined in JEG3
cells. It would be relevant to examine the effect of IL-6 and also other cytokines on
MMPs. It could be that cytokine stimulation of MMP production occurs via a
stimulation of prostaglandins, so prostaglandin assays could be carried out to test this
hypothesis.
As discussed previously in this chapter, it would also be useful to carry out these
experiments in isolated chorion trophoblasts and amnion epithelial cells to further
elucidate the cell types involved in regulation of prostaglandin action and MMP
production and activation.
The MMPs investigated in this thesis were MMP-2 and MMP-9. Other MMPs are
involved in the process of parturition (see section 5.4) and these could be studied. For
example, the prostaglandin effect on the collagenases, such as MMP-1 and MMP-8
could be interesting, as these degrade many of the constituents of fetal membranes.
MMP-7 also targets collagen IV, which is a major component of basement membrane in
the amnion and chorion.
6.6 Summary
In summary, this study has established some of the actions of PGE2 and PGF2a, their
intracellular signalling systems, and links to tissue remodelling by MMPs at the feto-
matemal interface at the time of labour. It has pointed the way to several other areas for






Appendix 1: Buffer Compositions










DPBS containing 80 mg/1 gentamycin and 5 mg/1 amphotericin B
1.1.3 Complete serum-free RPMI
To a 500 ml bottle of RPMI-1600, remove 10 ml and add 5 ml penstrep (5000 IU/ml
penicillin and 5 mg/ml streptomycin) and 5 ml growth factors (5 pg/ml insulin, 5 ug/ml
transferring, 5 ng/ml sodium selenite).
1.1.4 Complete DMEM
With serum: To a 500 ml bottle of DMEM, remove 65 ml and add 50 ml fetal calf
serum, 10 ml L-glutamine (200 mM stock) and 5 ml penstrep.
Serum-free: To a 500 ml bottle ofDMEM, remove 15 ml and add 10 ml L-glutamine
(200 mM stock) and 5 ml penstrep.
1.1.5 Trypan Blue
0.5 mg/ml trypan blue in 0.85 % NaCl
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1.2 Immunohistochemistry Buffers










10 ml TBS, 0.5 g BSA, 3 drops goat serum (from ABC kit)
Use to dilute primary and secondary antibodies
1.2.4 ABC-HRP
Use from kit. Make up 20 min in advance.
Dilute stock Tris (see TBS wash buffer, 1.2.7) to 50 mM and add 1 drop reagent A and 1
drop reagent B
1.2.5 DAB
Use from kit (Vector). To 5 ml distilled water, add 2 drops buffer stock solution, 4 drops
DAB stock and 2 drops of H2O2 stock
1.2.6 Citrate Buffer (xlO)
0.1 M citric acid (monohydrate) in water
Adjust to pH 5.5 using NaOH, dilute 1 in 10 for use
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1.2.7 TBS wash buffer
Make stock 1M Tris. Adjust to pH 7.4 using 5N HC1





Glacial acetic acid 57.1 ml/1
0.5 M EDTA pH8.0 100 ml/1
Dilute 1 in 50 for use
1.4 Assay Buffers
1.4.1 Protein Assay
1.4.1.1 0.2 N Sodium Hydroxide
4 g NaOH in 500 ml water
1.4.1.2 3 % w/v Sodium carbonate
15 g Na2C03 in 500 ml 0.2 M NaOH
1.4.1.3 4 % w/v Potassium Sodium Tartrate
4g KNa Tartrate 100 in ml water
1.4.1.4 2 % w/v Copper Sulphate-5-Hydrate





3 % Na2C03 24 ml
4 % KNa Tartrate 0.5 ml
2 % Copper Sulphate-5-Hydrate 0.5 ml
'Reagent S' 105 pi
1.4.1.6 Folin and Ciocalteu's Phenol Reagent




Na acetate 1 M
Methoxyamine HC1 0.1 M
ethanol 10 % v/v
Adjust to pH 5.6 with 5N HC1






2-methylisothiazolone (in 1:1 1 mM
DMF/DMSO)
Bromonitro dioxane (in 1:1 DMF/DMSO) 1 mM
200




Tween-20 0.05 % v/v
pH 7-7.5
1.4.2.4 ELISA buffer +/- Tween
Component Concentration
NaCl 150 mM
Tris-HCl pH7.2 100 mM





Tween-20 0.05 % v/v
1.4.2.5 25 % MOX buffer
25 % Methyloximating solution in ELISA buffer with Tween
1.4.2.6 Phosphate buffer




Component Volume for 24 ml
100 mM Sodium acetate pH 6.0 20 ml
Tetramethylbenzidine in DMF 2 ml
Urea-peroxidase 0.3 g/50 ml in 100 mM 2 ml
sodium acetate pH 6.0















SDS 0.1 % w/v
Protease inhibitor tablet 1 tablet/ 50 ml
Adjust to pH 7.4 with 5N HC1
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1.5.1.2 NP40 Lysis Buffer
Component Concentration
NaCl 150 mM
Tris pH 7.4 50 mM
EDTA 10 mM
EGTA lOmM
NP40 0.6 % v/v
Glycerol 10 % v/v
Protease inhibitor tablet 1 tablet/10 ml
1.5.1.3 Sample application buffer
Component Concentration
Tris 1.5 % w/v
SDS 4.0 % w/v
Dithiothretiol (DTT) 2.0 % w/v
Bromophenol blue 0.05 % w/v
Adjust to pH 6.75 with 5N HC1, store -20 °C




SDS 1.0 % w/v












Adjust to pH 7.4 with 5N HC1
1.5.1.7 TTBS
Tween 20 0.05 % v/v in TBS xl
1.5.1.8 Membrane Blocking buffer




SDS 1 % w/v
Adjust to pH 2.5 with 5N HC1
1.5.2 Gelatin Zymography/Reverse Zymography
1.5.2.1 Sample Application Buffer
Component Concentration
Glycerol 20 % w/v
SDS 2.0 % w/v
Bromophenol blue 0.04 % w/v
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Adjust to pH 8.0 with 5N HC1




Triton-X-100 2.5 % v/v
Adjust to pH 7.5 with 5N HC1
1.5.2.5 Gelatin Zymography Triton X-100 wash
2.5 % Triton X-100 in TBS 1:10






Brij-35 0.02 % v/v
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Adjust to pH 7.6 with 5N HC1








Glacial acetic acid 10%
water 60%
1.5.2.9 Staining solution
0.5 % w/v Coomassie Brilliant Blue R250 in destaining solution
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Appendix 2: Gel compositions
2.1 Western Blot
2.1.1 Resolving gel (for 2 gels 1.5 mm thick)
Component Volume (for 10% gel) Volume (for 12 % gel)
ddH20 8.1ml 6.7 ml
Tris 1.5 M pH 8.8 5.0 ml 5.0 ml
10 % SDS 200 pi 100 pi
10 % ammonium persulphate 100 pi 100 pi
Acrylamide/Bis 6.6 ml 8.0 ml
TEMED 10 pi 10 pi
Before addition of TEMED, mixture was de-gassed via water pressure/dessicator
vacuum for 10 min
2.1.2 Stacking gel 4 % (for 2 gels 1.5 mm thick)
Component Volume
ddH20 6.1 ml
Tris 0.5 M pH 6.8 2.5 ml
10 % SDS 100 pi






2.2.1 Resolving gel 7.5 % (for 2 gels 0.75 mm thick)
Component Volume
ddH20 3.85 ml
Tris 1.5 MpH8.8 2.5 ml
Gelatin 10 mg/ml 1.0 ml
10 % SDS 100 pi
10 % ammonium persulphate 50 pi
Acrylamide/Bis 2.5 ml
TEMED 5 pi
NB. Gelatin was dissolved in the microwave prior to addition.
2.2.2 Stacking gel 4 % (for 2 gels 0.75 mm thick)
Component Volume
ddH20 3.05 ml
Tris 0.5 M pH 6.8 1.25 ml
10 % SDS 50 pi





2.3.1 Resolving gel 12 % (for 2 gels 0.75 mm thick))
Component Volume
ddH20 1.69 ml
Tris 1.5 MpH8.8 2.5 ml
Gelatin 10 mg/ml 1.0 ml
10 % SDS 100 pi
10 % ammonium persulphate 50 pi
Acrylamide/Bis 4.0 ml
Solution A 0.66 ml
TEMED 5 pi
2.3.2 Stacking gel 5 % (for 2 gels 0.75 mm thick)
Component Volume
ddH20 2.89 ml
Tris 0.5 M pH 6.8 1.25 ml
10 % SDS 50 pi
10 % ammonium persulphate 50 pi
Acrylamide/Bis 0.812 ml
TEMED 5 pi
2.4 PCR Product Gels
1.8 g agarose in 120 ml TAE buffer (appendix 1.3).




The source of all materials used for all experiments is detailed in the table below. They
have been sorted into sections according to the methods used. Unless otherwise stated,
all acids, solvents and salts were purchased from BDH, Lutterworth, UK, and all cell
culture sterile plasticware from Coming Life Sciences, NY, USA.
Materials - Tissue/Cell culture Source
formaldehyde Sigma, Poole, UK
paraffin Bayer Diagnostics, Newbury, UK
DPBS Gibco, Paisley, UK
heparin LeoLabs Ltd., Risborough, UK
gentamycin Sigma, Poole, UK
Amphotericin B Sigma, Poole, UK
RPMI Gibco, Paisley, UK
penstrep Gibco, Paisley, UK
Growth factors Sigma, Poole, UK
Capillary matting B&Q Edinburgh, UK
JEG3 cell-line European Collection of Cell Cultures
(ECACC), Salisbury, UK
DMEM Gibco, Paisley, UK
Fetal calf serum Gibco, Paisley, UK
L-glutamine Gibco, Paisley, UK
Trypsin/EDTA Gibco, Paisley, UK
Trypan blue BDH, Lutterworth, UK
Indomethacin Sigma, Poole, UK
IBMX Sigma, Poole, UK
pge2 Upjohn, Kalamazoo, MI, USA
PGF2a Upjohn, Kalamazoo, MI, USA
210
endix 3
DMSO Sigma, Poole, UK
PD98059 (MEK inhibitor) Calbiochem, Nottingham, UK
U73122 (PLC inhibitor) Calbiochem, Nottingham, UK
AG1478 (EGFR kinase inhibitor) Calbiochem, Nottingham, UK
AH6809 (EP2 antagonist) Cayman Chemicals, Ann Arbor, Michigan
ONO-AE2-227 (EP4 antagonist) Dr. Henry Jabbour, HRSU, MRC
AL8810 (FP antagonist) Sigma, Poole, UK
IL-6 Peprotech, London, UK
Materials -Immimohistochemistry Source
AAS Sigma, Poole, UK
BSA Sigma, Poole, UK
Hydrogen peroxide Sigma, Poole, UK
Triton-X-100 BDH, Lutterworth, UK
Cytokeratin 1° Ab (#Z622) Dako Corp, Santa Barbara, CA, USA
EP2 1° Ab (#101750) Cayman Chemicals, Ann Arbor,
Michigan
EP4 1° Ab (#101775) Cayman Chemicals, Ann Arbor,
Michigan
FP 1° Ab (#101802) Cayman Chemicals, Ann Arbor,
Michigan
PGDH 1° Ab (Tai et al 1990) Prof H.H. Tai, Lexington, Kentucky,
USA
ABC Vectastain Kit Vector Laboratories, Peterborough, UK
DAB Vactastain Kit Vector Laboratories, Peterborough, UK
haematoxylin Sigma, Poole, UK
Eosin BDH, Lutterworth, UK
Pertex Cell Path, Hemel Hempstead, UK
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Materials - PCR Source
Tri-reagent Sigma, Poole, UK
Chloroform Sigma, Poole, UK
Isopropanol Sigma, Poole, UK
Nuclease free water Promega, Madison, USA
DNase treatment reagents Promega, Madison, USA
RT-reaction reagents Applied Biosystems, Foster City, CA
PCR primers MWG Biotech, Ebersberg, Germany
RT-PCR reagents Promega, Madison, USA
100 bp DNA ladder Promega, Madison, USA
Blue/Orange 6x loading dye Promega, Madison, USA
Lightcycler mix Roche Diagnostics, Mannheim, Germany
Materials - Assays Source
BSA Sigma, Poole, UK
Reagent'S' Biorad, Hemel Hempstead, UK
F& C Reagent BDH, Lutterworth, UK
Tween-20 Sigma, Poole, UK
Phenol Red Sigma, Poole, UK
Polyvinyl pyrollidone Sigma, Poole, UK
2-methylisothiazolone Boehringer Mannheim, Lewes, UK
bromonitrodioxane Boehringer Mannheim, Lewes, UK
PGE2 antibody Diagnostics Scotland, Edinburgh, UK
Antiserum Prof. Rodney Kelly, HRSU, MRC
PGE2 assay link Prof Rodney Kelly, HRSU, MRC
Streptavidin peroxidase Boehringer Mannheim, Lewes, UK
Hydrogen Peroxide Urea Complex Sigma, Poole, UK
Tetramethyl benzidine in DMF Sigma, Poole, UK
cAMP assay kit (#RPN225) Amersham, Buckinghamshire, UK
212
Dowex resin Biorad, Hemel Hempstead, UK
Materials - Electrophoresis Source
Dialysis tubing Sigma, Poole, UK
Protease inhibitor tablets Roche Diagnostics, Mannheim, Germany
NP40 Calbiochem, Nottingham, UK
Glycerol BDH, Lutterworth, UK
DTT Sigma, Poole, UK
Bromophenol blue Biorad, Hemel Hempstead, UK
Tween-20 Sigma, Poole, UK
BSA Sigma, Poole, UK
Triton-X-100 BDH, Lutterworth, UK
Brij-35 solution Sigma, Poole, UK
Coomassie Brilliant Blue R250 Biorad, Hemel Hempstead, UK
Glacial acetic acid Sigma, Poole, UK
Ammonium persulphate Sigma, Poole, UK
Acrylamide Biorad, Hemel Hempstead, UK
TEMED Sigma, Poole, UK
Gelatin (Bovine #G-9382) Sigma, Poole, UK
Sec-butanol Sigma, Poole, UK
Zinc chloride Sigma, Poole, UK
Molecular weight markers Biorad, Hemel Hempstead, UK
ECL reagents Amersham, Buckinghamshire, UK
Kodak film Sigma, Poole, UK
Reverse Zymography Solution 'A' Dylan Edwards, UEA, Norwich
Agarose Sigma, Poole, UK
Ethidium bromide Sigma, Poole, UK
P42/44 phospho ERK 1° Ab (#9101(S)) Cell Signalling Technology
MMP-2 1° Ab (#1M33L) Calbiochem, Nottingham, UK
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MMP-9 1° Ab (#1B7013) Insight Biotechnology, Wembley, UK
TIMP-l 1° Ab (#T7562) Sigma, Poole, UK
TIMP-2 1° Ab (#AB19078) Chemicon, Harrow, UK
HMP-3 1° Ab (#T7812) Sigma, Poole, UK
TIMP-4 1° Ab (#AB816) Chemicon, Harrow, UK
DAR 2° Ab (#NA934) Amersham, Buckinghamshire, UK
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